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Triple negative breast cancer refers to a spectrum of breast tumours which are characterised by 
the lack of overexpressing hormone or HER2 receptors. These tumours present as high grade 
and tend to have reduced progression free survival rates because of their aggressive and 
metastatic behaviour. The lack of targeted therapies for triple negative breast cancer also 
contributes to the observed poor outcomes.  
During a genetic profiling screen of aggressive breast tumours, mRNA levels of IQGAP3 were 
specifically found to be upregulated in triple negative tumours compared to other types of the 
disease and normal tissue samples. IQGAP3 is the most recently discovered member of the 
IQGAP family of scaffold proteins. Even though IQGAP1 is a well described effector for the Rho 
GTPases and has also been heavily associated with tumourigenesis and cancer cell motility, far 
less is known about IQGAP3. The aim of this project was to investigate the role of IQGAP3 in 
triple negative breast cancer cell behaviour. At first, IQGAP3 was found to be expressed across 
a panel of triple negative cell lines. Modulating expression levels of IQGAP3 conferred 
morphological changes, disrupted cell migration and inhibited the ability of cells to form 
specialised invasive adhesion structures, termed invadopodia. Reduced expression of IQGAP3 
disrupted RhoA activity and actomyosin contractility. IQGAP3 was also found to interact with 
PAK6 and Filamin-A; proteins already associated with the regulation of cell morphology. Indeed, 
PAK6 overexpression rescued the IQGAP3 depletion phenotype. IQGAP domains have 
previously been suggested to have potential therapeutic value thus IQGAP3 could be a promising 
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Chapter 1 Introduction 
1.1 Breast cancer 
Breast cancer is one of the most commonly diagnosed types of cancer which despite medical 
advances in the recent years, represents one of the leading causes of cancer related deaths 
among women (Jemal et al., 2010).  The 5 year relative survival rate is almost 100% for early 
stage tumour but dramatically drops to 21% for stage IV patients highlighting the fact that early 
stage tumours can be adequately treated while the management of late stage diagnoses remains 
challenging (Hayat et al., 2007). A combination of genetic and environmental factors influence the 
development of breast cancer including mutations on the BRCA1 and BRCA genes, increasing 
age, obesity, alcohol and oral contraceptives (Rojas and Stuckey, 2016). Breast cancer is widely 
recognised as a very heterogeneous disease with distinct subtypes characterised by specific 
molecular markers and clinical outcomes (Hirata et al., 2014). Tumours marked by increased 
expression of oestrogen (ER) and progesterone (PR) receptors have a more differentiated 
appearance and are thought to be hormonally regulated as they respond better to drugs targeting 
hormone receptors such as Tamoxifen (Althuis et al., 2004).  Amplification of the human 
epidermal growth factor 2 (HER2) receptor is found in up to 30% of breast tumours and it is 
associated with aggressive disease and poor clinical outcomes (Hirata et al., 2014). Nonetheless, 
the development of targeted therapies such as the monoclonal antibody Trastuzumab and 
tyrosine kinase inhibitor Lapatinid have significantly improved outcomes (Hirata et al., 2014). 
Tumours lacking hormone and HER2 receptors are grouped under the disease spectrum known 
as triple negative breast cancer (TNBC) (Foulkes et al., 2010).   
 
1.1.1 Triple negative breast cancer 
Triple negative tumours exhibit mutations on the TP53 gene as well as on BRCA1 which normally 
functions as a DNA repair effector (Anders and Carey, 2009). TNBC tumours tend to have a less 
differentiated appearance largely presenting as grade 3 upon diagnosis. TNBC is also most 
commonly diagnosed among non-Caucasian ethnic groups, such as women of African origin, 
while retaining a highly proliferative and metastatic phenotype (Anders and Carey, 2009). In fact, 
TNBC patients show reduced progression-free and overall survival rates 3 years after initial 
diagnosis with the brain and visceral organs becoming the primary targets of metastatic disease 
(Anders and Carey, 2009). 
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Gene expression analysis of triple negative tumours showed that 6 TNBC subtypes can be 
identified (Lehmann et al., 2011). The major subtype of TNBC which also exhibits the highest 
mitotic potential is known as basal-like and is characterised by the expression of distinct 
cytokeratins found on the basal myoepithelium of the normal breast and in most cases the 
overexpression of the EGF receptor (Nielsen et al., 2004). Interestingly, Lehmann et al., 
separated the basal-like tumours that make the 70% of all triple negative tumours into basal-like 
1 and basal-like 2 (Lehmann et al., 2011). Basal-like 1 type tumours highly express genes related 
to DNA replication and cell cycle while basal-like 2 tumours particularly express growth factor 
signalling pathways such as the EGF pathway (Lehmann et al., 2011). Another significant type is 
the mesenchymal-like which is also divided into mesenchymal and mesenchymal stem-like 
subtypes. The former exhibits elevated expression of genes related to cell motility such as Rho 
GTPases and pathways such as the TGFβ and ALK pathways (Lehmann et al., 2011). Meanwhile, 
the mesenchymal stem cell-like type also incorporates growth factor signalling, low expression of 
claudins and a phenotype consistent to that of stem cells with low proliferation and low CD24 
expression (Lehmann et al., 2011). 
However, as reviewed by Reis-Filho and Tutt, micro-array based expression profiling revealed 
that 15 to 54% of basal-like tumours express ER, PR or HER2 receptors (Reis‐Filho and Tutt, 
2008) . This implies that basal-like cancers are not necessarily synonymous to TNBC despite their 
observed similarity and thus attention should be given in the context of therapeutically treating 
these two entities (Reis‐Filho and Tutt, 2008). Given that triple negative tumours are characterised 
by compromised DNA repair due to the BRCA1 mutations, platinum-based chemotherapy is 
usually the first choice of treatment (Hudis and Gianni, 2011). At the same time, highly proliferative 
tumours such as basal-like could benefit from anti-mitotic agents such as taxanes (Lehmann et 
al., 2011). Stagg and Allard reviewed the importance of lymphocytic infiltrate in some triple 
negative tumours and its association with clinical outcomes and argued that emerging 
immunotherapeutic approaches could benefit some patients (Stagg and Allard, 2013). However, 
they also stress the fact that given the heterogeneity of the disease only a fraction of patients will 
benefit from a single given approach (Stagg and Allard, 2013). Consequently, current TNBC 
patients cannot benefit from targeted therapy, which further contributes to the observed poor 





1.1.2 Tumour metastasis 
The diagnosis of metastatic disease is the leading cause of cancer mortality (Jemal et al., 2010) 
. Metastasis means that cells from the primary tumour have managed to invade the surrounding 
tissue of the tumour by degrading the extracellular matrix, intravasate into the vascular system, 
avoid immune surveillance, extravasate and finally colonise distant organs as reviewed by 
Valastyan and Weinberg (Valastyan and Weinberg, 2011), (figure 1.1). This involves the 
coordination of dramatic changes in cellular behaviour including the acquisition of a motile and 
invasive phenotype, cell survival in non-permissive environments such as the vasculature and 
proliferation at distant sites. Hence, there are several stages of metastasis that can be potentially 
therapeutically targeted and thus understanding the molecular mechanisms behind each stage is 
crucial (Palmer et al., 2011). 
Epithelial to mesenchymal transition (EMT) has been associated with the onset of metastasis. 
Loss of E-cadherin and apicobasal cell polarity are early events regulated by EMT inducers such 
as SNAIL, TWIST and TGFβ signalling (Thiery et al., 2009). Extracellular signals such as 
epidermal growth factor (EGF), hepatocyte growth factor (HGF) Insulin-Like growth factor 1 
(IGF1) have also been shown to induce a mesenchymal phenotype characterised by a front to 
rear polarity which is established by the activity of the Rho GTPases (Lamouille et al., 2014). In 
order to escape from the primary tumour, cells must penetrate the basement membrane which is 
achieved by secreting matrix metalloproteases (Kessenbrock et al., 2010), (figure 1.1). Cells can 
adopt different modes of invasion; one of which is the formation of actin rich protrusions capable 
of secreting MMPs, known as invadopodia (Friedl and Alexander, 2011; Lohmer et al., 2014).    
Indeed, inhibition of MMPs has been shown to prevent invasion in animal models (Kessenbrock 
et al., 2010)  while increased expression of MMP9 was found in aggressive HER2 positive and 
triple negative breast tumours and correlated with higher rates of metastasis (Yousef et al., 2014). 
However, MMPs also act as signalling mediators in physiological processes which can explain 
why MMP inhibitors failed to improve clinical outcomes in human clinical trials (Kessenbrock et 
al., 2010). Once outside the BM, cancer cells interact with the tumour supporting stroma which 
contains a variety of cells including macrophages, adipocytes and endothelial cells that provide 
further environmental cues promoting an invasive behaviour (Valastyan and Weinberg, 2011),  
(figure 1.1).  
Metastatic tropism refers to the cross-talk between tumour cells and distant organ sites that create 
a permissive environment for tumour cells to colonise those organs (Lorusso and Rüegg, 2012). 
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For example, hormonally regulated breast tumour cells preferentially metastasize to the bone 
where they hijack molecular signals normally regulating bone remodelling and ensure their 
survival and proliferation (Lorusso and Rüegg, 2012). However, triple negative tumours exhibit a 
different organ metastatic tropism than the hormonally influenced tumours as they are more likely 
to spread rapidly to visceral organs including the lungs and liver (Dent et al., 2009). 
 
Figure 1.1 Schematic of the metastatic cascade. Cells from the primary tumour acquire the ability to 
breach the basement membrane and escape into the surrounding stromal tissue. From there, some of these 
cells intravasate into the lymphatics or vasculature through which they can travel, extravasate and colonise 




1.2 The significance of cancer cell motility 
One of the most important hallmarks in cancer progression and metastasis is tumour cells 
acquiring the ability to move and travel through the vasculature or the lymphatics in order to 
colonise distant organs (Friedl and Wolf, 2003). The first step to cell movement is the ability of 
the cell to alter its morphology and engage with the extracellular environment resulting in a 
polarised shape (Lauffenburger and Horwitz, 1996).  
 
1.2.1 Actin organisation 
Changes in cell morphology are mediated by the dynamic actin cytoskeleton. Actin filaments are 
polymers of monomeric actin forming a double stranded helix with characteristic barbed and 
pointed ends (Blanchoin et al., 2014; Pollard, 1986). Polymerisation is dependent on the 
concentration of the available actin monomers and occurs more favourably at the barded end of 
the filament followed by hydrolysis of ATP coupled to the actin monomer subunits (Pollard, 1986). 
Regulatory proteins controlling the assembly and disassembly of actin filaments create the 
architectural structures of the actin cytoskeleton that provide shape and movement features. For 
example, cross-linking of actin filaments dictate cell shape and provide structural rigidity while 
branching actin networks enable the formation of lamellipodia and forward movement (Blanchoin 
et al., 2014). Parallel actin filaments are observed in filopodia, which are finger-like structures 
known to sense the extracellular environment (Mattila and Lappalainen, 2008). Furthermore, 
stress fibres are bundles of cross-linked actin filaments with crucial functionality in migrating cells 
(Kassianidou and Kumar, 2015). Stress fibres link the cell with the extracellular matrix via focal 
adhesions and also provide the structural basis for the maturation of focal complexes into focal 
adhesions ultimately acting as mechanosensing structures and enabling directional cell migration 
(Burridge and Wittchen, 2013; Kassianidou and Kumar, 2015). Furthermore, anti-parallel actin 
bundles provide the base for the contractile unit together with non-muscle myosin II (NMMII) 
(Kassianidou and Kumar, 2015).  NMMII is made of two heavy chains, 2 regulatory light chains 
and 2 essential light chains (Vicente-Manzanares et al., 2009).  The heavy chains of NMMII hold 
ATPase activity and can also bind filamentous actin while the essential light chains provide 
structural stability to the heavy chains (Vicente-Manzanares et al., 2009). Phosphorylation of the 
regulatory light chains on Ser19 creates the necessary conformational change that allows the 
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formation of myosin filaments and enhances hydrolysis of ATP (Vicente-Manzanares et al., 2009).  
Ultimately, myosin thick filaments slide towards the barbed end of actin filaments with opposite 
polarity thereby inducing tension and contractility (Kassianidou and Kumar, 2015; Murrell et al., 
2015). Importantly, myosin IIB activity is enriched in ventral stress fibres at the cell rear 
contributing to front to back polarity and tail retraction in migrating cells (Kassianidou and Kumar, 
2015; Vicente-Manzanares et al., 2008).  
 
1.2.2 Models of cell migration    
The extracellular environment is a crucial influencing factor leading to differential results 
depending on whether cell migration is considered in 2D and 3D in vitro studies, or intravital in 
vivo studies thus making the study of cell migration challenging and complex (Clark and Vignjevic, 
2015). Nonetheless, studies in 2D cell migration have provided much of our understanding 
regarding cell motility while the main mechanisms have also been confirmed in 3D; for example 
forward cell extension is defined by the same molecular and structural characteristics both in 2D 
and 3D (Petrie and Yamada, 2012).  Cells migrate either individually or collectively (figure 1.2); 
individual cell migration has been studied extensively but interestingly the significance of 
collective cell migration has been highlighted at the invasive front of breast tumours in organoid 
systems where invading leader cells were reported to express E-cadherin and other basal 
epithelial markers (Cheung et al., 2013). Additionally, intravital imaging of MDA-MB-231 and low 
passage primary breast cancer cells revealed that these cells migrated as multi-cellular streams 
and that this particular mode of invasion was associated with increased intravasation and 
circulating tumour cells in the blood vessels of a mouse model (Patsialou et al., 2013). Multi-
cellular streaming is an intermediate mode of migration which involves cells migrating in a single 
line while forming short-lived cell junctions (figure 1.2), (Friedl et al., 2012).  
Cell migration is also classified according to the shape of migrating cells as well as their 
engagement with the extracellular matrix (Friedl and Wolf, 2010). Mesenchymal migration is 
adopted by cells extending a pseudopod that gradually lead to lamellipodia dynamics and an 
elongated morphology (figure 1.2). The protrusion then engages with the extracellular matrix 
forming strong focal adhesions that create high traction forces pulling on the surrounding matrix 
(Friedl, 2004). Large focal adhesions have a slower turnover rate and are thus associated with 
slower cell speed (Friedl, 2004). Localised pericellular proteolysis mediated by MT1-MMP behind 
the leading protrusion realigns the extracellular matrix and reduces cell stress during forward 
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moving as it creates paths of least resistance (Friedl and Wolf, 2009). Focalised matrix 
degradation together with cell body contraction mediates the forward pulling of the cell body and 
finally cell tail retraction ultimately achieving cell displacement (Friedl and Wolf, 2010, 2009). In 
fact, when colon cancer L-10 cells migrate collectively, the front leader cells adopt a mesenchymal 
mode of migration and locally degrade the matrix which in turn provides migration tracks for the 
following cells which retain cell-cell junctions (Friedl, 2004).  
Amoeboid migration is adopted by rounded bleb forming cells lacking stress fibres and mature 
focal adhesions (figure 1.2). Cell contractility resulting from the activation of myosin light chain 
induces an increase in the intracellular hydrostatic pressure which in turn can locally disrupt the 
actin cytoskeleton and allow cytosolic content to form blebs against the plasma membrane 
(Lämmermann and Sixt, 2009). Amoeboid cell movement is thus not mediated by actin 
polymerisation and the generation of traction forces; rather by a propulsive mechanism driven by 
actomyosin contractility (Fackler and Grosse, 2008). Nonetheless, amoeboid melanoma cells 
have been shown to secrete high levels of MMPs such as MMP9 and MMP13 suggesting that 
matrix degradation is important in the amoeboid mode of migration as well (Orgaz et al., 2014). 
Furthermore, the lack of engagement with the surrounding matrix makes the amoeboid movement 
type much faster than the mesenchymal one (Lämmermann and Sixt, 2009). The morphology of 
migrating cells depends on a number of factors concerning the extracellular matrix like its 
dimension and rigidity as well as the expression of adhesive and proteolytic determinants (Friedl 
and Wolf, 2010). Increased matrix stiffness signals via integrins and promotes cell elongation and 
the formation of focal adhesions (Friedl and Wolf, 2010). Contrary to rigid environments, soft 
matrices like the lymphatics and vasculature allow cells to squeeze through and thus promote the 
amoeboid mode of migration (Krakhmal et al., 2015). Cell confinement mediated by the pores in 
the surrounding matrix also support an elongated morphology while larger gaps promote a 
rounded morphology (Friedl and Wolf, 2010). Ultimately, the ability of cells to modulate their 
morphology according to the extracellular micro-environment is referred to as cell plasticity. This 
is a crucial feature maintained by cancer cells as it allows them to survive and migrate through 
structurally heterogeneous tissues (Friedl and Alexander, 2011). Breast cancer cells have been 
shown to exhibit the ability to modulate their morphology based on the extracellular environment. 
For example, triple negative MDA-MB-231 and BT-549 cells grown in laminin rich extracellular 
matrix cluster together and form elongated projections via which they keep in contact (Kenny et 
al., 2007). However, MDA-MB-231 cells invaded a 3D matrigel matrix while displaying a rounded 
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morphology and high contractility at the cell rear as indicated by the microbeads displacement 
and the accumulation of pMLC (Poincloux et al., 2011). Breast cancer cell invasion has been 
associated with amoeboid movement; oestrogen receptors of ER positive tumour cells are lost at 
the invasive front as well as lymph metastases. Additionally, loss of ER induced loss of vinculin 
which in turn increased actomyosin contractility and amoeboid migration in MCF7 cells (Gao et 
al., 2017). Furthermore, MTLn3E cells overlaid with a collagen gel were able to invade by 
distorting the matrix. The observed matrix deformation was reported to be independent of 
protease activity and was mediated by generating contractile force induced by ROCK and myosin 
light chain activation (Wyckoff et al., 2006). Interestingly, different factors modulating RhoA 
activity have been reported to dictate cell plasticity in breast cancer cells; Net1 is a RhoA GEF 
necessary for the induction of amoeboid invasion of MDA-MB-231 cells in matrigel (Carr et al., 
2013) while E3 ubiquitin ligase Smurf1 degrades RhoA thereby allowing the formation of 









Figure 1.2 Modes of cell migration. Cells can either migrate individually or collectively. In individual cell 
migration, cells can either adopt a mesenchymal or an amoeboid mode. Mesenchymal migration is 
characterised by an elongated morphology and matrix degradation while the amoeboid type is mainly driven 
by high contractility resulting in a rounded blebby cell morphology. In collective cell migration cells can either 





1.2.3 Invadopodia: A special protrusion in mediating metastasis 
Extracellular matrix degradation and invasion is a crucial part of the metastatic cascade 
(Valastyan and Weinberg, 2011). Twist is a well characterised transcriptional factor promoting 
metastasis. Twist  has been shown to upregulate expression of platelet derived growth factor 
receptor α (PDGFRα) which in turn stimulates Src activity ultimately resulting in the formation of 
actin rich membrane protrusions which can target the secretion of MMPs and degrade the 
extracellular matrix in human mammary epithelial HMLE cells(Eckert et al., 2011), (figure 1.3). 
These structures are known as invadopodia and have been implicated in the local invasion, 
intravasation and metastasis of breast cancer cells to the lung (Eckert et al., 2011; Gligorijevic et 
al., 2012). In fact, recent advances in intravital microscopy have also allowed the visualisation of 
extravasating MDA-MB-231LN  cells extending invadopodia into the extravascular stroma of the 
chorioallantoic membrane (CAM) of the chicken embryo (Leong et al., 2014).  
Invadopodia are complex structures incorporating adhesion proteins, actin binding proteins, 
metalloproteases with Rho GTPases and their effectors contributing to their dynamic formation 
and activity (Murphy and Courtneidge, 2011).  
Extracellular signals stimulate the formation of invadopodia via the activation of plasma 
membrane receptors initiating signalling cascades (Hoshino et al., 2013). In breast cancer cells 
activation of EGFR, Met and TGFβ receptors has been shown to induce formation of invadopodia 
(Mandal et al., 2008; Rajadurai et al., 2012; Yamaguchi et al., 2005). Similar results have been 
reported for head and neck squamous carcinoma cells when VEGF becomes activated (Lucas et 
al., 2010). Activation of these signalling cascades meet at stimulating a set of kinases, particularly 
Src but also ERK and PAKs that induce the formation of invadopodia (Foxall et al., 2016). Src 
phosphorylates various substrates including cortactin and Tks5 which constitute hallmark 
elements of invadopodia formation (Murphy and Courtneidge, 2011), (figure 1.3). Tks5 is an 
adaptor protein shown to be crucial for invadopodia formation by specifically localising early  and 
marking invadopodia sites as well as acting as a scaffold for other invadopodia elements such as 
cortactin (Crimaldi et al., 2009; Murphy and Courtneidge, 2011; Seals et al., 2005). PAK1 
mediated phosphorylation of cortactin Ser113 has been shown to be important for invadopodia 
formation and activity (Ayala et al., 2008). Src phosphorylation of cortactin as well as active Cdc42 
stimulate the Arp2/3 complex via N-WASP and WIP ultimately initiating actin polymerisation 
(Murphy and Courtneidge, 2011; Tehrani et al., 2007). Apart from the activation of the Arp2/3 
complex, ERK induced cortactin phosphorylation on tyrosine residues (tyr421) releases cofilin 
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and enables its actin filament severing activity thereby also contributing to actin polymerisation 
and the elongation of the invadopodium protrusion (Oser et al., 2009), (figure 1.3). Ultimately, 
the invadopodia core consists of branched actin filaments at the base of the protrusion while 
unbranched actin bundles mediated by the actions of mDia and fascin, are responsible for 
invadopodia elongation and are observed closer to the tip of the protrusion (Schoumacher et al., 
2010). Furthermore, inactivation of cofilin activity by cortactin which is once again able to 
sequester cofilin upon dephosphorylation is required for the stabilisation of invadopodia structures 
(Oser et al., 2009). Additionally, spatial regulation of RhoC activity by p190RhoGEF and 
p190RhoGAP also regulates cofilin activity via ROCK and LIMK (see section 1.3.1); RhoC 
remains active around the protrusion, ultimately inactivating cofilin and therefore restricting the 
direction of the elongating protrusion (Bravo-Cordero et al., 2011). Cross-linking proteins such as 
Filamin-A (see section 1.3.5) and fascin have also been reported to localise at invadopodia 
promoting stability (Li et al., 2010; Takkunen et al., 2010).  
Invadopodia maturation ultimately involves the targeting and secretion of metalloproteases 
(MMPs). Cortactin once again appears crucial for the secretion of MMP2 and MMP9 as well as 
the presentation of MT1-MMP on the tip of the invadopodia protrusion (Clark et al., 2007) , (figure 
1.3). Interestingly, the association of cortactin to MT1-MMP endosomes is facilitated by MT1-
MMP tyrosine phosphorylation by LIMK (Lagoutte et al., 2016). Meanwhile, atypical PKC 
phosphorylates cortactin on MT1-MMP late endosomes facilitating trafficking in triple negative 
breast cancer cells (Rossé et al., 2014). Interestingly, under the influence of Cdc42 and RhoA, 
IQGAP1 (see section 1.3.2.1) interacts with components of the exocyst complex to regulate the 
accumulation of MT1-MMP at invadopodia ultimately potentiating matrix degradation (Sakurai-
Yageta et al., 2008).  
Moreover, little is known regarding the dissolution of invadopodia but recently Rac1 induced PAK1 
was reported to phosphorylate cortactin which lead to cortactin becoming detached from the actin 
rich structure ultimately marking the turnover of invadopodia in breast cancer cells (Moshfegh et 
al., 2015). Additionally, phosphorylation of the actin cross-linking protein AFAP-110 on Ser 277 
has also been reported to be important for the turnover of the protrusion (Foxall et al., 2016).  
Finally, even though a wide range of regulatory elements within the invadopodia life-cycle have 
been identified, what determines the spatio-temporal regulation of their activity remains largely 
unknown. Nonetheless, invadopodia formation has been proposed as a promising target to 
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prevent metastasis ultimately suggesting that inhibiting invadopodia could be beneficial in treating 




Figure 1.3 Invadopodia components. Cancer cells are able to form protrusions that secrete 
metalloproteases degrading the extracellular matrix. The formation of the protrusion is induced by 
extracellular signals that converge on kinases such as Src, a master regulator of invadopodia. Src 
phosphorylates major invadopodia components Tsk5 and cortactin that are crucial for invadopodia formation 
and elongation. Actin polymerisation is induced by activated Arp2/3 complex and supported by the severing 
activity of cofilin. Once the actin rich protrusion is stabilised, the presentation of MT1-MMP mediated by 





1.3 Rho GTPase pathways and cell migration 
1.3.1 The Rho GTPases 
The Rho GTPases are key regulators of cytoskeletal dynamics and cell motility, enabling the 
architectural variability observed in actin structures like invadopodia and creating a series of 
morphological changes during cell migration (Ridley et al., 2003; Spuul et al., 2014).The most 
prominent and well-studied members of the family are Rho, Rac and Cdc42  which cycle from an 
inactive GDP bound form to an active GTP bound form thanks to guanine-nucleotide exchange 
factors (GEFs) and back to an inactive GDP bound one due to the hydrolysing activity of GTPases 
activating proteins (GAPs) (Ridley, 2001), (figure 1.4). Another mechanism via which the activity 
of Rho GTPases is prevented is via GDP dissociation inhibitors (GDIs) which sequester GDP 
bound Rho GTPases thereby preventing GEF activity and also bind GTP bound Rho GTPases 






Figure 1.4 Regulation of Rho GTPase activity. Inactive GDP bound Rho GTPases become activated by 
GEFs and cycle back to an inactivated form by GAPs. GDIs sequester inactive Rho GTPases from activation 





The Rho GTPases have well characterised roles in controlling cytoskeletal dynamics and cellular 
architecture. Rac1 induces the extension of the lamellipodium at the early stages of cell migration 
by activating Arp2/3 which is a protein complex whose actin nucleating action creates actin 
filaments on the sides of pre-existing ones thereby resulting in a branching actin filament network 
at the leading cell edge (Ridley et al., 1992; Ridley, 2001), (figure 1.5). Cdc42 is responsible for 
the establishment of cell polarity (Etienne-Manneville and Hall, 2001; Vega and Ridley, 2008)   as 
well as the formation of actin rich filopodia which are dynamic structures that could be dictating 
directional migration by sensing the surrounding space as reviewed (Mattila and Lappalainen, 
2008; Ridley, 2001), (figure 1.5). After the forward extension of the front part of the cell, focal 
complexes are formed in response to Rac providing preliminary attachments with the ECM 
(Rottner et al., 1999). These immature focal complexes develop into focal adhesions with the 
downregulation of Rac and activation of Rho (Nobes and Hall, 1995; Ridley and Hall, 1992; 
Rottner et al., 1999). Rac has also been shown to induce the expression of MMP2, MMP9 and 
MT1-MMP ultimately contributing to the focalised matrix degradation that creates paths of least 
resistance in order for the cell to move forward (Friedl and Wolf, 2009; Parri and Chiarugi, 2010).    
Rho regulates actin contractility via ROCK which induces myosin light chain (MLC) 
phosphorylation by directly phosphorylating MLC and inhibiting MLC phosphatase (Fukata et al., 
2001; Parri and Chiarugi, 2010). Additionally, Rho is responsible for the formation of actin stress 
fibres which attach onto focal adhesions ultimately providing rigidity and tension (Chrzanowska-
Wodnicka and Burridge, 1996; Ridley and Hall, 1992), (figure 1.5). The dynamic turnover of focal 
adhesions is equally important for efficient cell migration as together with contractility, it allows 
the cell body to follow the extended front edge of the cell (Ridley, 2001). Once again Rac activates 
PAK which in turn interacts with paxillin and induces the structural dissolution of focal adhesions 
(Ridley, 2001; Zhao et al., 2000). Meanwhile, Rho activity and cell contractility is also required for 
cell tail retraction as detachment of the cell rear is disrupted upon loss of Rho activity (Parri and 
Chiarugi, 2010; Sun et al., 2013), (figure 1.5). The tightly regulated activity of the Rho GTPases 
is also required during the invadopodia lifecycle; Cdc42 and RhoA have been associated with 
invadopodia formation and elongation respectively (Spuul et al., 2014)  while both are thought to 
be important for matrix degradation (Sakurai-Yageta et al., 2008). Additionally, Rac1 has been 




While there are distinct roles attributed to Rho GTPases, the cross-talk between them as well as 
the spatiotemporal regulation of their activity is just as important in ensuring effective cell 
migration. To begin with, Cdc42 has been shown to activate Rac and induce focal complexes in 
Swiss 3T3 cells, suggesting a synergistic relationship between Rac1 and Cdc42 (Nobes and Hall, 
1995). In agreement with this is the fact that both Rac1 and Cdc42 induce actin polymerisation 
by activating the Arp2/3 complex via the actin nucleators SCAR/WAVE and N-WASP respectively 
(figure 1.5), (Ma et al., 1998; Olson and Sahai, 2009). Meanwhile, an antagonistic relationship 
between Rac and Rho is widely accepted. In fact, a bistable relationship has been described 
between Rac1 and RhoA activity with inhibition of PAK influencing the switch between the two 
steady states and ultimately conferring changes in migration and morphology (Byrne et al., 2016). 
Additionally, mathematical modelling supported by in vitro work have suggested that the activation 
state of MEK creates a feedback loop that determines the localised activity of Rac1 or RhoA; the 
Sos1 – Eps8 – Abi1 complex is responsible for relaying the inhibition of MEK which in turn 
promotes Rac1 activity and suppression of RhoA (Hetmanski et al., 2016a, 2016b). Furthermore, 
cell plasticity in melanoma cells has been also shown to be regulated by shifts between Rac1 and 
RhoA activity; Rac activity induced by DOCK3, a Rac GEF, is needed for the mesenchymal mode 
of migration while ROCK downregulates Rac activity via ARHGAP22 a Rac GAP ultimately 
promoting the amoeboid type of migration  in A375M2 cells (Sanz-Moreno et al., 2007). Ultimately, 
the fine spatiotemporal regulation of the Rho GTPases by their respective GEFs and GAPs 
controls efficient cell migration and morphology (Byrne et al., 2016).  Nonetheless, once activated, 
the Rho GTPases signal via multiple effectors that potentiate Rho GTPase activity and control 
cytoskeletal dynamics. 
The primary consequence of Rac and Cdc42 is actin polymerisation during the extension phase 
of lamellipodia and filopodia respectively (Ridley, 2001). Rac signals via IRSp53 and WAVE to 
activate Arp2/3 while Cdc42 achieves Arp2/3 activation via WASP (Ridley, 2001), (figure 1.5). 
This cascade creates a branching architecture in the extending actin cytoskeleton as Arp2/3 is 
favouring the addition actin filaments on the side of pre-existing ones (Mullins et al., 1998; Ridley, 
2001). Apart from directly inducing actin polymerisation Rac1 influences cytoskeletal dynamics 
by binding to phosphatidylinositol-4-phosphate 5-kinase (PIP 5-kinase) which synthesizes 
phosphatidylinositol-4,5-bisphosphate (PIP2), that in turn removes capping proteins such as 
gelsolin from the barbed end of actin filaments ultimately encouraging actin polymerisation (Tolias 
et al., 2000), (figure 1.5). Moreover, Rho primarily acts via ROCK to influence phosphorylation of 
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MLC and induce actomyosin contractility; either by directly phosphorylating MLC or by inhibiting 
MLC phosphatase (MP) (Amano et al., 1996; Katoh et al., 2001; Kimura et al., 1996). ROCK 
together with mDia induce the formation of stress fibres (Ridley, 1999; Tominaga et al., 2000). 
Activated ROCK can also phosphorylate LIMK ultimately inhibiting cofilin and stabilising stress 
fibres (Ohashi et al., 2000; Ridley, 2001), (figure 1.5). The signalling networks influencing Rho 
GTPase activity involve multiple kinases and other regulatory elements; this thesis is going to 
focus primarily on the IQGAP family of scaffold proteins but also on p21-activated kinases (PAKs) 







Figure 1.5 Rho GTPase effectors regulate cytoskeletal dynamics. Rac1 and Cdc42 regulate membrane 
protrusions by activating the Arp2/3 complex and inducing actin polymerisation. They also signal via PAK 
and LIMK to inactivate cofilin and inhibit actin depolymerisation. Another mechanism promoting actin 
polymerisation is the uncapping of actin filaments induced by the Rac1 – PIPK-5 – PIP2 signalling pathway. 
Regulatory proteins support these processes either by scaffolding or cross-linking. RhoA induces the 
formation of stress fibres via mDia but also by signalling via ROCK and LIMK. RhoA also induced actomyosin 
contractility by activating MLC via ROCK. Ultimately, Rac1 and Cdc42 are primarily active at the cell front 
regulating the formation of lamellipodia and filopodia respectively while RhoA regulates cell contractility and 






1.3.2 IQGAP family of scaffold proteins 
The IQGAP family of scaffold proteins has received a lot of attention as Rac1 and Cdc42 effectors 
(Briggs and Sacks, 2003). IQGAP1 was the first member of the family to be discovered and was 
initially shown to interact with activated Rac1 and Cdc42 (figure 1.5) and becoming enriched at 
COS7 cell areas with membrane ruffling as well cell junctions of MDCK cells (Kuroda et al., 1996). 
Since then, IQGAP1 has been implicated in various cytoskeletal processes including directional 
cell migration, cell adhesion and cell polarity while another two IQGAP members, IQGAP2 and 
IQGAP3 have also been identified sharing some functionality but also harbouring unique 
properties (Smith et al., 2015). 
Recently, a genetic profiling screen based on approximately 200 tumours that was performed at 
the Breast Cancer Now Unit of Guy’s Hospital and King’s College London (de Rinaldis et al., 
2013)  revealed that IQGAP3  is upregulated in TNBC compared to other classes of breast cancer 








Figure 1.6 IQGAP3 mRNA levels in breast tumours. mRNA profiling was performed on a cohort of 
approximately 200 invasive breast tumours from patients treated at Guy’s hospital between 1979-2007 (de 
Rinaldis et al., 2013). IQGAP3 mRNA levels were found to be upregulated in triple negative tumours 
compared to hormonally regulated tumours, tumours over-expressing HER2 as well as normal tissue 
samples. This information and schematic used was kindly offered by Professor Andrew Tutt and colleagues 





IQGAPs exhibit significant sequence homology and comparable structures (White et al., 2009). 
The structural domains shared by IQGAPs allow them to harbour multiple interacting partners and 
exhibit varied properties (Smith et al., 2015), (figure 1.7). Studies on IQGAP1 have expanded 
our knowledge on the function of IQGAP domains. At the N-terminus IQGAPs have a calponin 
homology domain (CHD) that has the potential to maintain a high affinity interaction with the actin 
cytoskeleton but also bind calmodulin and Ca2+(Ho et al., 1999; Smith et al., 2015).  Towards the 
middle of the protein sequence, IQGAPs have an IQ region containing 4 IQ motifs; these IQ 
domains interact with calcium and calmodulin, myosin essential light chain (essential MLC) and 
S100B (Pathmanathan et al., 2011). This region also mediates interactions with EGFR and MEK 
(Smith et al., 2015) and is also responsible for IQGAP1 homo-dimerisation (Ren et al., 2005). 
IQGAPs have a WW domain which has been shown to interact with ERK (Roy et al., 2004). Even 
though WW domains are known to interact with proline rich sequences, ERK lacks a proline rich 
motif while the interaction is mediated via a region of the WW domain other than the WW motif 
(Smith et al., 2015). Towards the C-terminus of IQGAPs there is a GAP related domain (GRD) 
which binds the Rho family members Rac1 and Cdc42 maintaining their active GTP bound state 
(Ho et al., 1999; Smith et al., 2015). Despite the name and homology with GAPs, the catalytic 
arginine finger normally seen in GAPs is replaced by a threonine residue in the GRD which 
abolishes the hydrolytic activity of the domain without disrupting binding to Ras (Kurella et al., 
2009). This explains why IQGAPs can maintain the activated state of the Rho GTPases. Finally, 
a RasGAP C-terminal domain has been described as unique to IQGAPs and is known to mediate 
a variety of interactions for example with E-cadherin, APC and CLIP-170 (Abel et al., 2015), 
(figure 1.7). Despite their observed homology, IQGAPs have different expression patterns. 
IQGAP1 is ubiquitously expressed while IQGAP2 and IQGAP3 are much more tissue restricted 
(White et al., 2009). IQGAP2 is primarily expressed in the liver but has also been found in the 
salivary glands, thyroid, stomach, kidneys, testis, prostate and platelets while IQGAP3 is 
expressed in the brain, lung, small intestine, colon and testis (White et al., 2009). The observed 
difference in expression across different tissues might suggest that despite their high homology, 








Figure 1.7 Schematic domain structure of IQGAP proteins. Starting from the N-terminus IQGAPs share 
homologous domains; a calponin homology domain (CHD), a WW domain, an IQ domain containing 4 IQ 
motifs, a GAP related domain and a C-terminus RasGAP domain that is unique to IQGAPs. Percentages 
indicate the amino acid identity of IQGAP2 and IQGAP3 domains compared to the equivalent domains of 






IQGAP1 has been associated with multiple cellular processes by interacting with more than 130 
binding partners thanks to its multifunctional domains (Hedman et al., 2015). Initially it was 
observed to bind the actin cytoskeleton and active Cdc42 and Rac1 but not RhoA in a 
Ca2+/calmodulin dependent manner thereby acting as a cross-linking protein and scaffold in 
regulating the actin cytoskeleton (Bashour et al., 1997; Ho et al., 1999; Kuroda et al., 1996). The 
interaction of IQGAP1 with the Rho GTPases has been extensively described; recently it was 
proposed that the GRD domain interacts with Rac1 and Cdc42 with different affinities while the 
RasGAP-CT is also important in mediating the interaction of IQGAP1 with the Rho GTPases 
(Nouri et al., 2017). Additionally, the regions on IQGAP1 interacting with Rac1 and Cdc42 are 
overlapping but not identical (Nouri et al., 2017). In fact, IQGAP1 has been shown to maintain the 
active state of Cdc42 by inhibiting its GTPase activity (Swart-Mataraza et al., 2002). IQGAP1 
mediated regulation of Rac1 appears to be more complex as it has been shown to promote Rac1 
mediated migration in glioma cells (Hu et al., 2009) while promoting Rac1 deactivation by 
interacting with RacGAP1 in U-2OS osteosarcoma cells (Jacquemet et al., 2013). Since then, 
IQGAP1 has also been reported to bind GTP bound prenylated RhoA (Casteel et al., 2012).  
In addition, IQGAP1 has been implicated in cell polarisation as it has been reported to bind CLIP-
170 which in turns interacts with elongating microtubules at the cell periphery (Fukata et al., 2001; 
Parri and Chiarugi, 2010). This interaction allows a complex between CLIP-170, IQGAP1 and 
activated Rac1/Cdc42 to be formed which in turn recruits elongating microtubules towards the 
leading cell edge of Vero cells ultimately implicating IQGAP1 in cell polarisation (Fukata et al., 
2001). The implication of IQGAP1 in directional cell migration was further confirmed when Choi 
et al., also showed that IQGAP1 is localised close to the leading edge of MDA-MB-231 cells (Choi 
et al., 2013). This localisation is mediated by the type Iγ phosphatidylinositol 4-phosphate 5-
kinase (PIPKIγ) recruiting IQGAP1 at the leading edge where IQGAP1 is also able to bind 
Phosphatidylinositol 4,5 bisphosphate (PIP2) (Choi et al., 2013). The interaction between 
IQGAP1 and PIP2 confers the necessary conformational change that triggers IQGAP1 to activate 
key actin polymerisation regulators N-WASP and Arp2/3 complex. Loss of the interaction between 
IQGAP1 and PIP2 leads to subsequent loss of a single leading edge and thus directional 
migration (Choi et al., 2013).  
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Additionally, IQGAP1 is also involved in cell adhesion as it was found that calmodulin regulates 
the association of IQGAP1 with e-cadherin thus disrupting cell junctions in MCF7 cells (Li et al., 
1999). Furthermore, the interaction between IQGAP1 and PAK6 induced cell dissociation in 
colony forming prostate cancer DU-145 cells upon HGF stimulation (Fram et al., 2014). 
Moreover, IQGAP1 also acts as a scaffold for the mitogen activated kinase cascade (MAPK) 
cascade potentially becoming implicated in many biological functions such as cell proliferation 
and differentiation (Brown and Sacks, 2006).  Indeed, IQGAP1 has been found to selectively bind 
KRAS. This interaction did not depend on the activity status of the kinase or the ability of KRAS 
to bind its downstream effectors. Furthermore, overexpression of IQGAP1 in pancreatic cells 
enhanced the interaction of a gain of function KRASV12 with BRaf as well as the activation of 
ERK (Matsunaga et al., 2014). IQGAP1 was reported to bind ERK2 via a sequence within its WW 
domain other than the actual WW motif. This binding facilitated ERK2 activation upon epidermal 
growth factor (EGF) stimulation (Roy et al., 2004). Interestingly, both overexpression and 
depletion of IQGAP1 attenuated EGF induced ERK activation (Roy et al., 2004). Since then, it 
has been argued that the IQ domain of IQGAP1 is more important in mediating the interaction 
with ERK1/2(Bardwell et al., 2017). Moreover, IQGAP1 is necessary for ERK and Akt 
phosphorylation during cardiac function and remodelling in response to prolonged pressure 
overload (Sbroggiò et al., 2011). Additionally, overexpression of IQGAP1 increased Akt 
phosphorylation in IQGAP1 null MEFs ultimately suggesting that IQGAP1 is also important for the 
PI3K-Akt signalling cascade (Choi et al., 2016). Based on the effect of modulating IQGAP1 levels 
on ERK and Akt activation, it has been suggested that levels of IQGAP1 might dictate which 




IQGAP2 was identified soon after IQGAP1 displaying 62% homology to its predecessor sharing 
the same domains while also interacting with Rac1 and Cdc42 without displaying GTPase activity 
(Brill et al., 1996).  Interestingly, IQGAP2 appears to be the only IQGAP able to interact with GDP 
bound Rac1 and Cdc42 (Brill et al., 1996). Nonetheless, despite the early discovery of IQGAP2, 
far less is known about IQGAP2 than IQGAP1. The human testis specific splice IQGAP2 variant 
has been reported to have 3 IQ motifs instead of 4 (Wang et al., 2009). In platelets, IQGAP2 
localises diffusely in the cytoplasm whereas upon thrombin stimulation IQGAP2 associates with 
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Arp2/3 and acts as a scaffold for cytoskeletal dynamics ultimately localising at filopodia (Schmidt 
et al., 2003). Interestingly, this interaction is regulated by GTP bound Rac1 and not Cd42 (Schmidt 
et al., 2003). Additionally, IQGAP2 interacts with and mediates the effects of activated RhoG in 
NIH3T3 cells (Wennerberg et al., 2002).  Furthermore, IQGAP1 and IQGAP2 appeared to have 
different localisation in the gastric epithelium with IQGAP1 localising in the cortex of chief and 
neck mucous cells while IQGAP2 localised in the nuclei and cell contacts in isolated rabbit gastric 
glands (Chew et al., 1998). IQGAP2 has also been found in a complex with c-AMP dependent 
protein kinase (PKA) and Protein kinase A-anchoring protein 220 (AKAP-220). The formation of 
this complex enables the PKA induced phosphorylation of IQGAP2 on Thr 716 which in turn 
supports the interaction of IQGAP2 with Rac1-GTP and induced membrane ruffling (Logue et al., 
2011).  
   
 
1.3.2.3 IQGAP3 
When IQGAP3 was identified as a member of the IQGAP family, it was also found to act as a 
scaffold for Rho GTPases Rac1 and Cdc42 thereby controlling the remodelling of the actin 
cytoskeleton (Wang et al., 2007), (figure 1.8). The interaction of IQGAP3 with the Rho GTPases 
is not as extensively investigated as the one of IQGAP1 even though the C-terminus of IQGAP3 
containing the GRD interacted with both Rac1 and Cdc42 (Wang et al., 2007).  Additionally, 
IQGAP3 and not IQGAP1 appeared to induce neurite outgrowth in PC12 cells and axonal 
elongation in primary hippocampal neurons (Wang et al., 2007). This observation not only 
reinforced the role of IQGAP3 in contributing to cytoskeletal dynamics, it also validated the fact 
that despite the high homology shared by IQGAP1 and IQGAP3, these two IQGAPs could also 
harbour unique functionality. Consistent with this, IQGAP3 was found to specifically localise in 
actively proliferating transit amplifying cells within the crypts of murine small intestine tissue 
samples (Nojima et al., 2008). IQGAP3 expression was also diminished in cultured Eph4 cells 
after they reached confluency and stopped proliferating. Additionally, ectopic expression of 
IQGAP3 in quiescent NIH-3T3 cells induced expression of Ki67, suggesting that IQGAP3 can 
induce cell cycle re-entry (Nojima et al., 2008). Indeed, IQGAP3 was uniquely found to regulate 
proliferation by binding GTP-bound Ras thereby activating ERK2 ultimately proving that IQGAP3 
also acts as a scaffold for the MAPK cascade (Nojima et al., 2008), (figure 1.8).  
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IQGAP3 was also reported to be involved in cell migration as loss of IQGAP3 expression 
decreased clustering of Adenomatous polyposis coli (APC) at the leading cell edge of PC12 cells 
(Caro-Gonzalez et al., 2012). Upon activation by ERK2 phosphorylation, APC dissociates from 
actin and binds the elongating microtubules during cell extension thereby contributing to cell 
migration (Caro-Gonzalez et al., 2012). Loss of IQGAP3 might thus be interfering with the ERK 
induced APC phosphorylation that promotes APC clustering at the cell front (Caro-Gonzalez et 
al., 2012). Furthermore, even though IQGAP1 and IQGAP2 were shown to localise in specific 
structures during zebra-fish development, IQGAP3 was found to be present in proliferating areas 
irrespective of specific tissues. Morpholinos targeting IQGAP3 mRNA were used to inhibit 
IQGAP3 expression in zebra-fish embryos. IQGAP3 depletion inhibited cell proliferation and 
migration during zebra-fish development as shown by the position and number of IQGAP3 
depleted cells at 24 hours post fertilisation (Fang et al., 2015). Additionally, Yang et al., 
demonstrated that IQGAP3 inhibited the migration, invasion and proliferation abilities of the lung 
cancer cell line A549. This study also suggested that IQGAP3 elicits its proliferation promoting 
effects by binding to ERK1 upon EGF stimulation and facilitating its activation (Yang et al., 2014), 
(figure 1.8). However, the mechanism via which IQGAP3 might be contributing to lung cancer 
cell migration remains unknown. In addition to proliferation, IQGAP3 has also been reported to 
be involved in cytokinesis; even though both IQGAP1 and IQGAP3 appear to affect cytokinesis 
only IQGAP3 was shown to specifically interact with anillin regulating the localisation of RhoA and 
pMLC to the furrow (Adachi et al., 2014), (figure 1.8). The unique properties of IQGAP3 in 
proliferation and cytokinesis further reinforce the notion that despite the similarity shared by 
IQGAPs, each member of the family can still maintain unique functionality. Interestingly, even 
though all IQGAPs have been reported to bind Rac1 and Cdc42, their association with Rho 
appears to be more complex. It has been widely reported that IQGAPs do not directly interact 
with Rho (Adachi et al., 2014; Wang et al., 2007; White et al., 2009). Nonetheless, IQGAP1 was 
recently reported to interact with GTP bound prenylated RhoA (Casteel et al., 2012). 










Figure 1.8 Schematic of known IQGAP3 binding partners. F-actin interacts with the calponin homology 
domain (CHD). Anillin binding was localised in the region containing the CHD and the WW domain. The 
location of ERK1 binding on IQGAP3 was not explored but ERK1 has been shown to interact with the WW 
and the IQ domains of IQGAP1. Rac1 and Cdc42 interact with the GAP related domain.  Finally, no single 
domain was found necessary for Ras binding as Ras interacted with all the IQGAP3 domain mutants; 





1.3.3 IQGAPs in cancer 
IQGAPs have been associated with neoplasia in various studies. In fact IQGAP1 mRNA levels 
are upregulated in various malignancies including colorectal, head and neck, breast, lung and 
liver cancers (White et al., 2009). This may come as no surprise given the implication of IQGAP1 
with cell migration, invasion and adhesion as well as its scaffolding activity for the MAPK cascade, 
a pathway heavily associated with tumourigenesis (Hedman et al., 2015; White et al., 2009).   In 
fact, after IQGAP1 was identified as a key regulator of H-Ras targeted tumourigenesis, it was 
suggested that the WW peptide of IQGAP1 could be therapeutically significant. This was 
supported by the fact that when it was systemically administered in a mouse model of pancreatic 
cancer, the WW peptide inhibited tumour growth and significantly increased survival rates 
(Jameson et al., 2013). Additionally, high levels of both IQGAP1 and IQGAP3 are required to 
drive squamous cell carcinoma in an in vivo xenograft skin model while the expression of the IQ 
domain in Ras driven organotypic tissues are substantially less proliferative disordered and 
invasive and display reduced p-ERK staining (Monteleon et al., 2015). Interestingly, in this study 
the WW domain did not exhibit any anti-tumourigenic effects (Monteleon et al., 2015). IQGAP1 is 
also important in invadopodia mediated matrix degradation by targeting MT1-MMP at the tip of 
the protrusions in MDA-MB-231 cells (Sakurai-Yageta et al., 2008). 
While IQGAP2 is mainly expressed in the liver, IQGAP2 deficient mice develop hepatocellular 
carcinoma which is also accompanied by overexpression of IQGAP1 and loss of membrane E-
cadherin (Schmidt et al., 2008). In fact, mice deficient for both IQGAP1 and IQGAP2 had a 
decreased incidence of hepatocellular carcinoma and improved survival suggesting that the 
malignant phenotype resulting from loss of IQGAP2 is dependent on IQGAP1 (Schmidt et al., 
2008). These results together with the fact that decreased IQGAP2 expression is marked in 
gastric and prostate cancers support the notion of IQGAP2 being a tumour suppressor in spite of 
the tumorigenic activity of IQGAP1 (Smith et al., 2015).  
IQGAP3 has also become increasingly associated with malignancy. IQGAP3 mRNA levels have 
been found to be upregulated in lung tumours where it is believed to drive tumourigenesis by 
interacting with ERK1 and promoting proliferation migration and invasion in A-549 lung cancer 
cells (Yang et al., 2014). Additionally, IQGAP3 expression was found to be increased in the 
plasma of hepatocellular carcinoma patients and also correlated with tumour size hence its value 
as a prognostic marker is now starting to be considered (Qian et al., 2016). IQGAP3 could also 
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be acting as an oncogene in pancreatic cancer as mRNA levels of IQGAP3 were also upregulated 
in pancreatic tumours while depleting IQGAP3 in BXPC-3 and SW1990 pancreatic cancer cell 
lines (Xu et al., 2016).  Finally, IQGAP3 protein and mRNA expression has been shown to be 
increased in breast tumours compared to samples of adjacent normal tissue (Hu et al., 2016). In 
contrast to the mRNA screen based on the Guy’s Hospital tissue sample cohort (de Rinaldis et 
al., 2013), (figure 1.6) this study found that levels of IQGAP3 were higher in HER2 positive cells 
compared to the triple negative MDA-MB-231 cells (Hu et al., 2016). Hence this study did not 
focus on triple negative breast cancer. IQGAP3 depletion in ZR-75-30 and BT474 breast cancer 
cells reduced their proliferation, migration and invasion capacities. Interestingly, IQGAP3 
depletion also reduced expression of pERK1/2 and Twist (Hu et al., 2016). Nonetheless, the exact 
mechanism via which IQGAP3 is implicated in breast cancer cell migration was not investigated. 
Furthermore, despite the defined role of IQGAP1 in invadopodia activity, it is not known whether 
IQGAP3 maintains such role. This thesis will thus give particular attention in investigating a 
potential implication of IQGAP3 in invadopodia dynamics.   
 
1.3.4  The p21- activated kinases  
Some of the better characterised effectors of the Rho GTPases are the p21 activated kinases 
(PAKs); a family of Serine/Threonine kinases implicated in multiple cellular processes through 
that capacity (King et al., 2014). Indeed, PAKs are involved with cell growth and proliferation, as 
well as with the regulation of cytoskeletal dynamics thus controlling cell morphology, migration 
and invasion (King et al., 2014; Rane and Minden, 2014). There are 6 PAK isoforms that are 
separated in 2 groups based on their sequence and structural homology; group I consists of 
PAK1-3 while group II consists of PAK4-6 (King et al., 2014). The two groups display some key 
structural and regulatory differences (Arias‐Romero and Chernoff, 2008). All PAKs have a 
regulatory and a catalytic domain (figure 1.9). At the N-terminus of group I PAKs, the GTPase 
binding domain (GBD) can be found. The GBD also contains some over-lapping sequences with 
an auto-inhibitory domain (AID) that is crucial for the activation state of the kinase (Arias‐Romero 
and Chernoff, 2008; Bokoch, 2003). Other regulatory components include proline rich regions that 
act as substrates for interacting partners with Src homology 3 (SH3) domains (Bokoch, 2003; 
Rane and Minden, 2014). The catalytic kinase domain lies at the C-terminus of all PAKs (King et 
al., 2014), (figure 1.9). In their inactivated state, group I PAKs exist as homo-dimers as the AID 
binds the kinase domain inhibiting its catalytic activity. This translates to the fact that group I PAKs 
46 
 
have low basal activity. Binding of either Rac1 or Cdc42 induces a conformational change that 
releases the kinase domain from its inhibited state (Bokoch, 2003; Zenke et al., 1999). This in 
turn allows PAK1 to auto-phosphorylate at various sites including Thr 423 within the catalytic 
domain that maximises its enzymatic ability. Even after the dissociation of the activator Rho 
GTPase, PAK1 remains active to relay downstream effects (Bokoch, 2003; Zenke et al., 1999).  
 
The first N-terminal proline rich region interacts with the adaptor protein Nck (Bokoch et al., 1996)   
while the second proline rich region binds Growth Factor Receptor-bound protein 2 (Grb2) (Puto 
et al., 2003), (figure 1.9). Both interactions are enhanced upon growth factor receptor stimulation 
suggesting that PAK1 can translocate to the plasma membrane (Arias‐Romero and Chernoff, 
2008; Bokoch et al., 1996; Puto et al., 2003).  Another proline rich region mediates the interaction 
of group I PAKs with PIX which is a Rac1 and Cdc42 GEF that recruits PAK1 to Rac1 and Cdc42 
induced focal complexes in Hela cells (Manser et al., 1998), (figure 1.9). These proline rich 
domains might also serve as binding regions to the WW domain of IQGAPs (Hedman et al., 2015).   
 
Even though group II PAKs also contain an N-terminal GBD and C-terminal kinase domain, there 
are district differences in their structure and regulation (figure 1.9). Group II PAKs preferentially 
interact with Cdc42 while induction of their kinase activity is not dependent on the interaction with 
Cdc42 (Arias‐Romero and Chernoff, 2008). Initially only PAK5 was reported to harbour a 
recognised AID functioning like the one observed in PAK1 (Ching et al., 2003). Nonetheless, work 
on the N-terminus of PAK4 has identified a conserved region across group II PAKs that could 
maintain the inactive state of the kinase and also reduce PAK6 activity (Ha et al., 2012). PAK4 
also has a unique binding site within its C-terminus for β5 integrin; PAK4 mediated 
phosphorylation of β5 integrin is important for cell migration in CS-1 cells (Li et al., 2010; 
Takkunen et al., 2010).    
PAK isoforms have differential expression distribution and a variety of different substrates 
implicating them in cytoskeletal dynamics, signal transduction, and gene transcription (Arias‐








Figure 1.9 Schematic of PAK structure. All PAKs have an N-terminal regulatory domain and a C-terminal 
catalytic domain containing the Ser/Thr kinase region. In the regulatory Group I PAKs have a GTPase 
binding domain (GBD) that has overlapping sequence with the auto-inhibitory domain (AID). Group I PAKs 
also have several proline rich regions mediating interactions with SH3 domains. A binding site for PIX has 
also been identified. In group II PAKs there is no universally accepted AID, although putative auto-inhibitory 






PAK1 was at first identified in the brain but was also detected in the spleen, lung and testis (Arias‐
Romero and Chernoff, 2008; Manser et al., 1994). Active PAK1 is heavily involved in cytoskeletal 
dynamics downstream of Rac1 and Cdc42 and localises at the membrane ruffles, cell protrusions 
and periphery of migrating cells (Parrini, 2012). PAK1 has also been shown to phenocopy Cdc42 
in Swiss 3T3 cells in inducing filopodia suggesting that it might also influence cytoskeletal 
dynamics downstream of Cdc42 (Sells et al., 1997). Activated PAK1 interacts and phosphorylates 
LIMK on Thr 508 which confers Rac1 induced membrane ruffling in BHK cells by inhibiting cofilin 
mediated actin depolymerisation (Edwards et al., 1999). PAK1 also phosphorylates paxillin at Ser 
273 and promotes GIT1 binding to paxillin as well as targets the complex of GIT1-PIX-PAK1 at 
the leading edge of CHO-K1 cells ultimately enhancing Rac induced protrusion and focal 
adhesion turnover (Nayal et al., 2006). Consistent with this, inhibition of PAK1 reduced actin flow 
within the lamella, displaced myosin IIA and disrupted the architecture and turnover of focal 
adhesions in PtK1 cells (Delorme-Walker et al., 2011). However, Dart et al., reported that PAK1 
depletion in MDA-MB-231 cells did not affect paxillin phosphorylation at Ser273 whereas PAK4 
depletion reduced levels of S273 phosphorylation (Dart et al., 2015).  At the same time, PAK1 
has been shown to phosphorylate MLCK ultimately reducing active MLC and peripheral cell 
spreading in BHK-21 cells (Sanders et al., 1999). PAK1 also binds Filamin-A via its CRIB domain 
and phosphorylates Filamin-A on Ser 2152 which in turn confers membrane ruffles and 
lamellipodia in MCF7 and M2 cells. Interestingly, binding of Filamin-A on the CRIB domain of 
PAK1 induces kinase activity (Vadlamudi et al., 2002). Additionally PAK1 also signals via the 
MAPK cascade to control stability of lamellipodia in macrophages (Smith et al., 2008). Indeed 
PAK1 can phosphorylate both MEK1 and Raf1 (King et al., 2014).  
 
PAK1 is implicated in multiple signalling pathways that promote malignancy. Indeed, PAK1 
expression is upregulated in cancers of the  breast, colon, kidney, prostate as well as melanoma, 
yet no activating mutations have been identified (Rane and Minden, 2014). Furthermore, 
depletion of PAK1 in prostate cancer PC3 cells inhibited transendothelial cell migration and 
tumour growth in mouse xenografts while expression of MMP9 was significantly reduced 
ultimately implicating PAK1 in prostate cancer microinvasion (Goc et al., 2013). Interestingly, 
PAK1 was found to be involved with invadopodia formation in melanoma cells (Nicholas et al., 
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2016). PAK1 expression also correlated with colorectal cancer progression from normal tissue to 
lymph node metastasis (Carter et al., 2004). In fact PAK1 drives colon cancer DLD1 cell 
proliferation migration and survival through activation of ERK and Akt (Huynh et al., 2010). 
Moreover, PAK1 phosphorylates the oestrogen receptor (ER) on Ser 305 mediating its 
transactivation  and thus regulating the expression of downstream gene targets such as the 
progesterone receptor (PR). Indeed, ectopic expression of constitutively active PAK1 in murine 
mammary glands during pregnancy and lactation led to mammary hyperplasia (Wang et al., 
2002). These mice later displayed pre-malignant and malignant lesions which expressed high 
levels of phosphorylated MEK1/2 and p38MAPK (Wang et al., 2005). Additionally, phosphorylated 
PAK1 localised in the nuclei in cells of advanced tumours  in the polyoma middle-T antigen 
transgenic mouse model of breast cancer suggesting that PAK1 transcriptional activity is involved 
in breast cancer tumourigenesis and progression (Wang et al., 2005). Localisation of PAK1 in the 
nucleus has also been linked with tamoxifen resistance in MCF7 cells (Holm et al., 2006).  
Ultimately, the use of PAK inhibitors in combination with standard taxane based chemotherapy 
was deemed as a promising therapeutic strategy for breast cancer (Ong et al., 2015). 
 
1.3.4.2 PAK6 
PAK6 was first identified as an androgen receptor (AR) binding partner in a yeast two hybrid 
screen. In fact, PAK6 bound to the ligand binding domain of AR and inhibited AR signalling (Yang 
et al., 2001).  Soon after, PAK6 was also found to interact with ERα inhibiting ER induced 
transcription (Lee et al., 2002). The fact that PAK6 interacts and inhibits the downstream 
transcriptional activity of hormone receptors suggests that PAK6 could contribute to the 
development of hormonally independent tumours that are known to be aggressive (Schrantz et 
al., 2004).   
A truncated C-terminal mutant of PAK6 displayed higher kinase activity than the full length protein 
consistent with the hypothesis that group II PAKs also possess an auto-inhibitory mechanism 
(Yang et al., 2001). PAK6 can be inhibited by p38 MAP kinase inhibitor SB203580 and increases 
with p38 MAP kinase upstream activator MKK6 suggesting that p38 MAP is involved in the 
regulation of PAK6 activity in HEK-293 cells (Kaur et al., 2005). PAK6 expression has been 
detected in the prostate, testis, brain, kidney and placenta (Jaffer and Chernoff, 2002; Yang et 
al., 2001).  Additionally, PAK6 expression was reported in prostate and breast cancer cell lines 
including the PC3 and MDA-MB-231 cells while it was also increased in primary, metastatic and 
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recurrent prostate tumours compared to normal prostate epithelium (Kaur et al., 2008). 
Furthermore mass-spectrometry and immunoprecipitation assays confirmed that IQGAP1 and 
protein phosphatase 1B (PP1B) associate with PAK6 (Kaur et al., 2008). Indeed, PAK6 was 
shown to promote cell junction disassembly by associating with IQGAP1 and e-cadherin upon 
HGF stimulation in DU-145 cells (Fram et al., 2014). Additionally, similarly to PAK1, depletion of 
PAK6 also reduced MMP9 expression in PC3 cells (Goc et al., 2013).  Furthermore, depletion of 
PAK6 expression induced a cell-cycle arrest at G2/M phase which was further enhanced by 
docetaxel in LAPC-4 and PC3 cells (Wen et al., 2009). This is an interesting observation as 
IQGAP3 depletion also inhibits cell proliferation in Eph4 cells (Nojima et al., 2008) and thus a 
potential synergy between PAK6 and IQGAP3 should be investigated.  Inhibition of cell invasion 
in vitro as well as tumour growth in vivo induced by PAK6 depletion was also enhanced by 
docetaxel suggesting that this synergy could be exploited therapeutically (Wen et al., 2009). The 
clinical implication of PAK6 in prostate cancer is further supported by the fact that PAK6 depletion 
increased radiosensitivity of PC3 and DU-145 cells potentially because PAK6 is preventing 
apoptosis by phosphorylating BAD (Zhang et al., 2010). Nonetheless, despite the characterised 
role of PAK6 in prostate cancer, little is known about PAK6 in other settings such as breast cancer 
and whether inhibition of PAK6 would have an effect in breast tumour growth.  
 
1.3.5 Filamin-A 
The activity of the Rho GTPases is also regulated by Filamin-A (Stossel et al., 2001). Filamin-A 
is an actin filament binding and cross-linking protein that has been shown to influence the 
architecture and organisation of the actin cytoskeleton (Flanagan et al., 2001; Wang et al., 1975), 
(figure 1.5). Filamin-A first acquired its name due to the fact that it was found to localise with actin 
filaments (Wang et al., 1975).  There are 3 human Filamins (Filamin-A, B and C); all of them 
display actin-filament cross-linking activity while maintaining the capacity of attaching binding 
partners to the plasma membrane (van der Flier and Sonnenberg, 2001). Ultimately, through 
these features, filamins contribute to the complex cytoskeletal architecture adopted by migrating 
cells (Stossel et al., 2001).  
Filamins are found as homo-dimers of large peptide chains that associate with each other via 
their C-termini. The actin binding domain (ABD) consisting of two calponin homology domains lies 
at the far N-terminus of each monomer and its similar to those found in other actin binding 
domains such as α-actinin and calponin (van der Flier and Sonnenberg, 2001). Following the 
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ABD, each filamin monomer contains 2 rod domains made of 24 anti-parallel β-sheets. These are 
interrupted by two calpain sensitive hinge domains (Nakamura et al., 2007; Stossel et al., 2001). 
The rod domains mediate the interactions with binding partners while the hinge domains 
contribute to the elasticity observed in the actin networks reconstituted in vitro (Gardel et al., 
2006). Ultimately, dimerization results in a Y shape of the filamin dimer which enables the cross-
linking activity of the protein (Nakamura et al., 2007), (figure 1.10). 
The association of Filamin-A with cytoskeletal dynamics already suggests that Filamin-A is 
important in cell migration. This is well characterised in M2 melanoma cells lacking Filamin-A 
expression compared to the M2 sub-line A7 that express Filamin-A. Indeed, M2 cells make 
unstable protrusions and blebs while displaying compromised migration. Unlike the M2 cells, 
Filamin-A reconstituted A7 cells displayed improved elasticity, protrusion stability and cell motility 
(Cunningham et al., 1992). Interestingly, similar levels of Arp2/3 were detected in both cell types 
further confirming the importance of Filamin-A in regulating cytoskeletal architecture and stability 
(Flanagan et al., 2001). Consistent with this, Filamin-A binds Rac1, Cdc42 and RhoA although 
the functional significance of these interactions is not well described (Ohta et al., 1999; Stossel 
et al., 2001). Filamin-A has been reported to mediate Rho activity during the retraction of the 
neutrophil neuropod by controlling the localisation of pMLC and RhoA (Sun et al., 2013). Filamin-
A has also been implicated in the antagonistic cross-talk between Rac and Rho which was 
discussed earlier; Filamin-A is required for the ROCK induced FilGAP mediated Rac inactivation 
in melanoma A7 cells (Ohta et al., 2006).The role of Filamin-A is perhaps to provide spatial control 
of FilGAP in areas where it can be phosphorylated by ROCK and inactivate Rac (Ohta et al., 
2006). Filamin-A has also been shown to interact with β1 integrin and vimentin thus regulating 
the cell surface expression of β1 integrin and cell spreading on collagen (MacPherson and 
Fagerholm, 2010). Furthermore, a complex of Filamin-A and IQGAP1 recruits RacGAP1 to β1 
integrin active sites at the cell periphery to downregulate Rac1 and ensure directional cell 
migration (Jacquemet et al., 2013). These examples suggest that Filamin-A favours RhoA activity 
over Rac1 activity. Apart from supporting cytoskeletal architecture and stability Filamin-A also has 
mechanosensing properties. Filamin-A enables cells to adapt to mechanical force stresses by 
changing its conformation thereby revealing previously hidden interacting regions, ultimately 
allowing the integration of Filamin-A in further signalling pathways (Razinia et al., 2012).  In fact, 
the interaction of Filamin-A with FilGAP has also been shown to prevent HEK-293 cells under 
mechanical stress from undergoing apoptosis (Shifrin et al., 2009).  
52 
 
Interestingly, apart from regulating cytoskeletal dynamics and cell shape Filamin-A has other 
functions. Indeed, Filamin-A is involved in DNA repair by interacting with BRCA1 in the nucleus 
of HCT116 cells (Velkova et al., 2010). Also, calpain induced cleavage yields C-terminal 
fragments that interact with the androgen receptor and translocate to the nucleus thereby 
disrupting AR signalling (Loy et al., 2003; Nakamura et al., 2011). 
Given the implication of Filamin-A in cell migration, it may come as no surprise that Filamin-A is 
involved in human diseases including cancer (Yue et al., 2013). However, the role of Filamin-A in 
cancer progression is far from clear. Filamin-A is over-expressed in many cancers including the 
one of the breast, prostate, lung, colon as well as melanoma (Savoy and Ghosh, 2013). Cyclin 
D1 interacts and phosphorylates Filamin-A at Ser1459 and Ser2152 regulating Filamin-A 
mediated cell migration and invasion in MDA-MB-231 cells (Zhong et al., 2010). Additionally, 
Filamin-A is also phosphorylated by Akt at Ser2152 and drives arsenic induced cell migration in 
human bronchial epithelial cell line, BEAS-2B cells while Filamin-A expression has been 
associated with poor survival in lung cancer adenocarcinoma patients (Li et al., 2015). Meanwhile, 
nuclear Filamin-A was found in benign prostate tissue while cytoplasmic Filamin-A localisation 
was linked with prostate cancer progression and metastasis (Bedolla et al., 2009). Consequently, 
it has been argued that cytoplasmic Filamin-A promotes migration and metastasis while nuclear 
Filamin-A regulates transcription and inhibits tumour growth (Savoy and Ghosh, 2013). 
Consistent with its pro-metastatic activity Filamin-A has been found at invadopodia (Takkunen et 
al., 2010) and linked with IQGAP1 (Jacquemet et al., 2013). However, whether Filamin-A is 





Figure 1.10 Schematic of Filamin-A structure. Filamin-A is a homo-dimer of 2 large monomers. At the N-
terminus of each homo-dimer lies an actin binding domain (ABD). This is followed by 24 β-sheets that 
become interrupted by 2 hinge regions providing flexibility. Each monomer is thus separated in two rod 





1.4 Project Aims 
The aim of the project was to investigate the role of IQGAP3 in triple negative breast cancer cells 
and to identify potential mechanisms via which IQGAP3 is involved in cell migration. Specific 
objectives comprised the following: 
 Characterise the expression levels of IQGAP3 in a panel of triple negative breast cancer 
cell lines and identify the most suitable cell models to further this study. 
 Assess the effect of modulating IQGAP3 expression in specific cell phenotypes such as 
cell morphology, random 2D migration and invadopodia activity. 
 Identify IQGAP3 binding partners and explore their functional significance in the context 
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Chapter 2 : Materials and Methods 
2.1  Materials 
2.1.1 General materials 
3-(4,5-Dimethylthiazol-2-yl)-2,5-
Diphenyltetrazolium Bromide (MTT) 
Sigma-Aldrich, UK 
4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) 
A&E Scientific 
4’, 6-diamidino-2-phenylindole (DAPI) Sigma-Aldrich, UK 
Acrylamide (30%) Severn Biotech Ltd, UK 
Alexa Fluor® 488 Phalloidin Invitrogen, UK 
Agarose Invitrogen, UK 
Ammonium persulfate (APS) Sigma-Aldrich, UK 
Ampicillin Sigma-Aldrich, UK 
Aprotinin Sigma-Aldrich, UK 
Beta (β)- mercaptoethanol Sigma-Aldrich, UK 
Bovine serum albumin (BSA) VWR International, UK 
Bovine serum albumin (BSA)- Fatty acid free VWR International, UK 
Bromophenol blue Bio-Rad 
Calcium phosphate transfection kit Invitrogen, UK 
Cell dissociation buffer Sigma-Aldrich, UK 
Coverslips 13mm Scientific Laboratories Supplies 
DH5αTM competent Escherichia coli (E. coli) 
cells 
Invitrogen, UK 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, UK 
Dithiothreitol (DTT) Sigma-Aldrich, UK 
Dulbecco’s Modified Eagle’s Medium 
(DMEM) 
Sigma-Aldrich, UK 
Duolink® In Situ Detection Reagents Red Sigma-Aldrich, UK 
Enhanced chemiluminescence (ECL) Prime 
western blotting detection reagent 
GE Healthcare Life Sciences, UK 
Ethanol BDH Laboratory Supplies, UK 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich, UK 
Fibronectin Sigma-Aldrich, UK 
FluorSaveTM Reagent Calbiochem, UK 
Foetal bovine serum (FBS) GIBCO®, Invitrogen, UK 
Formaldehyde ThermoFisher  Scientific, USA 
X-ray film Scientific Laboratory Supplies, UK 
Gateway® LR ClonaseTM enzyme kit 




Gelatin- Type A from porcine skin Sigma-Aldrich, UK 
GFP-TRAP ChromoTek, Germany 
Glutaraldehyde solution, Grade I, 25% Sigma-Aldrich, UK 
Glycerol Sigma-Aldrich, UK 
Glycine Sigma-Aldrich, UK 
HCl VWR International, UK 
HiPerfect transfection reagent Qiagen Ltd, UK 
Insulin solution, human  Sigma-Aldrich, UK 
Kanamycin solution Sigma-Aldrich, UK 
Leupeptin Sigma-Aldrich, UK 
Lipofectamine 2000 Invitrogen, UK 
Luria-Bertani agar (LB-agar) Sigma-Aldrich, UK 
Luria-Bertani broth (LB-broth) tablets Sigma-Aldrich, UK 
Methanol VWR International, UK 
Milk powder Marvel, UK 
NEB®-10 beta competent E.coli cells (high 
efficiency) 
New England Biolabs, UK 
Nitrocellulose membrane PerkinElmer, UK 
NonidetTM P40 substitute (NP-40) Sigma-Aldrich, UK 
Nuclease-free water ThermoFisher  Scientific, USA 
Oleoyl-L-α-lysophosphatidic acid sodium salt 
(LPA) 
Sigma-Aldrich, UK 
OptiMEM Invitrogen, UK 
Paraformaldehyde (PFA) Sigma-Aldrich, UK 
Penicillin-Streptomycin Sigma-Aldrich, UK 
Phalloidin CruzFluor™ 647 Conjugate Santa Cruz 
Phenylmethylsulfonylfluoride (PMSF) Sigma-Aldrich, UK 
Phosphate buffered saline (PBS) tablets Oxoid Limited, UK 
Dulbecco’s PBS with Calcium and 
Magnesium 
GIBCO®, Invitrogen, UK 
Dulbecco’s PBS without Calcium and 
Magnesium 
LONZA, UK 
PierceTM ECL  western blotting substrate ThermoFisher  Scientific, USA 
Precision Plus ProteinTM All Blue standards Bio-rad, UK 
Precision Plus ProteinTM dual colour 
standards 
Bio-rad, UK 
Purelink® HiPure Plasmid Filter Maxi-prep kit Invitrogen, UK 
Puromycin Sigma-Aldrich, UK 
Rhodamine Phalloidin ThermoFisher  Scientific, USA 
Rhodamine B Isothiocyanate Sigma-Aldrich, UK 
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Roswell Park Memorial Institute (RPMI)-1640 
medium 
Sigma-Aldrich, UK 
Slide-A-Lyzer® dialysis cassette ThermoFisher  Scientific, USA 
Sodium borohydride Sigma-Aldrich,UK 
Sodium Chloride (NaCl) Sigma-Aldrich, UK 
Sodium dodecyl sulphate (SDS) Sigma-Aldrich, UK 
Sodium fluoride (NaF) Alfa Aesar, UK 
Sodium hydroxide (NaOH) Sigma-Aldrich, UK 
Sodium orthovanadate (Na3VO4) New England Biolabs, UK 
Sucrose Sigma-Aldrich, UK 
Tetramethylethylenediamine (TEMED) Sigma-Aldrich, UK 
Tris-base Sigma-Aldrich, UK 
Triton X-100 VWR International, UK 
Tween® 20 VWR International, UK 
Table 2-1 General reagents 
 
2.1.2 Buffers 
Blocking solution 5% w/v milk powder or 5% w/v BSA in Tris 
buffered saline (TBS)-Tween 
GFP-Trap wash/dilution buffer 10 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM 
EDTA 
GFP-Trap Lysis buffer 10 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM 
EDTA, 0.5% NP-40 
Gel Sample buffer (2x) 100 mM Tris-HCl pH 6.8, 4% w/v SDS, 20% 
v/v glycerol, 2% β-mercaptoethanol, 0.2% w/v 
bromophenol blue. 
Stripping buffer 25 mM Glycine pH 2, 1% w/v SDS 
Protease inhibitor cocktail 1 mM DTT, 10 µg/ml leupeptin, 1 µg/ml 
aprotinin, 10 mM PMSF, 10 mM NaF, 1 mM 
Na3VO4        
SDS-PAGE running buffer (10x) 250 mM Tris-base, 1.92 M Glycine, 1% w/v 
SDS 
SDS-PAGE transfer buffer (10x) 250 mM Tris-base, 1.92 M Glycine. 
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TBS-Tween 25 mM Tris-HCl pH 7.6, 50 mM NaCl, 0.1% 
v/v Tween 20 
Table 2-2 Buffers 
 
 
2.1.3  Antibodies 
 
Antibody Species Company Dilution for IF Dilution for WB 
β-actin Mouse Sigma-Aldrich - 1:5000 





Filamin-A Rabbit Genetex - 1:1000 





IQGAP3 Mouse Abnova - 1:500 
IQGAP3 Rabbit Sigma-Aldrich 1:50 1:500 
Phospho – 
myosin light 





c-myc (9E10) Mouse Santa-Cruz 1:50 1:1000 








Antibody Species Company Dilution for IF Dilution for WB 
Alexa Fluor®488  
anti-mouse 
Goat Invitrogen 1:400 - 
Alexa Fluor®488  
anti-rabbit 
Goat Invitrogen 1:400 - 
Alexa Fluor®568 
anti-rabbit 
Goat Invitrogen 1:400 - 
Alexa Fluor®647  
anti-mouse 




 Invitrogen 1:1000  
Alexa Fluor® 
488 Phalloidin 




 Santa Cruz 1:300  
HRP conjugated 
anti-mouse 
Goat DAKO  1:2000 
HRP conjugated 
anti-rabbit 
Goat DAKO  1:2000 
Table 2-4 Secondary antibodies and Phalloidin stains 
 
2.1.4 Oligonucleotide sequences 
Primer 5’-3’ sequence 
IQGAP3 Forward ATGGAGTGCTGCTGGCCAAG 
AttB2 Reverse TTGTACAAGAAAGCTGGG 
Table 2-5 Sequencing primers 
 
siRNA 5’-3’ sequence Company 
Negative control (non-
silencing) 
AAUUCUCCGAACGUGUCACGU Qiagen, UK 
Silencer Select (s43270) 
IQGAP3 siRNA (oligo 1) 












pcDNA-DEST47 GFP vector Kind gift from Sans-Moreno lab, King’s 
College London, UK 
ORFEXPRESS™-Shuttle Clone GC-E2954-
CF IQGAP3 entry vector 
Genecopoeia, USA 
pDESTTM  HA vector Invitrogen, UK 
IQGAP3-GFP Generated by author 
IQGAP3-HA Generated by author 
IQGAP1-GFP Claire Wells lab, King’s College London, UK 
IQGAP2-myc Kind gift from Professor David Sacks, NIH 
GFP alone  Claire Wells lab, King’s College London, UK 
PAK1-myc Claire Wells lab, King’s College London, UK 
PAK6-myc Claire Wells lab, King’s College London, UK 
PAK6-GFP Claire Wells lab, King’s College London, UK 





2.2.1 Generation of tagged IQGAP3 expression constructs 
In order to make tagged IQGAP3 expression constructs, the GatewayTM Technology system was 
employed. To create GFP and HA tagged IQGAP3 constructs the IQGAP3 entry clone was 
transferred into the pcDNA-DEST47 GFP vector and pDESTTM  HA vector respectively using the 
LR reaction. The entry clone was mixed with the respective destination vector and TE buffer and 
2μl of LR Clonase enzyme II mix was added to each mix. The reactions were then incubated at 
25°C for 1h. To terminate the reactions, 1 μl of Proteinase K was added and the mix was 
incubated at 37°C for 10 min. Each reaction was then used to transform chemically competent E. 
coli cells. 
 
2.2.2 Transformation of Escherichia coli cells 
NEB®-10 beta E.coli cells normally stored at -80°C were thawed on ice. 1 μl of the LR reaction 
mix or plasmid DNA was then added to the cells, without vigorous pipetting.  The mixtures were 
then put on ice for 30 minutes. Bacteria were then transformed by heat shock. Tubes containing 
the bacteria and DNA were incubated at 42°C for 30 seconds and were then returned to ice for 
another 2 minutes. 500 μl of LB-broth were added to the transformed E.coli cells which were then 
shaken at 37°C for 1 hour at 225rpm. 100μl of the transformed bacteria were then spread onto 
LB-agar plates containing the appropriate antibiotic. Plates were then placed inverted in an 
incubator set at 37°C overnight. On the following day 3 colonies were picked and grown in LB 
broth supplemented with the appropriate selection antibiotic. A small fraction of the yielded culture 
was used to make a glycerol stock while the rest was used for DNA purification. 
 
2.2.3 DNA plasmid purification 
Plasmid DNA was isolated and purified from the grown E.coli cultures using the Invitrogen 
Purelink® HiPure Plasmid Filter Maxi-prep kit according to the manufacturers’ protocol. The 
purified DNA was resuspended in TE buffer and the yielded DNA concentration was determined 
in ng/μl using a Nano-drop system. The newly made IQGAP3 expression constructs were 
sequenced by Europhin MWG Operon using an IQGAP3 forward primer and a reverse primer 





2.2.4 Culture of human cell lines 
Human breast cancer MDA-MB-231 cells and Human Embryonic Kidney HEK293 cells were 
obtained from Claire Wells, King’s College London and were grown in Dulbecco’s modified 
Eagle’s media (DMEM) supplemented with 10% v/v FBS and 1 mM penicillin-streptomycin. 
Human breast cancer cell lines HCC38, HCC1937 and HCC1143, MDA-MB-436 and MCF10A 
were obtained from the Breast Cancer Now Unit of King’s College London. The HCC38, HCC1143 
and HCC1937 cells were grown in Roswell Park Memorial Institute-1640 (RPMI-1640) media 
supplemented with 10% v/v FBS and 1 mM penicillin-streptomycin. The MDA-MB-436 cells were 
grown in RPMI-1640 supplemented with 10% v/v FBS, 1 mM penicillin-streptomycin, 10μg/ml 
human insulin and 16μg/ml Glutathione. The MCF10A cells were grown in DMEM/F12 
supplemented with 5% FBS, 1mM penicillin-streptomycin 20μg/ml EGF, 800ng/ml 
hydrocortisone, 100ng/ml cholera toxin and 20μg/ml insulin. The BT-549 cells were obtained from 
Dr Phillippe Chavrier, Centre de Recherche Institut Curie and were grown in RPMI supplemented 
with 10% v/v FBS and 1 mM penicillin-streptomycin and 10μg/ml human insulin. All cell lines were 
maintained at 37°C in a humidified tissue culture incubator with 5% of atmospheric CO2. Cells 
were passaged before confluency was reached. In order to passage cells, growth media were 
aspirated and cells were washed with Phosphate Buffered Saline (PBS). Cells were detached by 
incubating them with trypsin/EDTA for 5 min at 37°C. Following detachment, trypsin was 
deactivated by adding equal volumes of growth media and cells were pelleted by centrifugation 
at 1200 rpm for 5 minutes. The cell pellet was then resuspended in appropriate volumes and 
seeded in flasks or dishes at appropriate dilutions.   
 
2.2.5 Freezing down and thawing out cells  
In order to freeze cells down, cells were subjected to normal passaging but instead of re-
suspending them in growth media, cells were split in cryovials containing 90% FBS, 10% DMSO 
solution. Sealed cryovials were then placed in a cryo-freezing container at -80°C to ensure 
freezing at a slow rate. Cells were later stored in a liquid nitrogen tank for long-term storage.  
In order to thaw cells out, the cryovials were removed from liquid nitrogen and were thawed in a 
37°C water bath. Growth media were added in the cell suspension to dilute the DMSO even 
further followed by a 5min centrifugation at 1200 rpm. Cells were then resuspended in fresh 




2.2.6 Acid or ethanol treatment of coverslips 
For immunofluorescent staining experiments, 13 mm diameter round glass coverslips were 
submerged in a solution of 60% 1 M hydrochloric acid (HCl) and 40% of 70% ethanol. On the next 
day the mixture was discarded before dH2O was added and boiled. The coverslips were then 
rinsed six times with fresh dH2O and placed on paper to dry followed by being autoclaved. 
For the invadopodia assay, coverslips were placed in petri dishes avoiding overlap and scratches. 
Coverslips were rocked in 70% ethanol for 30 min and then in 96% ethanol for further 30 min. 
Coverslips were then left to dry in the tissue culture hood and petri dishes were sealed with 
parafilm.  
 
2.2.7 Fibronectin coating of cell plates or glass coverslips 
Human fibronectin solution was diluted at a 10μg/ml concentration and added to the desired 
container at appropriate volumes followed by a 30 min incubation at 37°C. The fibronectin solution 
was then washed out twice with PBS followed by seeding the cells onto the coated surface. 
 
2.2.8 Cell proliferation Assay 
Cells were seeded in 96 well plates coated with fibronectin at a cell density of 1000 cells/ml in 
growth media. On the day of the assay and following two PBS washes, 50μl of methyl 
thiazolyldiphenyl tetrazolium bromide (MTT) diluted in serum free media (0.5mg/ml) were added 
to the cells and the plates were incubated at 37°C for 3 hours. The MTT was then aspirated and 
replaced with equal volumes of DMSO.  The 540 nm absorbance was measured using an Alpha-
fusion plate reader. Three technical replicates were included for each condition. The proliferation 





2.2.9 Transient transfection with the Lipofectamine 2000 reagent 
MDA-MB-231 and BT-549 cells were seeded at 105 cells/ml and incubated overnight. On the 
following day, growth media were replaced with fresh media without antibiotics. The following 




2cm tissue culture plate 
(2ml) 
10cm tissue culture plate    
(10 ml) 
Tube A 
3μl of lipofectamine 200 
100μl of OptiMEM media 
15μl of lipofectamine 200 
500μl of OptiMEM media 
Tube B 
3μg of DNA  
100μl of OptiMEM media  
15μg of DNA  
500μl of OptiMEM media 
Table 2-8 Lipofectamine 2000 transfection reaction mix. 
 
After 5 minutes at room temperature, tube A mixture was added to tube B and were left to incubate 
for further 15 min at room temperature prior to being added to the cells. Cells were incubated with 
the transfection mix overnight. Subsequent experiments followed the following day or cells were 
left to recover with fresh media for another 24h.  
 
2.2.10 Transient transfection with the Calcium Phosphate kit 
HEK-293 cells were seeded at a 105 cells/ml density and were incubated overnight at 37°C. On 
the following day, media were changed 4 hours before transfection. Transfection mixes were 
prepared as described below:  
 2 cm culture dish (2ml) 10 cm culture dish (10ml) 
Tube A 
6μl of 2.5M CaCl2 
4μg DNA 
Make up to 60μl with sterile 
water 
30μl of 2.5M CaCl2 
20μg DNA 
Make up to 300μl with sterile 
water 
Tube B 
60 μl 2x Hepes buffered 
saline 
300μl 2x Hepes buffered 
saline 
Table 2-9 Calcium Phosphate kit transfection reaction mix. 
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Following the preparation of the reaction mix, contents of tube A were slowly added to tube B with 
aeration and left for 30 min at room temperature. The mixture was added to the cells drop-wise 
and cells were incubated overnight at 37°C. On the following day, cells were replenished with 
fresh media and were left for another 24 hours to recover.  
 
2.2.11 Transient transfection with the Hiperfect reagent 
Cells were seeded at 2x104 cells/ml and were incubated overnight at 37°C. On the day of 
transfection, media were changed and 3μl of 20μM siRNA were added to 97μl optiMEM along 
with 10μl of the hiperfect reagent. The mixture was left for 15 min at room temperature before 
being added drop-wise to the cells resulting in a 30nM working siRNA concentration (table 2-6). 
Cells were then incubated for appropriate time periods. Optimal IQGAP3 knockdown was 
achieved between 72h and 96h post transfection.  
 
2.2.12 Lysophosphatidic Acid (LPA) treatment of cells 
LPA sodium salt was dissolved in 0.1% fatty acid free BSA:PBS to achieve a 5mM stock solution. 
The mixture was placed in a water bath at 37°C for 1h in order for the LPA to be fully dissolved. 
The solution was then stored at 4°C. Prior to LPA treatment, cells were replenished with fresh 
growth media. The LPA stock solution was also put on the roller and brought to room temperature. 
4μl of stock solution were added in each well to achieve a 10μM working solution. Cells were 
incubated with LPA for 30 min. A control well was included which was treated with 4μl of 0.1% 
fatty acid free BSA:PBS alone. Following incubation cells were washed with PBS and immediately 
fixed with 4% PFA.  
 
2.2.13 Immunofluorescence 
All immunofluorescent staining experiments were performed on cells seeded at appropriate 
density on fibronectin coated coverslips. On the day of immunofluorescent labelling, cells were 
washed 3 times with PBS and fixed with 4% PFA for 20 min. Following another 3 PBS washes, 
cells were permeabilised with 0.2% X-triton to break the cell membranes for 5 minutes. Following 
another 3 washes, coverslips were blocked with 5% FBS for 30 min and 3% BSA:PBS for another 
30 min. Cells were then incubated with the primary antibody appropriately diluted in 3% BSA:PBS 
for 2 hours in the dark (table 2-3).  Once again, cells were washed 3 times with PBS. Secondary 
antibodies along with Phalloidin and DAPI were diluted appropriately in 3% BSA:PBS. Cells were 
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then incubated with the prepared mixture for 1h in the dark (table 2-4). Coverslips were then 
washed twice in PBS and once in ddH2O before being mounted on glass slides with the Fluorsave 
reagent. Coverslips were left in room temperature overnight and then stored at 4°C in the dark. 
Cells were imaged on an Olympus IX71 microscope using Image ProPlus AMS software. 
 
2.2.14 Image processing and cell shape analysis 
Cell images were loaded on ImageJ where cells were manually drawn around to determine the 
cell shape. Shape descriptive parameters such as cell area and relative circularity were obtained 
for each cell. A circularity value of 1 indicates a perfect circle. Cell elongation was evaluated by 
the relative elongation parameter which was calculated by subtracting the circularity value from 
1. 90 cells over 3 independent experiments were included in shape analyses.  
 
2.2.15 Proximity ligation assay (PLA) 
The proximity ligation assay was performed using the Duolink® In Situ Detection Reagents Red 
based on the manufacturer’s protocol. BT-549 cells over-expressing IQGAP3-HA alone or 
IQGAP3-HA together with PAK6-myc or PAK1-myc were used in this assay to assess the 
interaction between IQGAP3 and PAK1 as well as IQGAP3 and PAK6. The procedure of 
fluorescent staining was followed as normal up until the incubation with the primary antibodies; in 
this case all conditions were probed for IQGAP3 and myc with primary antibodies raised in rabbit 
and mouse respectively as the PLA protocol requires the use of antibodies of opposite species. 
After the incubation with the primary antibodies, cells were then washed twice with buffer A 
provided with kit. From then on, 60 μl open droplet reactions were used. All incubations were 
performed in a dark and well humidified environment at 37°C. Plus and Minus PLA probes were 
diluted 1:5 in 3% BSA:PBS-Tween and were allowed to mix for 20 min at room temperature. 
Mixtures were added onto cells and incubated for 1h followed by another two washes with buffer 
A. Ligase was then diluted by 1:40 in ligation stock and added onto cells for 30 min. Ligation 
events were then amplified by adding polymerase diluted by 1:80 in amplification stock for 1 hour 
and 40 min. Cells were then washed twice with buffer B and twice with 0.01% buffer B. Cells were 
then subsequently stained with phalloidin 488 for 1h, washed twice with PBS, once with ddH2O 
and then left to dry. Coverslips were then inverted on mounting medium with DAPI and sealed 
with nail polish. After 10 min coverslips were stored at -20°C. In parallel to the PLA assay 
conventional immunofluorescent staining using secondary antibodies was also performed to 
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determine transfection efficiencies of IQGAP3-HA and myc tagged PAK1 and PAK6. The PLA 
signal of imaged cells was quantified using the particle analysis plugin of ImageJ. The cell area 
of each cell was also obtained and a ratio of PLA signal over cell area was calculated for each 
cell. 
 
2.2.16 Preparation of TRITC conjugated gelatin 
Gelatin was dissolved in 61 mM NaCl and 50 mM sodium borohydrite; pH was set at 9.3 and the 
mix was incubated for one hour at 37°C.  1.8mg rhodamine was then added to the gelatin and 
was mixed by rolling for 4 h in the dark at room temperature. The rhodamine-conjugated gelatin 
(TRITC-gelatin) was then filtered through a 0.45 μm filter and injected into a dialysis cassette and 
left to dialyse against PBS for 3 days with frequent changes of PBS. Dialysed TRITC-gelatin was 
then spun down at 4000 rpm for 2 min before mixing it with 1 g sucrose by rolling. 1ml aliquots 
were stored at 4°C in the dark. 
 
2.2.17 Invadopodia assay 
While working in the dark, ethanol-washed coverslips were then coated with 200μl of TRITC-
gelatin solution and incubated for 10 min at room temperature. Coverslips were then fixed with 
0.5% glutaraldehyde for 15 min before being washed with PBS. The coverslips were then 
quenched with 5 mg/ml of sodium borohydride in PBS for 3 min followed by 3 PBS washes. The 
TRITC-gelatin coated coverslips were then sterilised in 70% ethanol, left to dry and then incubated 
with DMEM for 1 h at 37°C. Cells to be tested on the invadopodia assay were dissociated with 
cell dissociation buffer before seeding them at 2×104 cells in 1 ml on each TRITC-gelatin coated 
coverslips. Cells were then incubated for appropriate time periods at 37°C and fixed with 4% PFA. 
Staining was performed as described above with Phalloidin 488 so that the actin cytoskeleton 
fluoresces green against the red gelatin. 150 cells over 3 independent experiments were imaged 
to determine % of cells with invadopodia capacity.  
 
2.2.18 Random 2D migration assay 
Cells were seeded at appropriate density on 10μg/ml coated wells of a 6 well plate. On the day 
of imaging, growth media were replaced with 3 ml of fresh media along with 60μl of HEPES buffer. 
The plates were sealed and imaged under the Olympus IX71 microscope using Image Pro Plus 
AMS software at 37°C. Cell images were taken every 5 min for 16 hours. Files were extracted, 
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saved as AVI and then loaded on the Manual tracking plugin of ImageJ to obtain the X and Y 
coordinates of each frame. Analysis was then performed on Mathematica using the Chemotaxis 
6.0 notebooks developed in-house by Graham Dunn and Gareth E. Jones. At least 30 cells were 
tracked and analysed over 3 independent experiments. 
 
2.2.19 Preparation of cell lysates 
In order to check for protein expression, cell lysates were prepared preferably when cells reached 
approximately 80% confluency.  Cells were washed twice with PBS followed by adding 2x gel 
sample buffer in appropriate volumes according to the size of the plate. Cells were then scraped 
off and pipetted into Eppendorf tubes. Lysates were then boiled for 5min and stored at -20°C. 
 
2.2.20 Immunoprecipitation using the GFP trap 
Cells were washed with ice cold PBS and scraped into Eppendorf tubes. The tubes were then 
centrifuged at 300x g for 3 minutes at 4°C followed by another 2 washes with ice cold PBS. Cells 
were then resuspended in GFP trap lysis buffer (table 2-2) containing the protease inhibitor 
cocktail. In the case of assessing interactions of over-expressed IQGAP3-GFP in HEK-293 cells, 
cell conditions were lysed in half the volume of lysis buffer and were subsequently mixed together. 
Lysates were left on ice for 30 min, mixing them every 10 min. In the meantime, the GFP trap 
beads were equilibrated by washing them 3 times with the GFP trap wash buffer (table 2-2). 
Lysates were then centrifuged at 20,000 x g for 10 minutes at 4°C and their supernatants were 
mixed with the beads and placed on the rotor for 1h at 4°C. A small fraction of each lysate was 
kept to check for protein expression. Following rotation, the beads along with the trapped proteins 
were washed 3 times with the GFP wash buffer. 2x sample buffer was added to the washed beads 
and the beads were boiled for 10 min.  
 
2.2.21 Gel electrophoresis and immunoblotting 
Samples were boiled again prior to being subjected to gel electrophoresis. Lysates were loaded 
on 6.5%-12.5% gels and proteins were separated by sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) at 125V for 1.5h in 1x running buffer. Proteins were then blotted 
onto nitrocellulose membrane for 1-2 hours at 100V in 1x transfer buffer (table 2-2). Blots were 
then blocked in TBST with either 5% w/v non-fat milk powder, or 5% w/v BSA for 1 hour at room 
temperature. Blocked membranes were then rolled overnight at 4°C in primary antibody diluted 
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appropriately in the same blocking solution (table 2.3). Membranes were then washed 3 times for 
10 min in TBST to wash off unbound primary antibody. Membranes were then rolled in appropriate 
dilution of secondary antibody in the appropriate blocking solution for 1h at room temperature 
(table 2.4). Following that, membranes were washed in TBST as before and probed proteins were 
visualised using the Pierce enhance chemiluminscence (ECL) kit. 
 
2.2.22 Stripping of nitrocellulose membranes 
In cases where re-probing of membranes was required, membranes were rocked in mild stripping 
buffer twice for 15 min each time (table 2-2). Membranes were subsequently washed with PBS 
for 5 minutes and were ready to be blocked and re-probed with the appropriate primary antibody 
as described above. 
 
2.2.23 Densitometry 
Densitometric analysis of protein bands was performed on ImageJ where each band was 
attributed a mean grey value according to its intensity. These values were normalised to the 
background noise as well as the loading control used in each experiment. In some experiments, 
values were also made relative to the control condition.  
 
2.2.24 Statistical analysis 
Statistical analysis was performed where it was required always using datasets generated from 3 
independent experiments. Analysis involved one-way Analysis of Variance (ANOVA) followed by 
Tukey’s post hoc testing or unpaired t-tests based on the experimental conditions. Statistical 
analysis was reached when P≤0.05. One star (*) indicates a P value ≤0.05, (**) indicate a P value 







Characterisation of triple negative 
breast cancer cell lines.  
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Chapter 3 : Characterisation of triple negative breast cancer cell 
lines 
3.1 Introduction 
This project originated from a tissue micro-array where mRNA levels of IQGAP3 (a scaffold 
protein involved in cytoskeletal dynamics) were found to be upregulated in triple negative tumours 
compared to other types of breast cancer and normal tissue (de Rinaldis et al., 2013), (figure 
1.6). The aggressive behaviour exhibited by triple negative tumours is largely attributed to their 
invasive and metastatic capacity (Anders and Carey, 2009). Tumour cells undergo extensive 
cytoskeletal rearrangements including changes in cell adhesion and polarity in order to become 
motile (Thompson et al., 2005). Consequently, cell morphology and cell migration are features 
that have been extensively studied in the context of cancer cell metastasis and will also be 
carefully considered in this chapter.  
The invasive behaviour of triple negative tumours (Liedtke et al., 2008)  led us to hypothesise that 
increased expression of IQGAP3 might be contributing to triple negative breast cancer cell motility 
and invasion. IQGAP3 is the third and most recently discovered member of the IQGAP family of 
scaffold proteins which are all involved in cytoskeletal dynamics by interacting with Rac1 and 
Cdc42 as well as the actin cytoskeleton (White et al., 2009). Despite their high homology and 
structural similarity, IQGAPs have distinct expression patterns; IQGAP1 appears to be 
ubiquitously expressed while the expression of IQGAP2 and IQGAP3 is much more tissue 
restricted with IQGAP3 primarily being found in the brain, lung, testis and the bowel (White et al., 
2009). Their structural similarity suggests that IQGAPs could have overlapping activity but their 
expression pattern supports the possibility of unique functionality as well.  
IQGAP1 being the first family member to be discovered is also the most extensively characterised 
(Smith et al., 2015). IQGAP1 has a well described role in biological processes such as cell 
migration and adhesion hence it is perhaps not surprising that this particular IQGAP has been 
found to be upregulated in multiple carcinomas (White et al., 2009). For example, IQGAP1 is 
reported to be involved in cell adhesion as the association of IQGAP1 to e-cadherin (which is 
normally antagonised by calmodulin) disrupts cell-cell junctions (Li et al., 1999). It is not known 
whether IQGAP3 plays a similar role in cell adhesion.  
Additionally, IQGAP1 has been reported to localise at the leading cell edge where it promotes 
directional cell migration; IQGAP1 is found in a complex with CLIP-170 and activated Rac1/Cdc42 
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which in turn recruits elongating microtubules towards the leading cell edge of Vero cells 
ultimately implicating IQGAP1 in cell polarisation (Fukata et al., 2001). Furthermore, IQGAP1 is 
also able to bind Phosphatidylinositol 4, 5 bisphosphate (PIP2); this interaction is crucial for the 
subsequent activation of Arp2/3 and the formation of a single leading cell edge (Choi et al., 2013). 
Meanwhile the role of IQGAP3 in cell migration is less well described; although IQGAP3 has also 
been reported to promote clustering of Adenomatous polyposis coli (APC) at the leading cell edge 
where it normally regulates the elongating microtubule network (Caro-Gonzalez et al., 2012).  
Moreover, IQGAP3 but not IQGAP1 induce neurite outgrowth in PC12 cells and axonal elongation 
in primary hippocampal neurons further supporting a role for IQGAP3 in the regulation of the actin 
cytoskeleton (Wang et al., 2007). Furthermore, IQGAP3 was reported to regulate the migration 
and invasion ability of A549 lung cancer cells by interacting with ERK1 upon EGF stimulation 
(Yang et al., 2014). Diminishing IQGAP3 in pancreatic cancer BXPC-3 and SW1990 cells also 
reduced their migration ability (Xu et al., 2016). Interestingly, increased expression of IQGAP3 
was recently reported in metastatic lung adenocarcinomas and was also linked to poor prognosis 
(Wu et al., 2015).  
Invasion is a crucial part of metastasis that allows tumour cells to escape from the primary tumour 
and enter the vasculature which then allows the colonisation of distant organs. Invasion has been 
shown to occur via multiple mechanisms; it can be contractility mediated and matrix degradation 
independent where pulling forces induce the forward movement of the cell in a 3D environment 
(Poincloux et al., 2011; Sahai and Marshall, 2003). Cell invasion can also be mediated via the 
formation of invadopodia (Leong et al., 2014). 
Invadopodia are actin rich protrusions that secrete metalloproteases able to degrade the 
basement membrane (Murphy and Courtneidge, 2011). This mechanism of invasion has been 
shown to be employed by breast cancer cells both in vitro and in vivo (Hashim et al., 2013; Leong 
et al., 2014). It is already known that IQGAP1 binds components of the exocyst complex and 
facilitates the delivery of MT1-MMP to these protrusions (Sakurai-Yageta et al., 2008), but 
whether IQGAP3 contributes to invadopodia activity is unknown.   
In contrast to IQGAP1 and IQGAP3 the function of IQGAP2 appears to be significantly different 
and unique. In fact, IQGAP2 is reported to have tumour suppressor properties as IQGAP2 
deficient mice develop hepatocellular tumours which exhibit increased expression of 
IQGAP1(Schmidt et al., 2008).  Deciphering the functional differences between IQGAP2 and the 
other members of the family in the context of cancer biology is thus perhaps more straightforward.  
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Ultimately, there is sufficient evidence suggesting that IQGAPs can have differential functionality 
despite their high homology (White et al., 2009). Consequently, the investigation of a specific role 






3.2.1 IQGAP expression 
At the beginning of this study priority was given to the establishment of crucial research tools such 
as the validation of a specific IQGAP3 antibody as well as tagged IQGAP genetic constructs. An 
IQGAP1-GFP construct as well as an IQGAP1 antibody was previously validated in our lab (Fram 
et al., 2014). A myc-tagged IQGAP2 construct was acquired to have a complete panel of the 
IQGAP family. A gateway compatible IQGAP3 entry clone was acquired and cloned in GFP and 
HA tagged destination clones. The resulting constructs were validated by sequencing and 
western blotting. In order to achieve good protein levels HEK-293 cells were transfected with 
IQGAP1-GFP, IQGAP2-myc, IQGAP3-GFP and IQGAP3-HA. Cell lysates were probed with anti-
GFP, anti-myc and anti-HA to confirm expression (figure 3.1A). Cell lysates were then probed 
with an IQGAP1 antibody which specifically detected IQGAP1 at 222kDa (195kDa is the expected 
size of IQGAP1 plus 27kDa which is the expected size of GFP) (figure 3.1B). The same lysates 
were then probed with a new commercially available IQGAP3 antibody.  The chosen IQGAP3 
antibody specifically detected IQGAP3-GFP at expected size of 212kDa (185kDa is the expected 




Figure 3.1 IQGAP constructs and antibody validation. HEK-293 cells were transfected with IQGAP1-
GFP, IQGAP2-myc, IQGAP3-GFP and IQGAP3-HA respectively. (A) Cell lysates were probed for GFP c-
myc and HA to confirm successful cloning and achieved transfection. (B) Cell lysates were probed for 
IQGAP1 to confirm IQGAP1 specificity. (C) Cell lysates were probed for IQGAP3 to check for IQGAP3 





3.2.2 IQGAP3 expression in triple negative breast cancer cell lines 
Evidence of IQGAP3 expression in breast cancer cell lines was obtained from a tissue micro-
array measuring IQGAP3 mRNA levels (de Rinaldis et al., 2013).  However, endogenous IQGAP3 
expression across a panel of triple negative breast cancer lines has never been shown before. 
We thus sought to confirm endogenous protein expression of IQGAP3 and IQGAP1 for 
comparison across a panel of triple negative cell lines, considering the different expression 
patterns exhibited by IQGAPs (White et al., 2009).  Probing for IQGAP2 was not performed taking 
into account that IQGAP2 has tumour suppressive properties (Schmidt et al., 2008)  and thus it 
would be unlikely for it to drive triple negative breast cancer metastasis.  The MCF10A cell line 
was included as a near normal representative (Soule et al., 1990).  
Quantification of expression levels revealed that both IQGAP1 and IQGAP3 are expressed across 
the chosen cell line panel (figures 3.2, 3.3). Interestingly, IQGAP3 levels are higher in the MB-
231 cell line compared to those observed in the near normal MCF10A cells (Soule et al., 1990), 
(figure 3.2B). Additionally, apart from the HCC38 cells that exhibited the lowest IQGAP3 levels 
across the panel, the remaining triple negative lines trended towards having a higher IQGAP3 
expression than the MCF10A cell line (figure 3.2B).  
Interestingly, IQGAP1 expression does not appear to follow the same trend across the cell line 
panel (figure 3.3). In fact, no triple negative cell line was observed to have higher levels of 
IQGAP1 compared to the MCF10A cells.  
Moreover, MB-231 cells, which had higher levels of IQGAP3 compared to MCF10A cells, are an 
established model for invasion studies (Holliday and Speirs, 2011). To further explore IQGAP3 
expression in triple negative breast cancer, we compared MB-231, MCF10A and another line 
known to be used in invasion studies and particularly invadopodia assays; the BT-549 cell line 
(Monteiro et al., 2013; Moshfegh et al., 2015; Yamaguchi et al., 2011). Indeed, IQGAP3 






Figure 3.2 IQGAP3 expression in triple negative breast cancer cell lines. (A) Cell lysates of a panel of 
triple negative lines including the near normal representative MCF10A cell line were probed for IQGAP3 
(Abnova, 185kDa). β-tubulin was used as a loading control (52kDa). (B) Expression levels were quantified 
by densitometric analysis on ImageJ and normalised against the loading control and background noise.  Bars 





Figure 3.3 IQGAP1 expression in triple negative breast cancer cell lines. (A) Cell lysates of a panel of 
triple negative lines including the near normal representative MCF10A cell line were probed for IQGAP1 
(195kDa). β-tubulin was used as a loading control (52kDa). (B) Expression levels were quantified by 
densitometric analysis on ImageJ and normalised against the loading control and background noise. Bars 





Figure 3.4 IQGAP3 expression. (A) Cell lysates of MCF10A, MB-231 and BT-549 cells were probed for 
IQGAP3 (Sigma, 185kDa). β-actin was used as a loading control (42kDa). (B) Expression levels were 
quantified by densitometric analysis on ImageJ and normalised against the loading control and background 






From the cell panel tested for IQGAP expression, the MB-231, BT-549, MB-436 and HCC38 were 
chosen to be further characterised in culture. This shortlisting of cell lines was decided based on 
reviewing published cell motility studies using triple negative cell lines, the observed IQGAP3 
expression levels as well as personal communications advising on ease of cell culture. The 
MCF10A cell line was also cultured as a representative near normal cell line.  
The MB-231, MB-436 and BT-549 cell lines fall under the mesenchymal-like category according 
to the TNBC subtypes classification published by (Lehmann et al., 2011). Interestingly, the 
mesenchymal-like cell lines appear to have increased expression of genes associated with cell 
motility such as the Rho pathway as well as genes associated with EMT (Lehmann et al., 2011). 
The basal-like type cell lines show increased expression of proliferation and DNA response 
associated genes such as the BRCA1 pathway (Lehmann et al., 2011).  
The MB-231 and MB-436 cells are epithelial spindle shaped cells that were derived from pleural 
effusions of patients at M.D. Anderson Hospital and Tumour Institute in 1973 and 1976 
respectively (Cailleau et al., 1978). The BT-549 is also a mesenchymal-like cell line derived from 
an invasive ductal carcinoma in 1978 (Littlewood-Evans et al., 1997).  The HCC38 cell line is of 
epithelial origin and was derived from a primary breast ductal carcinoma in 1992 (Gazdar et al., 
1998). The MCF10A cell line was derived from culturing fibrocystic breast tissue that was 
spontaneously immortalised (Soule et al., 1990). 
The invadopodia making MB-231 cells has traditionally been regarded as an invasive cell line in 
vivo and in vitro which is consistent with the aggressive behaviour of triple negative breast cancer 
(Holliday and Speirs, 2011). The BT-549 cell line also has invadopodia making capacity and has 
also been successfully employed in xenograft studies (Tate et al., 2012). The MB-436 and HCC38 
cells are also considered invasive given their ability to form tumours when injected orthotopically 
in immunocompromised mice (Iorns et al., 2012; Xu et al., 2015). However, MB-436 and HCC38 




3.2.3 Cell morphology 
Cell shape was primarily examined to check for particular morphological phenotypes that have 
been linked to cell invasion (Clark and Vignjevic, 2015). Cancer cells are normally in contact with 
extracellular matrix which involves a crucial part of the tumour microenvironment influencing 
cancer progression and metastasis (Bissell and Hines, 2011). Immunohistochemical analysis on 
primary breast tumour samples has in fact suggested that fibronectin expression correlates with 
poor prognosis and progression free survival (Bae et al., 2013). In order to examine cell 
morphology while trying to retain some aspects of the tumour microenvironment, cells were 
seeded on fibronectin coated glass coverslips and stained with TRITC phalloidin that stains the 
actin filaments as a marker of cell shape. Cell morphology features such as cell area and 
circularity were thus measured. The relative cell elongation parameter was obtained by 






Figure 3.5 Cell morphology. (A) Cells were seeded on fibronectin coated coverslips. Cells were 
subsequently fixed and stained with TRITC Phalloidin (red) indicating the actin cytoskeleton and DAPI (blue) 
indicating the nuclei. Scale bar = 10μm. Cells were imaged and analysis was performed on ImageJ to obtain 
(B) the cell area and (C) elongation index. Analysis was performed on 30 cells per experiment. Bars 





The first observation that was made is that unlike the normal MCF10A cells, all the breast cancer 
cell lines that were evaluated grew as single cells while no colony forming capacity was observed 
(figure 3.5A). The absence of colony forming cells indicates the loss of ability to form cell-cell 
interactions. This is one of the primary characteristics of epithelial to mesenchymal transition 
(EMT) which is accompanied by loss of e-cadherin expression that normally maintains cell-cell 
junctions and tissue integrity (Thiery, 2002). This feature is consistent with the aggressive 
behaviour of triple negative breast cancer.  
The cells were also evaluated in terms of other morphological features such as their area and 
elongation. In terms of their area, this feature varied a lot across the cell panel with the basal-like 
HCC38 cells appearing to have the largest cell area (figure 3.5A, 3.5B). The MB-231 and MB-
436 which also express high levels of IQGAP3 (figure 3.2B) were shown to be the most elongated 
cells consistent with their mesenchymal phenotype (figure 3.5C) but also have small cell area 
(figure 3.5B). Nonetheless, levels of IQGAP3 expression do not appear to strongly correlate with 
a particular morphological feature. 
 
3.2.4 Random 2D migration 
The migratory ability of the triple negative cell line panel was assessed by monitoring random cell 
movement on fibronectin coated plates (figure 3.6). Fibronectin is part of the interstitial ECM and 
influences cell behaviour by interacting with integrins (Huttenlocher and Horwitz, 2011)  so once 
again it was considered to be a suitable matrix for this assay.  
The MB-231 cell line is highly motile and has been widely used in both 2D and 3D migration 
assays (Holliday and Speirs, 2011). However, the migratory ability of the other cell lines chosen 
here has not been as extensively characterised.  
Manual cell tracking and analysis on Mathematica revealed that all cancer cell lines tested were 
highly motile apart from the BT-549 cell line which exhibited lower mean cell speed (figure 3.6). 
Again, levels of IQGAP3 expression did not correlate with cell speed as high IQGAP3 expressing 
MB-231 and MB-436 cells have the same cell speed as low IQGAP3 expressing HCC38 cells 





Figure 3.6 Random 2D migration on fibronectin. (A) Cell migration plots obtained on Mathematica after 
importing manual tracking data from ImageJ. (B) Quantification was performed on Mathematica. Bars 






Formation of invadopodia is considered indicative of invasive potential in vitro and in vivo (Eckert 
et al., 2011; Leong et al., 2014). We sought to examine the invasive potential of our cell lines 
knowing that MB-231 cells are widely used in invadopodia research (Mader et al., 2011) . In order 
to detect invadopodia formation in vitro, cells were seeded on glass coverslips previously coated 
with TRITC-conjugated gelatin. To allow invadopodia formation to occur cells were incubated at 
37°C for 3h and were subsequently fixed with PFA and stained with Phalloidin 488 resulting in 
green stained cells over a red stained matrix (Hashim et al., 2013). Cells were considered able to 
make invadopodia when the actin puncta revealed by the phalloidin stain indicating the protrusive 
structure of invadopodia coincided with black holes in the red gelatin indicating matrix degradation 
(Hashim et al., 2013).  
Out of the 4 cell lines that were subjected to the assay the HCC38 and MB-436 cells did not make 
any invadopodia (figure 3.7). Interestingly, reviewing the literature revealed that there is no 
published evidence of HCC38 or MB-436 cells being used in invadopodia assays. Together, these 
observations suggest that the HCC38 and MB-436 cells do not make invadopodia. As expected, 
the MB-231 cells exhibited definitive evidence of invadopodia formation and activity (figure 3.7A, 
3.7B) which is consistent with their widespread use in invadopodia research. The BT-549 cells 
showed very little evidence of invadopodia presence at the 3h incubation as only a few very small 
invadopodia were detected. This observation suggested that the BT-549 cells might require 
longer incubations on the gelatin matrix to form active invadopodia. Further characterisation of 




















































Figure 3.7 Invadopodia assay at 3h. (A) Cells were seeded on TRITC conjugated gelatin coated coverslips 
and incubated for 3h at 37°C. Coverslips were then fixed and stained with Phalloidin 488 (green) and cells 
were imaged. Scale bar corresponds to 10μm (B) Percentage of cells making invadopodia was determined 
for each individual experiment (N=3). Bars represent the mean percentage of cells making invadopodia and 







3.2.6 Characterisation of invadopodia activity in the BT-549 cells 
Previously published studies have proven the value of BT-549 cells in invadopodia research 
(Yamaguchi et al., 2011). This encouraged us to extend the characterisation of the BT-549 
invadopodia capacity in longer incubations. The BT-549 cells were thus seeded on TRITC-gelatin 
coated coverslips and were fixed after 3, 6, 8 and 24 hours in order to more closely monitor 
invadopodia activity (figure 3.8).  
Longer incubation periods in TRITC gelatin confirmed that the invadopodia making ability of BT-
549 cells is substantially enhanced. In fact, if left for 24 hours post seeding, approximately 43% 
of the population is found positive for degradation competent invadopodia (figure 3.8). However, 
the resulting degradation was found unsuitably extensive covering a large part of the cell area. 
This would render potential degradation analyses difficult to carry out and thus the 24h time-point 
was rejected.  
Meanwhile, the 6 and 8 hours of incubation periods recorded significant presence of mature 
invadopodia with well-defined degradation areas (figure 3.8). This was comparable to the 
invadopodia capacity of MB-231 cells (figure 3.7B) and therefore it was decided that an 
incubation time of 7h for BT-549 cells would be used for all subsequent invadopodia assays in 
the course of this study. 
IQGAP3 expression does not correlate with invadopodia capacity across the triple negative cell 
line panel under characterisation (figure 3.2B, 3.7). Therefore, this particular experiment does 
not provide much insight as to whether IQGAP3 might be implicated in invadopodia dynamics. It 
should however be noted that high IQGAP1 expressing MB-231 cells make invadopodia as 
opposed to low IQGAP1 MB-436 and HCC38 (figure 3.3B, 3.7). This agrees with the well 
described role of IQGAP1 in the delivery of MT1-MMP upon invadopodia mediated matrix 




Figure 3.8 Invadopodia activity in BT-549 cells. (A) BT-549 cells were seeded on TRITC gelatin coated 
coverslips which were fixed after 3, 6, 8 and 24 hours respectively. Coverslips were fixed and stained with 
Phalloidin 488 (green) and cells were imaged. Scale bar corresponds to 10μm (B) Percentage of cells 
making invadopodia was determined for each individual experiment (N=3). Bars represent the mean 








3.2.7 Invadopodia and cell morphology 
The in vitro invadopodia assay performed to assess the cells’ ability to make invadopodia revealed 
that only a fraction of the cell population makes invadopodia. This means that a significant number 
of cells are not invading at any given time-point. Considering the relationship between invasion 
and cell morphology, we sought to characterise the cell shape features in cells exhibiting 
invadopodia compared to cells not exhibiting invadopodia. Morphological analysis revealed that 
both BT-549 and MB-231 cells having invadopodia capacity exhibited greater cell area than cells 
which did not have invadopodia capacity (figures 3.9B, 3.10B). Additionally, BT-549 cells with 
invadopodia were significantly rounder than their non-invasive counterpart (figure 3.9C). The 
same trend was observed in the MB-231 cells; however, it did not reach statistical significance 
perhaps because the MB-231 cells are generally more spindle shaped (figures 3.5C, 3.10C). 
These findings suggest that perhaps a spread and rounder cell morphology is more permissive 








Figure 3.9 Relationship between invadopodia activity and cell morphology in BT-549 cells. (A) BT-
549 cells were seeded on TRITC gelatin and were fixed and stained with Phalloidin 488 7 hours later. Cell 
images were obtained and morphological analysis was performed on 30 cells making invadopodia and 30 
non invadopodia making cells. Scale corresponds to 10μm.  (B) Bar charts show the  cell area and (C) 
elongation measurements. Bars represent the mean values and error bars represent the SEM. Statistical 








Figure 3.10 Relationship between invadopodia activity and cell morphology in MB-231 cells. (A) MB-
231 cells were seeded on TRITC gelatin and were fixed and stained with Phalloidin 488 3 hours later. Cell 
images were obtained and morphological analysis was performed on 30 cells making invadopodia and 30 
non invadopodia making cells. Scale corresponds to 10μm. Bar charts show (B) the  cell area and (C) 
elongation measurements. Bars represent the mean values and error bars represent the SEM.  Statistical 







3.2.8 Cell models 
This study needed cell models baring features consistent with the aggressive behaviour exhibited 
by triple negative breast cancer. From the cell panel that was screened and characterised the 
MB-231 and BT-549 cell lines were deemed to be the most suitable since they were both motile 
and able to make invadopodia indicating an invasive behaviour. Additionally, the MB-231 cells 
trended towards having higher IQGAP3 expression, exhibited higher cell speed and a more 
elongated morphology than the BT-549 cells (figure 3.4). Using two lines that express different 
levels of IQGAP3 while exhibiting different morphological and migrational features was perceived 
as a positive feature for the progress of this project; especially when it comes to experiments 








This chapter outlines the characterisation performed on a panel of triple negative breast cancer 
cell lines in terms of their IQGAP3 expression levels, morphology, random 2D migration and ability 
to make invadopodia. This characterisation was performed in order to choose the most suitable 
lines that would be used as the cell models for future study.  
Having identified a specific IQGAP3 antibody we were able to progress previous mRNA studies 
to protein experiments. Western blotting revealed that IQGAP3 and IQGAP1 are expressed 
across the cell line panel tested including the normal MCF10A cells. Interestingly, IQGAP3 
expression levels tended to be higher across the triple negative lines compared to MCF10A cells 
with the exception of the HCC38 cells (figure 3.2). In contrast to IQGAP3, this trend was not 
observed in the case of IQGAP1 as the near normal MCF10A cells were one of the high IQGAP1 
expressing lines tested (figure 3.3). The expression pattern of IQGAP1 is perhaps not surprising 
as IQGAP1 has previously been reported as ubiquitously expressed across tissues (White et al., 
2009). Nonetheless, the expression trend of IQGAP3 appeared promising and supported the 
hypothesis that IQGAPs can have differential functionality and activity despite their high structural 
similarity (White et al., 2009).  
The triple negative cell lines that were further characterised all grew as single cells. The loss of 
junctions is an integral part of epithelial to mesenchymal transition (EMT) amongst other events 
such as cytoskeletal rearrangements, changes in polarity and upregulation of genes associated 
with the mesenchymal phenotype. These changes are translated into the formation of protrusive 
extensions allowing the acquisition of migratory and invasive capacity which eventually leads to 
the breach of the basement membrane (Lamouille et al., 2014). It is thus not surprising that cell 
lines representing aggressive triple negative tumours would share these traits.  
Morphological characterisation confirmed the mesenchymal phenotype of the MB-231 and MB-
436 cell lines considering they were found to be the most elongated lines. Mesenchymal cells 
have traditionally been regarded as the most aggressive fraction of the cell population found at 
leading edge of the invasive tumour (Kalluri and Weinberg, 2009). In spite of the motile and 
aggressive profile characterising mesenchymal cells, rounded cells can also have the capacity to 
move; the amoeboid movement type is characterised by a rounded morphology with blebs and 
prominent stress fibres as well as a fast and protrusive migration ability and has also been 
associated with breast cancer invasion (Cheung et al., 2013; Friedl and Wolf, 2010). Rho 
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signalling via ROCK drives amoeboid migration by inducing actomyosin contractility (Sahai and 
Marshall, 2003; Sanz-Moreno et al., 2011). In fact, the interplay of Rho and Rac can determine 
whether a cell will adopt a mesenchymal or amoeboid migration thus regulating cell plasticity 
(Sanz-Moreno et al., 2007). According to the Lehmann classification of triple negative breast 
cancer cell lines, MB-231, MB-436 and BT-549 fall into the mesenchymal stem like subtype whose 
genetic signature is enriched with upregulation of known EMT effectors such as components of 
the TGF-β and EGFR signalling pathways (Lehmann et al., 2011a). Interestingly, the very 
elongated MB-231 and MB-436 cells also had high IQGAP3 levels (figures 3.2B, 3.5C). IQGAP3 
has been reported to be associated with directional migration by promoting APC clustering at the 
leading cell edge (Caro-Gonzalez et al., 2012)  so perhaps this could contribute to the observed 
morphology. The role of IQGAP1 in polarity and cell migration is much better described (Choi et 
al., 2013; Fukata et al., 2001; Mataraza et al., 2007) ; however levels of IQGAP1 in MB-436 
appear to be lower than those of the near normal MCF10A but also the aggressive MB-231 cells 
(figure 3.3B). Despite these observations there is no strong correlation of IQGAP expression and 
cell morphology across the cell line panel.   
The study of random 2D migration revealed that all cell lines monitored by time-lapse microscopy 
were highly motile with the exception of BT-549 cells which were also motile but exhibited slower 
mean cell migration (figure 3.6B).  The significantly slower cell speed exhibited by the BT-549 
cells can be explained by potential differences in integrin expression. Along with their slower 
migration the BT-549 cells exhibited a very round morphology (figure 3.5A, 3.5C). Nonetheless, 
neither IQGAP1 nor IQGAP3 expression levels appear to correlate with the measured cell speeds 
across the cell line panel. 
Particular attention has been given to the invadopodia mediated matrix invasion during this study. 
This was encouraged by the fact that the interaction of IQGAP1 with the exocyst complex has 
been shown to be crucial for the presentation of MT1-MMP at invadopodia sites (Sakurai-Yageta 
et al., 2008). Considering the high homology between the IQGAP family members, it was decided 
to consider the potential involvement of IQGAP3 in invadopodia dynamics. Our cell panel was 
thus screened for invadopodia formation ability.  
Consistent with the current literature, only the MB-231 and BT-549 cells (both expressing higher 
levels of IQGAP3 than the MCF10A cells) could form invadopodia. MB-436 and HCC38 perhaps 
employ metalloprotease independent means of invasion as they have both been successfully 
employed in in vitro and in vivo invasion assays (Iida et al., 2012; Thompson et al., 1992). 
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However, the mode of invasion employed by these cell lines is not adequately characterised. 
Interestingly, the HCC38 and MB-436 cells exhibit low levels of IQGAP1 (figure 3.3B) which has 
been reported to be crucial for invadopodia mediated matrix degradation (Sakurai-Yageta et al., 
2008). 
Further analysis of cells making invadopodia showed that invadopodia capacity was associated 
with greater size and a rounder morphology (figures 3.9, 3.10). The relationship between 
morphology and invasion capacity is an ongoing matter of debate as multiple factors can influence 
both (Sahai and Marshall, 2003; Sanz-Moreno et al., 2007). The fact that there is no single 
mechanism of invasion has resulted in the investigation of cell plasticity which describes the ability 
of cancer cells to re-arrange their cytoskeleton and adopt different invasive mechanisms based 
on environmental cues (Friedl and Alexander, 2011). The cross-talk between Rac and Rho has 
been shown to regulate cell plasticity in melanoma and induce the switch between an amoeboid 
to a mesenchymal mode of migration (Sanz-Moreno et al., 2007). Migration of mesenchymal cells 
in 3D matrices is a result of a delicate synergy between adhesion and matrix proteolysis (Friedl 
and Wolf, 2009). In fact, work on HT-1080 fibrosarcoma and MB-231 3D cell migration suggests 
that areas of adhesion and matrix degradation are spatially distinct. Zones of matrix degradation 
were defined by the localisation of MT1-MMP and collagenolysis (Wolf et al., 2007). However, 
these studies did not measure invadopodia activity and thus it is difficult to determine how 
invadopodia are involved in cell migration and plasticity. It should also be noted that mechanisms 
governing migration can differ greatly between a 2D and a 3D environment given the more 
complex interaction with a 3D extracellular matrix (Friedl and Wolf, 2009). Nonetheless, our 
findings suggest that invadopodia capacity in triple negative breast cancer cell lines might be 
associated with cell spreading and hence one could argue that a cross-talk between invadopodia 
and cell adhesion does exist. In favour of this hypothesis are findings suggesting that β1 integrin 
activates tyrosine kinase Arg which in turn phosphorylates cortactin ultimately promoting 
invadopodia maturation (Beaty et al., 2013). However, FAK (a known focal adhesion turnover 




3.4 Future work 
The cell characterisation outlined in this chapter yielded the MB-231 and BT-549 cell lines as the 
most suitable cell models for this study. These cell lines were chosen because they are both 
motile, form mature invadopodia and express IQGAP3. It would be interesting to investigate the 
expression of EMT markers and known genetic traits involved in triple negative breast cancer in 
these cells. It should be noted that large scale studies adopt genetic approaches to identify high 
risk loci or frequently mutated genes (Lehmann et al., 2011). Even though this approach has 
proven to be very beneficial, the observed results are rarely validated at a protein level. This is 
crucial as potential changes observed at the genetic level may not necessarily translate to 
identical results at a protein level. Probing for markers such as p53, PI3K and components of the 
TGFβ signalling pathway such as SMADs and correlating their expression with the IQGAP3 levels 
observed might elucidate further signalling pathways that are active in triple negative breast 
cancer biogenesis.  
The implication of invadopodia activity in triple negative breast cancer invasion could be 
reinforced by correlating the invasive capacity of the cell line panel in an in vitro invasion assay 
such as a trans-well 3D invasion assay.  Further validation can involve subjecting our cell lines of 
interest in an in vivo invasion assay.  The use of zebrafish embryos in invasion assays offers an 
inexpensive, reliable and fast readout of invasion. The assay involves injecting fluorescent cells 
in the yolk sac and monitoring their migration to the embryo tail (Eguiara et al., 2011). This 
migratory ability requires the breach of the yolk sac similarly to distant metastasis demanding the 
breach of the basement membrane. Breast cancer cell lines such as the MCF7 cells have been 
successfully used in this assay (Eguiara et al., 2011). In fact this assay could be used to determine 
the mode of migration employed by MB-436 and HCC38 cells. Therefore, the characterisation of 
the migratory behaviour of triple negative cell lines in this assay could benefit this study, expand 
our knowledge over cancer cell migration in vivo through direct and real-time visualisation and 
reduce the need to use mice.  
Finally, to further investigate the relationship between invadopodia formation and cell spreading 
future experiments could compare focal adhesion formation between invadopodia making and 
non invadopodia making cell populations. This might elucidate potential variations in the focal 






Characterisation of IQGAP3 




Chapter 4 : Characterisation of IQGAP3 depletion and 
overexpression phenotypes 
4.1 Introduction 
The observed high levels of IQGAP3 in MB-231 cells, which are known to be motile and invasive 
(Holliday and Speirs, 2011), prompted further investigation on the role of IQGAP3 in cell motility 
phenotypes. One of the most widely used research strategies in the study of protein function is 
the assessment of defined phenotypes of interest following the modulation of protein expression 
levels. This method has been widely employed in the field of cell motility while examining 
phenotypical readouts such as morphological features as well as migration and invasion capacity. 
Modulating the expression levels of IQGAP1 has delivered a plethora of data on IQGAP1 
functions. The role of IQGAP1 in cell adhesion was further explored when E-cadherin was 
overexpressed in mouse fibroblasts and IQGAP1 was observed to accumulate in cell-cell 
junctions (Li et al., 1999). Over-expressing IQGAP1 in Swiss 3T3 cells revealed that IQGAP1 
localises at the leading cell edge of migrating cells (Mataraza et al., 2003). Additionally, reducing 
IQGAP1 levels by both siRNA and stable retroviral systems in MCF7 cells resulted in reduced cell 
migration through an in vitro transwell system (Mataraza et al., 2003). Moreover, inhibition of 
IQGAP1 expression has also highlighted the importance of IQGAP1 in the directionality of cell 
migration; IQGAP1 is found in a complex with Filamin-A and RacGAP1 which supresses Rac1 
and allows effective directional cell migration (Jacquemet et al., 2013). The importance of the 
IQGAP1 to PIP2 interaction in directional cell migration was also marked in IQGAP1 knockout 
MEFs which were transfected with a mutant IQGAP1 construct deficient of PIP2 binding. 
Disrupting the interaction of IQGAP1 with PIP2 led to a cell morphology characterised by multiple 
cell edges as well as loss of directionality in cell migration (Choi et al., 2013). Furthermore, 
overexpression of IQGAP1 in MB-231 cells revealed that IQGAP1 localises at invadopodia while 
IQGAP1 depletion reduced MT1-MMP accumulation and matrix degradation (Sakurai-Yageta et 
al., 2008). 
Moreover, both overexpression and knockdown of IQGAP1 in MCF7 cells inhibited MEK and ERK 
activation upon EGF stimulation suggesting that the ability of IQGAP1 to act as a scaffold for the 
MAPK cascade is concentration dependent (Roy et al., 2005, 2004). Additionally, B-Raf kinase 
activity was hindered in IQGAP1 knockout MEFs as well as in siRNA mediated IQGAP1 
knockdown 293H cells upon EGF stimulation (Ren et al., 2007). Overall, these studies have 
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marked the necessity of IQGAP1 scaffolding activity in the MAPK signalling cascade by 
modulating expression levels in various systems and by performing elegant immunoprecipitation 
experiments.  
Nonetheless, the role of IQGAP3 is far less extensively described. The study that identified 
IQGAP3 as a novel IQGAP isoform reported that reducing IQGAP3 expression inhibited axonal 
elongation in neuronal cells. Interestingly, axonal elongation was not affected by IQGAP1 
depletion (Wang et al., 2007). Perhaps the most striking finding on IQGAP3 function is that it 
regulates cell proliferation by activating ERK in a Ras dependent manner (Nojima et al., 2008). 
Indeed upon diminishing IQGAP3 expression in Eph4 cells cell proliferation was inhibited, levels 
of phosphorylated ERK were lost and active Ras was depleted. Meanwhile loss of IQGAP1 
expression had no such effect (Nojima et al., 2008).  
The implication of IQGAP3 in cell proliferation may inevitably prove problematic in experimental 
conditions where IQGAP3 expression is long-term inhibited. This becomes apparent in a study 
implicating IQGAP1 and IQGAP3 in normal skin homeostasis as well as squamous cell carcinoma 
tumourigenesis. In this study stable knockdown systems of different IQGAP levels are employed. 
Partial IQGAP3 depletion had no effect in primary keratinocyte proliferation, levels of 
phosphorylated ERK and levels of cyclin D1 while a near complete knockdown dramatically 
diminished all these features (Monteleon et al., 2015). From this study it can also be deduced that 
a very robust knockdown of IQGAP may be required to elicit phenotypical changes. 
Furthermore, both IQGAP1 and IQGAP3 are reported to be implicated in cytokinesis as loss of 
either family member resulted in binucleated Hela cells (Adachi et al., 2014). Both IQGAPs are 
thought to regulate localisation of RhoA at the cleavage furrow. However, only IQGAP3 was 
shown to directly bind anillin and thus IQGAP3 was reported as the principal IQGAP to regulate 
RhoA localisation via anillin (Adachi et al., 2014). Nonetheless, the effect of IQGAP1 depletion in 
RhoA localisation was also prominent but was thought to be independent of anillin (Adachi et al., 
2014). Consequently, IQGAP1 and IQGAP3 appear to work closely but still exhibit fine differences 
in functionality even in tightly regulated processes such as cytokinesis.  
Furthermore, even though there are some reports implicating IQGAP3 in cancer cell motility by 
diminishing IQGAP3 in A549 lung cancer cells (Yang et al., 2014) and BXPC-3 and SW1990 
pancreatic cancer cells (Xu et al., 2016), the available data is limited and the mechanism involved 
in largely unknown. 
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This chapter explores cellular phenotypes following modulation of IQGAP3 expression to identify 
possible molecular mechanisms through which IQGAP3 might promote triple negative breast 





4.2.1 Knockdown of IQGAP3 expression 
In order to investigate the effect of reducing IQGAP3 expression on our phenotypes of interest, 
siRNA sequences that can effectively diminish IQGAP3 expression were validated. Two 
oligonucleotides were tested along with a negative siRNA control and a wild-type untransfected 
control by western blotting. Almost complete IQGAP3 depletion was achieved at 72 hours (3 days) 
post transfection and was maintained at 96h (4 days) by both oligonucleotides tested in MB-231 
and BT-549 cells (figures 4.1, 4.2). As a result, assays investigating the effects of loss of IQGAP3 






Figure 4.1 IQGAP3 knockdown in MB-231 cells. MB-231 cells were transfected with 2 siRNA 
oligonucleotides. A negative siRNA control as well as a wild-type sample were included in the assay. (A) 
Representative blot indicating diminished IQGAP3 expression conferred by both oligonucleotides tested 72h 
post transfection. β-actin was used as a loading control (N=3). (B) Representative blot indicating diminished 
IQGAP3 expression conferred by both oligonucleotides tested 96h post transfection. β-actin was used as a 








Figure 4.2 IQGAP3 knockdown in BT-549 cells. BT-549 cells were transfected with 2 siRNA 
oligonucleotides. A negative siRNA control as well as a wild-type sample were included in the assay. (A) 
Representative blot indicating diminished IQGAP3 expression conferred by both oligonucleotides tested 72h 
post transfection. β-actin was used as a loading control (N=3). (B) Representative blot indicating diminished 
IQGAP3 expression conferred by both oligonucleotides tested 96h post transfection. β-actin was used as a 








4.2.2 Cell proliferation of IQGAP3 knockdown cells 
After establishing two siRNA sequences that can effectively diminish IQGAP3 expression the 
effect of IQGAP3 depletion was assessed in cell proliferation; given that IQGAP3 has been 
reported to regulate this cellular process (Nojima et al., 2008). MTT assays were performed 2, 3 
and 5 days post transfection and revealed that both oligonucleotides conferred a statistically 
significant reduction in cell proliferation in both MB-231 and BT-549 cells. This is consistent with 
previous studies reporting reduced proliferation in lung cancer, pancreatic cancer and her2 
positive breast cancer cell lines (Hu et al., 2016.; Xu et al., 2016; Yang et al., 2014).  The effect 
of IQGAP3 depletion in cell proliferation could potentially skew the analysis of migration and 
invasion experiments. Hence, the assays that were chosen to further this study were designed so 






Figure 4.3 Cell proliferation in IQGAP3 depleted cells. (A) IQGAP3 knockdown cells as well as negative 
control and wild-type (A) MB-231 and (B) BT-549cells were subjected to an MTT assay 2, 3 and 5 days post 
transfection. Bars represent the mean absorbance values and error bars represent the SEM. Statistical 
analysis was performed using one way ANOVA followed by Tukey’s post hoc testing. Comparisons between 
knockdown conditions and the negative control are indicated on the graph, (**) = p ≤ 0.01, (***) = p ≤ 0.001. 
There was no significant difference between the WT and the negative control conditions apart from Day 5 





4.2.3 Cell morphology of IQGAP3 knockdown cells 
Cell plasticity refers to the ability of cancer cell to alter their morphology and migrational properties 
depending on environmental cues of the tumour microenvironment (Friedl and Wolf, 2010). In 
fact, results on chapter 3 report that cells exhibiting invadopodia capacity are more rounded than 
the non-invasive population (figure 3.9). Potential changes in the morphology of triple negative 
breast cancer cells following IQGAP3 depletion could thus infer changes in their migratory and 
invasive ability. IQGAP3 depleted MB-231 and BT-549 cells were seeded on fibronectin coated 
coverslips. WT and cells transfected with negative siRNA control were included in the experiment. 
Cells were subsequently fixed and stained with TRITC phalloidin to mark the actin cytoskeleton 
96h post transfection. Morphological analysis revealed that both oligonucleotides used to reduce 
IQGAP3 expression induced a hyper-elongated phenotype which was observed in both cell lines 
(figures 4.4, 4.5). The altered morphology following IQGAP3 depletion was thought to be 
accompanied by changes in the migratory ability of the affected cells considering the innate 





Figure 4.4 Morphology of IQGAP3 depleted MB-231 cells. (A) IQGAP3 knockdown and control MB-231 
cells were seeded on fibronectin coated coverslips and were fixed 96h post transfection. Cells were then 
stained with TRITC phalloidin and DAPI. Imaged cells were subjected to morphological analysis on ImageJ. 
The scale bar corresponds to 10μm (B) Graphical representation indicating the elongation index of control 
and IQGAP3 knockdown cells. Bars represent the mean elongation values and error bars represent the 
SEM. Statistical analysis involved one way ANOVA followed by Tukey’s post hoc testing. Comparisons 
between knockdown conditions and the negative control are indicated on the graph, (***) = p ≤ 0.001. There 





Figure 4.5 Morphology of IQGAP3 depleted BT-549 cells. (A) IQGAP3 knockdown and control BT-549 
cells were seeded on fibronectin coated coverslips and were fixed 96h post transfection. Cells were then 
stained with TRITC phalloidin and DAPI. Imaged cells were subjected to morphological analysis on ImageJ. 
The scale bar corresponds to 10μm (B) Graphical representation indicating the elongation index of control 
and IQGAP3 knockdown cells. Bars represent the mean elongation values and error bars represent the 
SEM.  Statistical analysis involved one way ANOVA followed by Tukey’s post hoc testing. Comparisons 
between the knockdown conditions and the negative control are shown on the graph, (***) = p ≤ 0.001. There 




4.2.4 Random 2D migration of IQGAP3 knockdown cells 
Having established that IQGAP3 knockdown induces an elongated phenotype in both MB-231 
and BT-549 cells, (figures 4.4, 4.5) the ability of these cells to move on fibronectin was assessed. 
This approach also provided the opportunity to further examine the source of the observed 
elongated phenotype; whether it is a result of loss of tail retraction or over-extension of the leading 
edge. Control and knockdown cells seeded on fibronectin coated plates were monitored by time-
lapse microscopy for up to 16 hours. The imaging experiment was performed within the time 
window where IQGAP3 knockdown is most efficient which is between 72 and 96 hours post 
transfection (figures 4.1, 4.2). Notably, the chosen migration assay is not impacted by changes 
in proliferation rate induced by IQGAP3 depletion (figure 4.3). Imaged cells were manually 
tracked on ImageJ and mean cell speed as well as statistical analysis were obtained in 
Mathematica Notebooks written by Professor Graham Dunn (Whale et al., 2012). Analysis 
showed that mean cell speed was significantly reduced in knockdown conditions compared to 
control in both MB-231 and BT-549 cells (figures 4.6, 4.7). Additionally, it was observed that 
IQGAP3 depleted cells were either unable to retract their tail and move forward or extended 
protrusions towards opposing directions ultimately restricting their total displacement. Reduced 
migration ability upon IQGAP3 depletion has been shown in lung cancer and pancreatic cancer 
cells (Xu et al., 2016; Yang et al., 2014). However, a significant morphological change alongside 
reduced migration properties has never been reported before suggesting that the underlying 






Figure 4.6 Random 2D migration of IQGAP3 depleted MB-231 cells. (A): Control and IQGAP3 
knockdown MB-231 cells were seeded on fibronectin coated plates and monitored by time-lapse microscopy 
for 16 hours. Imaged cells were subsequently manually tracked on ImageJ, track plots, mean cell speed and 
SEM were obtained on Mathematica (B): Graphical representation of control and IQGAP3 knockdown cell 
speed.  Bars represent the mean cell speed and error bars represent the SEM. Statistical analysis involved 
one way ANOVA followed by Tukey’s post hoc testing. Comparisons between the knockdown conditions 
and the negative control are shown on the graph, (***) = p ≤ 0.001. There was no significant difference 







Figure 4.7 Random 2D migration of IQGAP3 depleted BT-549 cells. (A): Control and IQGAP3 knockdown 
BT-549 cells were seeded on fibronectin coated plates and monitored by time-lapse microscopy for 16 hours. 
Imaged cells were subsequently manually tracked on ImageJ, track plots, mean cell speed and SEM were 
obtained on Mathematica (B): Graphical representation of control and IQGAP3 knockdown cell speed. Bars 
represent the mean cell speed and error bars represent the SEM. Statistical analysis involved one way 
ANOVA followed by Tukey’s post hoc testing. Comparisons between the knockdown conditions and the 
negative control are shown on the graph, (***) = p ≤ 0.001. There was no significant difference between the 







4.2.5 Focal adhesion formation in IQGAP3 knockdown cells 
The reduced cell speed observed upon inhibiting IQGAP3 expression in MB-231 and BT-549 cells 
could be the result of impeded cell retraction and/or a change in cell adhesion dynamics. Indeed, 
cell adhesion is widely accepted as a crucial prerequisite for effective cell migration of 
mesenchymal cells (Huttenlocher and Horwitz, 2011). Focal adhesions act as “feet” that adhere 
firmly on the extracellular matrix while their dynamic formation and dissolution ensures forward 
moving (Ridley et al., 2003). RhoA regulates the formation of stress fibres and focal adhesions 
by inducing phosphorylation of myosin light chain and thus contractility (Chrzanowska-Wodnicka 
and Burridge, 1996; Ridley and Hall, 1992). Additionally, cell retraction is also under the regulation 
of Rho (Ridley, 2001). Consequently, we postulated that if diminished IQGAP3 was somehow 
interfering with Rho activity it would ultimately disrupt focal adhesion formation.  
Zyxin is not found in nascent focal complexes but localises in mature focal adhesions in response 
to local retraction or arrested elongation of the leading cell edge (Zaidel-Bar et al., 2003).  
Additionally, even though the formation of nascent focal complexes is under the regulation of Rac, 
their progression into mature focal adhesions is under the regulation of Rho (Rottner et al., 1999). 
Interestingly, ROCK 1 depleted keratinocytes had very few zyxin positive focal adhesions 
whereas the formation of zyxin enriched focal adhesions was unaffected in ROCK 2 knockdown 
cells (Lock et al., 2012). Hence the available evidence suggested that impaired contractility might 
disrupt recruitment of zyxin and thus maturation of focal adhesions (Chrzanowska-Wodnicka and 
Burridge, 1996; Lock et al., 2012; Zaidel-Bar et al., 2003). 
In order to test this hypothesis, control and IQGAP3 depleted MB-231 and BT-549 cells were 
seeded on fibronectin and fixed 96h post transfection. Cells were subsequently probed for zyxin 
and stained with phalloidin to indicate the actin cytoskeleton. Following imaging, control and 
knockdown cells were scored for mature focal adhesions based on their zyxin staining. Analysis 
revealed that formation of mature focal adhesions was significantly hindered in both triple negative 
lines tested upon loss of IQGAP3. Moreover, depletion of IQGAP3 led to very elongated triple 
negative breast cancer cells which were unable to form mature focal adhesions and move on 
fibronectin (figures 4.4 – 4.9). Even though reduced migration ability as a result of loss of IQGAP3 
has been shown (Hu et al., 2016; Xu et al., 2016), a concurrent morphological and adhesion 




Figure 4.8 Formation of focal adhesions in IQGAP3 depleted MB-231 cells. (A): Control and IQGAP3 
knockdown MB-231 cells were seeded on fibronectin and were fixed 96h post transfection. Scale bar 
corresponds to 10μm. Cells were stained for zyxin (1:400) and anti-rabbit 488 secondary antibody (1:600) 
as well as TRITC phalloidin. (B): Following imaging cells were scored for mature focal adhesions based on 
their zyxin staining. Bars represent the mean percentage of cells with focal adhesions and error bars 
represent the SEM. Statistical analysis involved one way ANOVA followed by Tukey’s post hoc testing. 
Comparisons between the knockdown conditions and the negative control are shown on the graph, (***) = p 






Figure 4.9 Formation of focal adhesions in IQGAP3 depleted BT-549 cells. (A): Control and IQGAP3 
knockdown BT-549 cells were seeded on fibronectin and were fixed 96h post transfection. Cells were stained 
for zyxin (1:400) and anti-rabbit 488 secondary antibody (1:600) as well as TRITC phalloidin. Scale bar 
corresponds to 10μm. (B): Following imaging cells were scored for mature focal adhesions based on their 
zyxin staining. Bars represent the mean percentage of cells with focal adhesions and error bars represent 
the SEM. Statistical analysis involved one way ANOVA followed by Tukey’s post hoc testing. Comparisons 
between the knockdown conditions and the negative control are shown on the graph, (***) = p ≤ 0.001. There 
was no significant difference between the WT and the negative control conditions. (N=3). 
4.2.6 Invadopodia making ability in IQGAP3 knockdown cells 
As well as cell matrix focal adhesions, cancer cells also generate degradation competent 
adhesions called invadopodia. The significance of invadopodia mediated invasion has been 
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confirmed in vitro and its relevance to cancer metastasis has been validated in vivo (Eckert et al., 
2011; Leong et al., 2014). IQGAP1 is known to localise at invadopodia and is involved in the 
delivery of MT1-MMP at the protrusion (Sakurai-Yageta et al., 2008). IQGAP3 has not been 
implicated in invadopodia dynamics before; therefore in order to test whether IQGAP3 is 
associated with these protrusions IQGAP3 depleted alongside control MB-231 and BT-549 cells 
were subjected to the invadopodia assay which had been previously optimised for each cell line 
(figures 3.7, 3.8). Cells were then stained with Phalloidin 488 and scored for the presence of 
degradation competent invadopodia. Analysis showed that the ability of both MB-231 and BT-549 
cells to make invadopodia is almost entirely lost upon IQGAP3 depletion as very few IQGAP3 
depleted cells were found positive for actin puncta coinciding with matrix degradation holes 
(figures 4.10, 4.11). Interestingly, IQGAP1 depletion disrupted MT1-MMP localisation at the 
protrusions as well as matrix degradation without however affecting the formation of invadopodia 
per se (Sakurai-Yageta et al., 2008). This observation suggests a difference in functionality 
between IQGAP1 and IQGAP3 as the IQGAP3 depleted cells not only lack matrix degradation 





Figure 4.10 Invadopodia Presence in IQGAP3 depleted MB-231 cells. (A): IQGAP3 knockdown and 
control MB-231 cells were seeded on TRITC gelatin coated coverslips and incubated for 3h. Cells were 
subsequently stained with Phalloidin 488 and scored for invadopodia presence. Scale bar corresponds to 
10μm. (B): Graphical representation of percentage of cells making invadopodia. Bars represent the mean 
percentage of cells with invadopodia and error bars represent the SEM.  Statistical analysis involved one 
way ANOVA followed by Tukey’s post hoc testing. Comparisons between the knockdown conditions and the 
negative control are shown on the graph, (***) = p ≤ 0.001. There was no significant difference between the 





Figure 4.11 Invadopodia Presence in IQGAP3 depleted BT-549 cells. (A): IQGAP3 knockdown and 
control BT-549 cells were seeded on TRITC gelatin coated coverslips and incubated for 7h. Cells were 
subsequently stained with Phalloidin 488 and scored for invadopodia presence. Scale bar corresponds to 
10μm. (B): Graphical representation of percentage of cells making invadopodia. Bars represent the mean 
percentage of cells with invadopodia and error bars represent the SEM. Statistical analysis involved one 
way ANOVA followed by Tukey’s post hoc testing. Comparisons between the knockdown conditions and the 
negative control are shown on the graph, (***) = p ≤ 0.001. There was no significant difference between the 




4.2.7 Morphology of IQGAP3 overexpressing cells 
Cells with reduced IQGAP3 expression display an altered cellular morphology, thus the 
morphological consequences of IQGAP3 overexpression were also assessed. GFP tagged 
IQGAP1 and IQGAP3 constructs (figure 3.1) were transfected in MB-231 and BT-549 cells. A 
GFP alone control was also included along with wild-type cells. Transfected cells were then 
seeded on fibronectin coated coverslips and fixed 48h post transfection. Interestingly, 
morphological analysis revealed that IQGAP3-GFP MB-231 and BT-549 cells were significantly 
more elongated their wild-type counterparts (figure 4.12, 4.13). IQGAP1-GFP BT-549 cells were 
found to be significantly more elongated than their wild-type counterparts but less elongated than 
the IQGAP3-GFP overexpressing cells (figure 4.13). However, the elongated phenotype 
observed following IQGAP3 overexpression was not as dramatic as the one observed in IQGAP3 
depleted cells. The quantification of the relative elongation parameter revealed that IQGAP3 
depleted cells are more elongated with a mean relative elongation value of 0.8 (figures 4.4, 4.5) 
whereas the IQGAP3 over-expressing cells exhibiting a mean relative elongation value of 0.6 
(figures 4.12, 4.13). This might suggest that different mechanisms drive the elongated 





Figure 4.12 Morphology of IQGAP overexpressing MB-231 cells. (A): MB-231 cells were transfected with 
IQGAP1-GFP or IQGAP3-GFP. A GFP alone and wild-type controls were included in the experiment. Cells 
were fixed 48h post transfection and stained with TRITC phalloidin and DAPI. IQGAP transfected and control 
cells were subjected to morphological analysis. Scale bar corresponds to 10μm. (B): Graphical 
representation of cell elongation index. Bars represent the mean elongation values and error bars represent 
the SEM. Statistical analysis involved one way ANOVA followed by Tukey’s post hoc testing. Comparison 
between the IQGAP3-GFP and the WT control is indicated on the graph, (***) = p ≤ 0.001. No other 





Figure 4.13 Morphology of IQGAP overexpressing BT-549 cells. (A): BT-549 cells were transfected with 
IQGAP1-GFP or IQGAP3-GFP. A GFP alone and wild-type controls were included in the experiment. Cells 
were fixed 48h post transfection and stained with TRITC phalloidin and DAPI. IQGAP transfected and control 
cells were subjected to morphological analysis. Arrow indicates the formation of lamella in the IQGAP3-GFP 
over-expressing cell. Scale bar corresponds to 10μm. (B): Graphical representation of cell elongation index. 
Bars represent the mean elongation values and error bars represent the SEM. Statistical analysis involved 
one way ANOVA followed by Tukey’s post hoc testing. Comparisons between the WT control and IQGAP1-
GFP as well as the WT control and IQGAP3-GFP are indicated on the graph, (**) = p ≤ 0.01, (***) = p ≤ 






4.2.8 Invadopodia formation in IQGAP3 overexpressing cells. 
IQGAP3 depletion inhibited invadopodia formation in MB-231 and BT-549 cells (figures 4.10, 
4.11). Transient overexpression of IQGAP3 was hence employed to see whether IQGAP3 
localises at invadopodia or has an effect in invadopodia mediated degradation thereby supporting 
a role of IQGAP3 in invadopodia dynamics.  
Upon considering the necessary tools for this experiment, it was decided that invadopodia 
markers other than the actin structure and the resulting degraded gelatin might be needed. 
Subjecting IQGAP3-GFP overexpressing cells to the invadopodia assay which involves seeding 
cells on TRITC conjugated gelatin required the detection of an invadopodia marker in the far-red 
spectrum. Cortactin was decided as the most appropriate candidate since it has been widely used 
in the literature as a defining marker of invadopodia presence (Foxall et al., 2016). An 
immunofluorescence staining protocol for cortactin using a secondary antibody emitting in the far-
red area of the wavelength spectrum was thus optimised and established for both cell lines. The 
immunofluorescence cortactin staining was deemed successful when the cortactin signal 
appeared to co-localise with actin puncta as well as degradation areas (figure 4.14).  
The assessment of IQGAP3-GFP overexpression in invadopodia dynamics was performed on the 
BT-549 cells alone. The low transfection efficiency of IQGAP3-GFP in MB-231 cells together with 
the fact that only a fraction of the cell population makes invadopodia rendered the experiment non 
feasible in MB-231 cells. BT-549 cells over-expressing IQGAP3-GFP or GFP alone along with 
wild-type cells were seeded on TRITC gelatin and were fixed following a 7h incubation. Cells were 
subsequently stained for cortactin as an indication of invadopodia presence. Morphological 
analysis revealed that IQGAP3 overexpressing cells retain their elongated shape when seeded 
on gelatin (figure 4.15A, 4.15B). Therefore, this effect is not specific to fibronectin coating. 
Furthermore, upon scoring cells for invadopodia presence it was discovered that the ability of 
IQGAP3-GFP over-expressing cells to make invadopodia is almost entirely lost as deduced by 
the absence of actin puncta and matrix degradation mediated holes (figure 4.15C). Thus 
localisation of IQGAP3-GFP at invadopodia was not possible. Again, considering the well 
described role of IQGAP1 in invadopodia mediated degradation (Sakurai-Yageta et al., 2008), 








Figure 4.14 Optimisation of cortactin immunofluorescence staining. Cells were seeded on TRITC 
gelatin and were incubated for 7h in the case of BT-549 cells and 3h in the case of MB-231. Cells were 
subsequently fixed and stained with cortactin (1:50) followed by alexafluor anti-mouse 647 secondary (1:400) 




Figure 4.15 Invadopodia formation in IQGAP3-GFP overexpressing BT-549 cells. (A): IQGAP3-GFP 
overexpressing cells alongside GFP alone and wild-type cells were seeded on TRITC gelatin coated 
coverslips and were incubated for 7h. Cells were then stained for cortactin and imaged. Scale bar 
corresponds to 10μm. (B): Graphical representation of the elongation index for each condition. Bars 
represent the mean elongation values and error bars represent the SEM. Statistical analysis involved one 
way ANOVA followed by Tukey’s post hoc testing. Comparisons between IQGAP3-GFP and the GFP alone 
control is shown on the graph, (***) = p ≤ 0.001. There was no significant difference between the WT and 
the GFP alone control conditions. (N=3). (C): Cells were scored for invadopodia formation for each condition. 
Bars represent the mean percentage of cells with invadopodia and error bars represent the SEM. Statistical 
analysis involved one way ANOVA followed by Tukey’s post hoc testing. Comparisons between IQGAP3-
GFP and the GFP alone control is shown on the graph, (***) = p ≤ 0.001. There was no significant difference 




4.2.9 Effect of modulating IQGAP3 expression in cytokinesis 
IQGAP1 as well as IQGAP3 have been reported to have an important role in cytokinesis. IQGAP3 
in particular has been shown to control RhoA localisation by uniquely interacting with anillin 
(Adachi et al., 2014). Diminishing either of the two IQGAPs conferred an increase in binucleate 
Hela cells suggesting that IQGAP depletion interferes with successful completion of cytokinesis 
(Adachi et al., 2014). This effect has only been reported in Hela cells which is a widely used cell 
line in mammalian cytokinesis studies. Consequently, the effect of inhibiting IQGAP3 expression 
in cytokinesis was examined in the triple negative breast cancer cell lines. Additionally, the effect 
of IQGAP3 overexpression in cytokinesis was also assessed. The incidence of binucleated cells 
as revealed by the DAPI stain was recorded for IQGAP3 depleted and overexpressing as well as 
control MB-231 and BT-549 cells. In contrast to studies in Hela cells, loss of IQGAP3 did not 
confer an increase in binucleate cells in either MB-231 or BT-549 cells (figure 4.16A, 4.16C). 
Interestingly though, IQGAP3-GFP overexpression conferred a significant increase in binucleated 
cells in both MB-231 and BT-549 cell populations while IQGAP1-GFP overexpression conferred 





Figure 4.16 Binucleate cells following modulation of IQGAP3 expression. (A): Percentage of binucleate 
MB-231 cells in knockdown and control conditions. Statistical analysis involved one way ANOVA testing, 
(non-significant p > 0.05). (B): Percentage of binucleate cells overexpressing IQGAP1-GFP, IQGAP3-GFP 
as well as control MB-231 cells. Statistical analysis involved one way ANOVA followed by Tukey’s post hoc 
testing. Comparisons between the WT control and IQGAP1-GFP as well as the WT control and IQGAP3-
GFP are shown on the graph, (**) = p ≤ 0.01, (***) = p ≤ 0.001. There was no significant difference between 
the WT and the GFP alone control conditions. (N=3). (C): Percentage of binucleate BT-549 cells in 
knockdown and control conditions. Statistical analysis involved one way ANOVA testing, (non-significant p 
> 0.05). (D): Percentage of binucleate overexpressing IQGAP1-GFP, IQGAP3-GFP as well as control BT-
549 cells. Statistical analysis involved one way ANOVA followed by Tukey’s post hoc testing. Comparison 
between the WT control and IQGAP3-GFP are shown on the graph, (*) = p ≤ 0.05. No other comparison 
reached statistical significance. (N=3). Bars represent the mean percentage of binucleate cells and error 




This chapter investigates cellular behaviour following the modulation of IQGAP3 expression 
levels. After validating two siRNA sequences that can effectively diminish IQGAP3 expression the 
effect of IQGAP3 depletion in cell proliferation was primarily validated. Consistent with previous 
published work (Hu et al., 2016; Xu et al., 2016; Yang et al., 2014), the MTT assays performed 
revealed that cell proliferation is reduced upon IQGAP3 depletion (figure 4.3). Work on the role 
of IQGAP in skin homeostasis suggested that a very robust knockdown may be needed to elicit 
IQGAP3 depletion mediated effects but at the same time the proliferation arrest may render 
several experimental assays unsuitable (Monteleon et al., 2015). The morphology, migration and 
invasion assays in this study are proliferation independent.  
IQGAP3 depletion leads to a hyper-elongated morphology in our triple negative breast cancer cell 
lines (figures 4.4, 4.5). Elongated cells feature a mesenchymal type of migration, dynamic 
turnover of focal adhesions and extension of a single leading cell edge via Rac activity (Friedl and 
Wolf, 2010). However, IQGAP3 normally binds and maintains Rac in its GTP bound activated 
state thereby promoting Rac activity (Wang et al., 2007). Loss of IQGAP3 would thus imply loss 
of Rac activity and ultimately lack of a single elongating leading cell edge. Therefore, the observed 
elongated morphology induced from IQGAP3 depletion is unlikely to be a result of Rac activity. 
Meanwhile, the imaged IQGAP3 knockdown cells as well as the time-lapse videos suggested that 
the elongated phenotype was likely to be a result of loss of tail retraction rather a hyper-extended 
leading cell edge. Tail retraction is a result of actomyosin contractility which is regulated by Rho 
(Friedl and Wolf, 2009). Additionally, IQGAP3 depleted cells exhibited a dramatic loss of mature 
focal adhesions (figures 4.8, 4.9) whose formation is also under the regulation of Rho 
(Chrzanowska-Wodnicka and Burridge, 1996; Ridley and Hall, 1992). Hence, IQGAP3 was 
thought to be implicated in maintaining Rho activity which was disrupted once IQGAP3 expression 
was lost. 
 
Interestingly, knockdown of RhoA conferred the same elongated phenotype in MB-231 cells as 
well as in prostate cancer cell lines PC3 and DU145 (Vega et al., 2011). These cells also exhibited 
reduced speed similarly to the IQGAP3 depleted MB-231 and BT-549 cells. Furthermore, the 
authors observed that RhoA knockdown cells extended towards opposing directions thereby 
affecting overall displacement (Vega et al., 2011). In fact, this is a feature that was also sometimes 
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observed in the triple negative breast cancer cell lines upon loss of IQGAP3 expression. This 
might suggest that IQGAP3 depletion could elicit the effects of RhoA depletion which agrees with 
the hypothesis proposing that IQGAP3 is involved in the regulation of Rho and actomyosin 
contractility.  
Meanwhile, overexpression of IQGAP3-GFP also mediated an elongated phenotype in both MB-
231 and BT-549 cells (figures 4.12, 4.13). Nonetheless, the IQGAP3 overexpressing cells were 
notably less elongated as revealed by the quantified relative elongation parameter (figures 4.5, 
4.13). Consequently, the elongated phenotypes resulting from both knockdown and 
overexpression of IQGAP3 are most likely results of entirely different signalling pathways. 
Interestingly, it has been suggested that expression levels of IQGAP1 dictate which pathway the 
protein is going to scaffold; IQGAP1 depletion or overexpression inhibit ERK activity while 
overexpression of IQGAP1 activates Akt (Choi and Anderson, 2017). A similar mechanism could 
be in place for IQGAP3; optimal levels of IQGAP3 might maintain Rho activity and actomyosin 
contractility while over-expressed IQGAP3 could be switching to enhancing Rac1 and Cdc42 
activity. 
Nonetheless, the effect of IQGAP3 overexpression in cell morphology has not been directly 
described before.  Upon IQGAP3 knockdown in neuronal cells, axonal extension is lost (Wang et 
al., 2007) and thus it can be deduced that IQGAP3 supports cell elongation. Consistent with this 
hypothesis, IQGAP3 is also involved in localising APC at the leading cell edge (Caro-Gonzalez 
et al., 2012). The interaction of IQGAP1 to APC has similarly been described as important for 
directional cell migration (Watanabe et al., 2004).  Hence, it is perhaps not surprising that 
IQGAP1-GFP also induced an elongating effect in BT-549 cells (figure 4.13) considering the well 
described role of IQGAP1 in directional cell migration and its localisation at the leading cell edge 
(M. Fukata et al., 2001; Watanabe et al., 2004). Furthermore, both IQGAPs act as scaffolds and 
stabilise Rac1 activity which in turn regulates the formation of lamellipodia during cell migration 
(Smith et al., 2015). Hence, the resulting elongated phenotype upon IQGAP overexpression 
agrees with previously published findings and thus it can be argued that IQGAP1 and IQGAP3 
appear to be functioning in parallel in this case, contributing to increased Rac activity and 
directional cell migration (Caro-Gonzalez et al., 2012; Fukata et al., 2001; Smith et al., 2015; 
Watanabe et al., 2004) . 
Nonetheless, there is also evidence suggesting that loss of IQGAP1 activity elicits its 
morphological and migrational consequences in an entirely different way compared to what is 
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presented in this chapter regarding the effects of IQGAP3 depletion. Multiple cell edges and loss 
of directionality were observed following transfection of a mutant IQGAP1 construct deficient of 
the PIP2 binding site in MEFs as well as transfection of an IQGAP1 mutant deficient of the 
Rac1/Cdc42 binding site in Vero cells (Choi et al., 2013; Watanabe et al., 2004). 
 Additionally, it was observed that the elongated IQGAP3 depleted cells also lacked mature focal 
adhesions (figures 4.8, 4.9). It has previously been reported that IQGAP1 is associated with focal 
adhesion dynamics. Indeed IQGAP1 stimulated PDGF induced focal adhesion formation in 
vascular smooth muscle cells by binding PDGF receptor- β and promoting its auto-
phosphorylation (Kohno et al., 2013).  Another study has suggested that HECTD1 ensures 
efficient formation of mature focal adhesions by marking IQGAP1 for ubiquitination while 
overexpression of IQGAP1-GFP significantly inhibited the formation of focal adhesions in MEFs 
(Shen et al., 2016). Even though it appears as though the data regarding the association of 
IQGAP1 with focal adhesions are conflicting; it can be argued that IQGAP1 and IQGAP3 are 
associated with focal adhesion dynamics even though the mechanisms involved remain unknown. 
This chapter showed that IQGAP3 depletion dramatically reduced invadopodia formation in MB-
231 and BT-549 cells (figures 4.10, 4.11).This might suggest that IQGAP1 and IQGAP3 function 
in the same pathway considering the role of IQGAP1 in delivering MT1-MMP to the protrusions 
(Sakurai-Yageta et al., 2008). However, reducing IQGAP1 expression had an effect in the 
invadopodia mediated degradation rather than the formation of the protrusion (Sakurai-Yageta et 
al., 2008)  whereas loss of IQGAP3 expression eliminated invadopodia entirely as measured by 
the loss of actin puncta and not just degradation mediated matrix holes. 
Nonetheless, the dramatic loss of invadopodia upon diminishing IQGAP3 expression does not 
necessarily mean that IQGAP3 is actively involved in invadopodia dynamics as this observed 
phenotype could also result from impaired RhoA activity and actomyosin contractility. In fact, work 
on melanoma cells has highlighted that the coordinated activation and inactivation of RhoA is 
crucial for the invadopodia lifecycle; with RhoA activity being important for invadopodia formation 
while RhoA inactivation allows the maturation of the protrusion (Nicholas et al., 2016).  
Furthermore, inhibition of either myosin II or ROCK led to loss of invadopodia mediated matrix 
degradation in breast cancer CA1D cells. However, the actual actin protrusions remained but 
appeared smaller (Alexander et al., 2008). Interestingly, diminishing ROCK1 expression 
decreased the number of invadopodia protrusions while diminishing ROCK2 expression reduced 
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invadopodia mediated matrix degradation but did not affect the number of invadopodia in SCC-
61 cells (Jerrell and Parekh, 2016).  
Meanwhile, overexpression of IQGAP3-GFP also eliminated invadopodia formation and activity. 
At the same time, IQGAP3 overexpressing triple negative breast cancer cells retained their very 
elongated morphology on gelatin which agrees with results outlined in chapter 3 where it was 
deduced that a rounded morphology is more permissive to the formation of invadopodia than an 
elongated cell morphology (figure 3.9). Consequently, by subjecting IQGAP3 knockdown and 
over-expressing cells to the invadopodia assay it has not been possible to pinpoint a potential 
mechanism via which IQGAP3 is associated with invadopodia dynamics. Nonetheless, this 
mechanism is arguably different to the one employed by IQGAP1. It can be postulated that excess 
IQGAP3 sequesters away crucial invadopodia components ultimately disabling the formation of 
the protrusion. Considering that IQGAP1 has over 100 known binding partners including cortactin 
(Hedman et al., 2015), it would not be surprising if IQGAP3 were able to interact with crucial 
invadopodia components too. Alternatively, it is likely that IQGAP3 is associated with invadopodia 
by dictating a balanced RhoA activity (Nicholas et al., 2016) and regulating actomyosin 
contractility which has previously been described as important for invadopodia dynamics (Jerrell 
and Parekh, 2016).   
Ultimately, this chapter suggests that IQGAP3 depletion and overexpression can lead to the same 
phenotypical effects such as an elongated morphology and loss of invadopodia capacity. Again, 
as suggested by Choi and Anderson, the activation of the responsible pathway may be dependent 
on expression levels (Choi and Anderson, 2017); optimal levels of IQGAP3 might maintain 
morphological integrity and invadopodia capacity while any variation in the IQGAP3 expression 
levels can induce a switch in the activated pathway and disrupt these features. 
Furthermore, IQGAP3 is known to regulate RhoA localisation at the cleavage furrow via a unique 
interaction to anillin during cytokinesis (Adachi et al., 2014). This suggests that IQGAP3 might be 
involved in regulating contractility without directly binding to Rho (Adachi et al., 2014; Wang et al., 
2007). IQGAP1 localises at the cell cortex throughout mitosis while IQGAP3 specifically localises 
at the cleavage furrow from metaphase until telophase (Adachi et al., 2014). Knockdown of either 
IQGAP1 or IQGAP3 affected the localisation of RhoA at the cleavage furrow suggesting that 
IQGAPs are involved in the formation of the contractile ring during cytokinesis by regulating the 
recruitment of RhoA (Adachi et al., 2014). However, reduction of IQGAP3 levels in MB-231 and 
BT-549 cells had no effect in the incidence of binucleated cells. In contrast to IQGAP3 depletion, 
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overexpression of IQGAP3-GFP significantly increased binucleate cells in both cell lines, while 
overexpression of IQGAP1-GFP had the same effect in MB-231 cells (figure 4.16).  Perhaps, 
poor spatiotemporal regulation of IQGAPs induced by overexpression may interfere with 
contractility and thus be the reason behind failed cytokinesis.  
Overall, evidence yielding from this chapter supports the hypothesis that IQGAP3 might be 
involved in the regulation of actomyosin contractility. The hyper-elongated morphology 
accompanied by loss of mature focal adhesions, migratory ability and formation of invadopodia 
that is observed following depletion of IQGAP3 expression may thus be a result of interfering with 
actomyosin contractility and not a consequence of disrupting each individual process. 
Nonetheless, IQGAP3 has not been implicated with actomyosin contractility before. In fact both 
IQGAP1 and IQGAP3 have traditionally been known to bind and act as scaffolds for Rac1 and 
Cdc42 and not Rho (Adachi et al., 2014; Kuroda et al., 1996; Wang et al., 2007). Interestingly 
though, a study employing immunoprecipitation experiments in HEK293T cells showed that 
IQGAP1 directly interacts with RhoA and RhoC and that the binding to RhoA is enhanced when 
RhoA is GTP-bound and prenylated (Casteel et al., 2012). More recently, it has also been 
reported that IQGAP1 binds RhoA in human airway smooth muscle cells and inhibits RhoA activity 
thereby reducing contractility (Bhattacharya et al., 2014). However, IQGAP3 has never been 
shown to bind Rho despite well designed immuno-precipitation experiments (Adachi et al., 2014; 
Wang et al., 2007). Furthermore, if the phenotypes emerging from IQGAP3 depletion are in fact 
a consequence of disrupted contractility then this would mean that IQGAP3 promotes contractility 
related pathways. Thus it might be speculated that IQGAP1 and IQGAP3 mediate opposing 
effects in cell contractility. IQGAPs have been previously reported to have opposing function, 
given that IQGAP2 is reported to have tumour suppressive action in hepatocellular carcinoma 
(Schmidt et al., 2008)  while IQGAP1 has been extensively described to promote carcinogenesis 
(White et al., 2009). Ultimately, differential functionality exhibited by IQGAP1 and IQGAP3 in triple 
negative breast cancer cell motility could also explain that IQGAP3 mRNA levels and not those 




4.4 Future work 
This chapter described the phenotypes that arise from diminishing and overexpressing IQGAP3. 
It can be argued that the observed elongated cells lacking mature focal adhesions that have lost 
the ability to move and make invadopodia may be a result of impaired actomyosin contractility 
caused by IQGAP3 depletion. It would be interesting to assess the effect of diminishing IQGAP1 
in the triple negative breast cancer cell lines and make a thorough and systematic comparison 
between IQGAP1 and IQGAP3 depletion in the cell motility phenotypes outlined in this chapter. 
This could potentially further support the argument that IQGAP3 possesses unique functionality 
in triple negative breast cancer. Moreover, an inducible knockdown system effectively reducing 
IQGAP3 expression on demand could allow experimenting with IQGAP3 depletion in more long-
term in vitro assays such as the spheroid invasion assay (Nicholas et al., 2016) which can validate 
the role of IQGAP3 in triple negative breast cancer cell invasion. Additionally, monitoring IQGAP 
overexpressing cells by time-lapse microscopy would further elucidate whether IQGAP1 and 
IQGAP3 can have complementary activities in cell migration. This however was deemed an 
unfeasible experiment given the low transfection efficiency of IQGAP3. 
The next chapter aims to provide a potential mechanism via which IQGAP3 is implicated in 
actomyosin contractility and confirm that IQGAP3 has the capacity to contribute to triple negative 











Chapter 5 : Investigation of IQGAP3 interacting partners 
5.1 Introduction 
Results outlined in chapter 4 showed that IQGAP3 depletion conferred cytoskeletal changes 
leading to a very elongated cell shape accompanied by loss of cell migration and invasion 
properties. Cytoskeletal dynamics are widely known to be under the regulation of the Rho 
GTPases (Hall, 1998). The conferred elongated morphology pointed towards the loss of cell 
contraction and tail retraction which is coordinated by Rho (Poincloux et al., 2011; Ridley, 2001). 
RhoA mediates actomyosin contractility by signalling via Rho kinase (ROCK) which in turn 
regulates the phosphorylation of myosin regulatory light chain ( regulatory MLC) in two ways; by 
inhibiting MLC phosphatase and by directly phosphorylating regulatory MLC (Amano et al., 2010; 
Katoh et al., 2001; Kimura et al., 1996). Indeed, phosphorylated myosin II stimulated neurite 
retraction in N1E-115 neuroblastoma cells following Rho-ROCK activity (Amano et al., 1998). The 
loss of phosphorylated MLC could thus explain the lack of tail retraction in IQGAP3 depleted triple 
negative breast cancer cells. Interestingly, IQGAP1 has been shown to bind myosin essential light 
chain (essential MLC) via one of its IQ motifs in a yeast two hybrid assay (Weissbach et al., 1998). 
More recent work employing native gel electrophoresis showed that in contrast to IQGAP2, 
IQGAP1 but also IQGAP3 interact with essential MLC (Atcheson et al., 2011; Pathmanathan et 
al., 2008). It is postulated that there is a functional difference between these interactions as the 
interaction of IQGAP3 with essential MLC is likely to be more transient as suggested by the less 
distinct gel shift observed (Atcheson et al., 2011). IQGAP3 is thus associated with a crucial 
contractility effector which further supports the hypothesis that IQGAP3 might be involved in the 
regulation of triple negative breast cancer cell contractility.  
Recent work in my lab has revealed a functional complex of PAK6 and Filamin-A upstream of 
Rho-ROCK which is able to elicit morphological changes and drive a more contractile phenotype 
in MB-231 cells (personal communication). In fact, similarly to IQGAP3, loss of PAK6 also led to 
an elongated morphology in MB-231 cells (personal communication) ultimately suggesting that 
IQGAP3 depletion might phenocopy the effect of reduced expression levels of PAK6. This 
observation sparked the investigation of whether IQGAP3 is part of the same pathway. 
IQGAP3 has not been shown to interact with any member of the PAK family. Interestingly though, 
IQGAP1 is reported to associate with PAK6 in breast cancer MCF7 cells (Kaur et al., 2008)  while 
135 
 
the same association disrupts cell junctions in response to HGF in prostate cancer DU145 cells 
(Fram et al., 2014). PAK6 is a group II PAK that has traditionally been thought to be a Cdc42 
effector (Schrantz et al., 2004)  and is known to bind the androgen and oestrogen receptors (AR 
and ERα) (Lee et al., 2002). It is thus not surprising that PAK6 expression has been validated in 
prostate and breast cancer cell lines (Kaur et al., 2008) . Similarly to IQGAP3, PAK6 expression 
is highly expressed in the brain and testis (Kaur et al., 2008; White et al., 2009). Furthermore, 
PAK6 induced neurite outgrowth in mouse striatum in vivo (Civiero et al., 2015) while IQGAP3 
was shown to regulate neurite outgrowth of PC12 cells in vitro (Wang et al., 2007). It is thus likely 
that there is a potential synergy between IQGAP3 and PAK6.  
Filamin-A was first isolated from chicken embryo gizzard cells where it was found to be arranged 
similarly to myosin (Wang et al., 1975). Since then, Filamin-A has been found to be a potent actin 
filament cross-linker (Flanagan et al., 2001).  Filamin-A has also been reported to influence cell 
spreading by interacting with p190RhoGAP and thus regulating Rho activity in human melanoma 
cells(Mammoto et al., 2007). Additionally, Filamin-A deficient melanoma cells were less 
contractile than Filamin-A repleted cells as shown by traction force microscopy (Kasza et al., 
2009). Interestingly, Filamin-A complexes with IQGAP1 upon β1 integrin activation and together 
they regulate directional cell migration by modulating Rac1 activity (Jacquemet et al., 2013). 
Meanwhile, Filamin-A overexpression has been marked in breast tumours and associated with 
disease progression and metastasis (Tian et al., 2013). The implication of Filamin-A with 
aggressive breast cancer together with the fact that it interacts with IQGAP1 further supported 
the investigation of a potential interaction of Filamin-A with IQGAP3.  
Hence, the work outlined in this chapter aims to provide evidence suggesting that IQGAP3 is 
implicated in contractility related pathways thereby being able to modulate triple negative breast 




5.2 Results  
5.2.1 Effect of IQGAP3 depletion in myosin light chain activation 
IQGAP3 has been reported to bind the essential MLC but the functional significance of this 
interaction remains unknown (Atcheson et al., 2011).  In order to test the hypothesis that IQGAP3 
is involved in the regulation of actomyosin contractility, the effect of IQGAP3 depletion was 
examined on phosphorylated levels of regulatory MLC. Regulatory MLC phosphorylation on 
Ser19 marks the activation of MLC which is then able to associate with actin and relay cell 
contraction (Katoh et al., 2001). Control and IQGAP3 depleted MB-231 and BT-549 cells were 
lysed 96h post transfection and were subjected to western blotting in order to assess the levels 
of phosphorylated MLC. Indeed, levels of phosphorylated MLC were significantly reduced by both 
oligonucleotides in both MB-231 and BT-549 cells (figures 5.1, 5.2). This finding suggests that 
IQGAP3 expression levels can have a profound effect on the activity of myosin light chain and 






Figure 5.1 Effect of IQGAP3 depletion on phosphorylated MLC in MB-231 cells. (A): Control and 
IQGAP3 knockdown MB-231 cells were lysed 96h post transfection and were subjected to western blotting. 
Samples were probed for IQGAP3 (185kDa) and phospho – MLC (18kDa). β-actin was used as a loading 
control (42kDa). (B): Levels of phospho-MLC were quantified by densitometric analysis on ImageJ and were 
normalised against the loading control, background noise and wild-type levels.  Bars represent the mean 
relative pMLC expression and error bars represent the SEM. Statistical analysis involved one way ANOVA 
followed by Tukey’s post hoc testing. Comparisons between knockdown conditions and the negative control 
are indicated on the graph, (*) = p ≤ 0.05. There was no significant difference between the WT and the 







Figure 5.2 Effect of IQGAP3 depletion on phosphorylated MLC in BT-549 cells. (A): Control and 
IQGAP3 knockdown BT-549 cells were lysed 96h post transfection and were subjected to western blotting. 
Samples were probed for IQGAP3 (185kDa) and phospho – MLC (18kDa). β-actin was used as a loading 
control (42kDa). (B): Levels of phospho-MLC were quantified by densitometric analysis on ImageJ and were 
normalised against the loading control, background noise and wild-type levels. Bars represent the mean 
relative pMLC expression and error bars represent the SEM. Statistical analysis involved one way ANOVA 
followed by Tukey’s post hoc testing. Comparisons between knockdown conditions and the negative control 
are indicated on the graph, (**) = p ≤ 0.01, (*) = p ≤ 0.05. There was no significant difference between the 







5.2.2 Effect of RhoA activation in cell morphology of IQGAP3 depleted cells 
Rho-ROCK signalling primarily coordinates cell contractility by regulating the phosphorylation of 
MLC (Katoh et al., 2001; Kimura et al., 1996). Having established that diminished IQGAP3 
reduces levels of activated MLC, the association of IQGAP3 within the Rho-ROCK signalling was 
then sought to be validated. In order to confirm that IQGAP3 depletion disrupts Rho-ROCK 
signalling and ultimately phosphorylation of MCL, it was postulated that re-activation of RhoA in 
IQGAP3 depleted cells would rescue the morphological phenotype caused by reduced levels of 
IQGAP3. Lysophosphatidic acid (LPA) is a bioactive phospholipid acting on G-protein coupled 
receptors on the cell membrane to induce RhoA activation (Kranenburg et al., 1999). LPA 
treatment ultimately leads to increased actomyosin contractility which morphologically translates 
to cell rounding and neurite retraction in N1E-115 neuronal cells (Kranenburg et al., 1999).  
Treating IQGAP3 depleted cells with LPA was hence employed as a means of re-introducing 
RhoA activity and cell contraction. 10μM of LPA for 30 min was determined as an optimal 
concentration and duration of treatment based on a study employing MB-231 cells to assess the 
effect of LPA on cell migration (Du et al., 2010). The control conditions of this experiment included 
cells transfected with negative siRNA control as well as cells transfected with oligo 2 which 
conferred the most robust reduction of IQGAP3 levels and the most pronounced morphological 
phenotype (figures 4.1, 4.4). LPA was dissolved in PBS containing 0.1% fatty acid free BSA 
hence IQGAP3 depleted cells treated with PBS containing 0.1% fatty acid free BSA alone were 
also employed as a technical control. Following LPA treatment cells were fixed and stained with 
TRITC phalloidin to mark the actin cytoskeleton. Morphological analysis of the imaged cells 
revealed that LPA treatment specifically rescued and reversed the elongated shape of both 
IQGAP3 depleted MB-231 and BT-549 cells (figures 5.3, 5.4) which is consistent with previous 
findings reporting cell retraction and ultimately cell rounding following LPA treatment (Kranenburg 
et al., 1999). In fact, LPA treated IQGAP3 depleted MB-231 cells were even found to be 
significantly rounder than the cells transfected with negative siRNA control suggesting a dramatic 
rise in contractility (figure 5.3). These findings suggested that IQGAP3 promotes actomyosin 
contractility by regulating RhoA – ROCK signalling hence the loss of RhoA activity and contractility 
upon IQGAP3 depletion. Consistently, the re-activation of RhoA in IQGAP3 depleted cells 
restored contractility and rescued the morphological defect in the triple negative breast cancer 
cells. However, the results do not suggest that IQGAP3 is implicated in LPA signalling; RhoA 
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activity is driven by multiple G-protein coupled receptors which are activated by physiological cues 





Figure 5.3 Effect of LPA treatment in the cell morphology of IQGAP3 depleted MB-231 cells. (A) : 
Negative siRNA control, oligo 2 mediated IQGAP3 knockdown, as well as oligo 2 mediated IQGAP3 
knockdown with or without 10μM of LPA were fixed 96h post transfection and stained with TRITC-phalloidin 
and DAPI. Scale bar corresponds to 10μm. (B): Imaged cells were subjected to morphological analysis and 
their elongation parameter was determined. Bars represent the mean elongation values and error bars 
represent the SEM. Statistical analysis involved one way ANOVA followed by Tukey’s post hoc testing. 
Statistically significant comparisons are indicated on the graph, (***) = p ≤ 0.001. There was no significant 






Figure 5.4 Effect of LPA treatment in the cell morphology of IQGAP3 depleted BT-549 cells. (A): 
Negative siRNA control, oligo 2 mediated IQGAP3 knockdown, as well as oligo 2 mediated IQGAP3 
knockdown with or without 10μM of LPA were fixed 96h post transfection and stained with TRITC-phalloidin 
and DAPI. Scale bar corresponds to 10μm. (B): Imaged cells were subjected to morphological analysis and 
their elongation parameter was determined. Bars represent the mean elongation values and error bars 
represent the SEM. Statistical analysis involved one way ANOVA followed by Tukey’s post hoc testing. 
Comparisons are indicated on the graph, (***) = p ≤ 0.001, (ns) = non-significant. There was no significant 




5.2.3  IQGAP3 and PAK6 can be found in the same complex 
The investigation of the potential interaction between IQGAP3 and PAK6 was prompted by 
evidence derived from unpublished data from our lab as well as the literature. PAK6 has also 
been found to function upstream of Rho regulating breast cancer cell contractility while PAK6 
depletion also conferred very elongated MB-231 cells (personal communication). Furthermore, 
IQGAP1 has already been shown to associate with PAK6 thereby providing a link between the 
two protein families (Fram et al., 2014)  In order to test whether IQGAP3 can be found in a 
complex with PAK6, immunoprecipitation experiments were carried out employing the GFP-TRAP 
system which provides specific and robust detection of protein interactions.  IQGAP3-GFP and 
PAK6-myc were overexpressed in HEK-293 cells which deliver high levels of expressed protein 
thus enabling the detection of potential interactions. Lysates of IQGAP3-GFP and PAK6-myc 
overexpressing cells were mixed together and incubated with the GFP-TRAP beads so that 
proteins found in a complex with IQGAP3-GFP can be isolated. Co-transfecting IQGAP3-GFP 
and PAK6-myc was avoided as the efficiency of IQGAP3-GFP overexpression was significantly 
hindered when co-transfection of the two constructs was attempted. The experiment included an 
IQGAP3-GFP alone positive control as well as PAK6-myc alone negative control. Samples were 
then subjected to western blotting and were probed for GFP to ensure that the GFP-TRAP beads 
have successfully pulled down IQGAP3-GFP. Samples were also probed for myc to assess 
whether PAK6-myc is found in a complex with IQGAP3-GFP. Indeed, the results of the 
immunoprecipitation experiment confirmed that PAK6 can be detected in a complex with IQGAP3 









Figure 5.5 Co- immunoprecipitation of IQGAP3 with PAK6 in HEK-293 cells. IQGAP3-GFP and PAK6-
myc were transfected in HEK-293 cells. Cells were lysed and lysates were mixed together. An IQGAP3-GFP 
overexpressing sample was used as technical positive control while a PAK6-myc alone over-expressing 
sample was used as a negative control. Samples were subjected to the GFP-TRAP immunoprecipitation 
assay followed by western blotting. IP samples were probed for GFP to validate the pull-down of IQGAP3-
GFP (212kDa) and for myc to check whether PAK6-myc is bound to IQGAP3-GFP (75kDa). The whole cell 
lysates were probed for GFP and myc to validate that the constructs have been adequately over-expressed. 




5.2.4 IQGAP3 and PAK1 can be found in the same complex 
IQGAP1 has only been known to associate with PAK6 out of the six members of the PAK family 
(Fram et al., 2014)  despite the fact that PAK1 is a far more extensively studied effector of the 
Rho GTPases (BISHOP and HALL, 2000) This observation together with the establishment of the 
novel association between IQGAP3 and PAK6 sparked the question of whether IQGAP3 is 
preferentially coupled with PAK6 (or group II PAKs) as opposed to PAK1. This was addressed by 
another immunoprecipitation experiment carried out in the same manner as the one that 
confirmed the interaction between IQGAP3 and PAK6. In this case, IQGAP3-GFP and PAK1-myc 
were transfected in HEK-293 cells separately and lysates were mixed together in order to be 
incubated with the GFP-TRAP beads. An IQGAP3-GFP alone sample and a PAK1-myc alone 
sample were included in the experiment as controls. Samples were subjected to western blotting 
and probed for GFP to validate the pull-down of IQGAP3-GFP. Samples were also probed for 
myc to check for the potential interaction between IQGAP3 and PAK1. Indeed, the results of the 
experiment showed that IQGAP3 can also be found in a complex with PAK1 (figure 5.6). This 
also constitutes a novel association that has never been reported before but whether it is relevant 
to the implication of IQGAP3 with the regulation of actomyosin contractility of triple negative breast 
cancer cells is unknown. Nonetheless, IQGAP3 is shown here to be able to be part of the same 
complex with both group I and group II PAK members (figures 5.5, 5.6) suggesting that IQGAP3 








Figure 5.6 Co- immunoprecipitation of IQGAP3 with PAK1 in HEK-293 cells. IQGAP3-GFP and PAK1-
myc were transfected in HEK-293 cells. Cells were lysed and lysates were mixed together. An IQGAP3-GFP 
over-expressing sample was used as technical positive control while a PAK1-myc alone over-expressing 
sample was used as a negative control. Samples were subjected to the GFP-TRAP immunoprecipitation 
assay followed by western blotting. IP samples were probed for GFP to validate the pull-down of IQGAP3-
GFP (212kDa) and for myc to check whether PAK1-myc is bound to IQGAP3-GFP (75kDa). The whole cell 
lysates were probed for GFP and myc to validate that the constructs have been adequately over-expressed. 




5.2.5 Endogenous IQGAP3 associates with PAK6 in BT-549 cells 
In order to further validate the significance of a complex containing IQGAP3 and PAK6 in triple 
negative breast cancer, another immunoprecipitation experiment was employed, this time in BT-
549 cells. This cell line was chosen instead of MB-231 cells as it delivers higher expression levels 
of proteins when subjected to transient overexpression. PAK6-GFP was thus overexpressed in 
BT-549 cells and a GFP alone overexpression was used a negative control. Lysates of the two 
conditions were prepared and incubated with the GFP TRAP beads to pull down PAK6-GFP. 
Samples were then subjected to western blotting where a GFP probe confirmed that GFP tagged 
PAK6 had been bound to the beads. Samples were then probed for IQGAP3 which ultimately 
confirmed that endogenous levels of IQGAP3 interact with overexpressed levels of PAK6-GFP in 
BT-549 cells (figure 5.7). This finding reinforced the hypothesis that a protein complex containing 
PAK6 and IQGAP3 is relevant and important in triple negative breast cancer. Technical difficulties 
did not allow the validation of the association between endogenous levels of IQGAP3 and PAK1 








Figure 5.7 Co-immunoprecipitation of IQGAP3 with PAK6 in BT-549 cells. PAK6-GFP and GFP alone 
were over-expressed in BT-549 cells. Lysates were then subjected to the GFP-TRAP immunoprecipitation 
assay followed by western blotting. IP samples were probed for GFP to validate the pull-down of PAK6-GFP 
(102kDa) and for IQGAP3 to check whether endogenous IQGAP3 is bound to PAK6-GFP (185kDa). The 
whole cell lysates were probed for GFP and IQGAP3 to validate expression of PAK6-GFP and IQGAP3. β-






5.2.6 Endogenous Filamin-A associates with PAK6 in BT-549 cells 
As mentioned before, unpublished data generated in our lab revealed a complex of PAK6 and 
Filamin-A being able to influence morphological changes through Rho signalling in MB-231 cells 
(personal communication). In order to validate the importance of this complex, binding of PAK6 
with Filamin-A was sought to be confirmed in BT-549 cells. Once again, PAK6-GFP was over-
expressed in BT-549 cells while a GFP alone overexpression was included as a negative control. 
Lysates of the two conditions were prepared and incubated with the GFP TRAP beads to pull 
down PAK6-GFP. Samples were then subjected to western blotting where a GFP probe confirmed 
that PAK6-GFP had been bound to the beads. Samples were subsequently probed for Filamin-A 
which ultimately confirmed that endogenous levels of Filamin-A associate with overexpressed 
levels of PAK6-GFP in BT-549 cells (figure 5.8).  
 
5.2.7 Endogenous Filamin-A associates with IQGAP3 in BT-549 cells 
Unpublished data suggesting that IQGAP3 depletion phenocopies PAK6 depletion in modulating 
cell morphology together with the newly established complexes of IQGAP3 and PAK6 as well as 
Filamin-A and PAK6 in BT-549 cells, suggested that IQGAP3 could also be part of the 
PAK6:Filamin-A complex influencing cytoskeletal dynamics. To address this, another 
immunoprecipitation experiment was employed aiming to detect a potential link between IQGAP3 
and Filamin-A. For this experiment, IQGAP3-GFP and GFP alone were overexpressed in BT-549 
cells. Lysates for each condition were prepared and were subsequently incubated with GFP-
TRAP beads in order to capture any proteins coupled to GFP-tagged IQGAP3. This was followed 
by western blotting where probing for GFP confirmed that IQGAP3-GFP had been successfully 
pulled down with the beads. Probing for Filamin-A detected that endogenous Filamin-A was found 
in a complex with overexpressing IQGAP3 in BT-549 cells (figure 5.9). This complex has not 
been reported before; nonetheless, it may come as no surprise considering that IQGAP1 has 









Figure 5.8 Co-immunoprecipitation of Filamin-A with PAK6 in BT-549 cells. PAK6-GFP and GFP alone 
were overexpressed in BT-549 cells. Lysates were then subjected to the GFP-TRAP immunoprecipitation 
assay followed by western blotting. IP samples were probed for GFP to validate the pull-down of PAK6-GFP 
(102kDa) and for Filamin-A to check whether endogenous Filamin-A is bound to PAK6-GFP (280kDa). The 
whole cell lysates were probed for GFP and Filamin-A to validate expression of PAK6-GFP and Filamin-A. 










Figure 5.9 Co-immunoprecipitation of Filamin-A with IQGAP3 in BT-549 cells. IQGAP3-GFP and GFP 
alone were over-expressed in BT-549 cells. Lysates were then subjected to the GFP-TRAP 
immunoprecipitation assay followed by western blotting. IP samples were probed for GFP to validate the 
pull-down of IQGAP3-GFP (212kDa) and for Filamin-A to check whether endogenous Filamin-A is bound to 
IQGAP3-GFP (280kDa). The whole cell lysates were probed for GFP and Filamin-A to validate expression 




5.2.8 Proximity Ligation Assay illuminates binding of IQGAP3 and PAK6 
Considering the newly found complex of IQGAP3 and PAK6 as well as their common phenotypic 
consequences, the relationship between IQGAP3 and PAK6 was sought to be further explored. 
This was primarily approached by a proximity ligation assay (PLA). This assay allows the 
detection of protein interactions by giving rise to a single immunofluorescent spot every time two 
proteins of interest are found in close proximity implying interaction (Söderberg et al., 2006). This 
is an elegant system as it not only offers opportunities for the quantification of interactions of 
interest, it can also provide information regarding the localisation of the interaction under 
investigation as it is performed in intact fixed cells.  
The first step of the PLA involves fixing and probing cells with primary antibodies of different 
species optimised for immunofluorescence. It thus became clear that the IQGAP3 antibody used 
in western blotting throughout the course of this study needed to be optimised for immuno-
fluorescent staining in order to be used in subsequent proximity ligation assays. In order to check 
whether the IQGAP3 antibody worked in immunofluorescence staining, IQGAP3-GFP was 
overexpressed in BT-549 cells seeded on fibronectin coated coverslips. Cells were subsequently 
fixed and stained with the IQGAP3 antibody followed by the anti-rabbit 568 secondary antibody 
and phalloidin 647 to mark the actin cytoskeleton. This approach allowed the identification of 
IQGAP3-GFP overexpressing cells by the GFP signal which could then be compared to the 568 
signal derived from the IQGAP3 immunofluorescence staining. This method revealed that the 
IQGAP3 antibody was able to detect overexpressing IQGAP3 when used at 1:50 concentration 









Figure 5.10 Validation of the IQGAP3 antibody (Sigma) in immunofluorescence staining. BT-549 cells 
were transfected with IQGAP3-GFP. Cells were fixed 48h post transfection and stained with IQGAP3 
(Sigma, 1:50) for 2h. Cells were subsequently incubated with anti-rabbit 568 secondary antibody was used 




After establishing that the IQGAP3 antibody detects overexpressed IQGAP3 by 
immunofluorescent staining it became clear that an antibody detecting PAK6 expression in fixed 
cells was necessary in order to proceed to proximity ligation assays assessing the interaction 
between IQGAP3 and PAK. However, currently there are no PAK antibodies suitable for detecting 
PAK expression by means of immunofluorescent staining. Hence, it became clear that in order to 
explore the interaction between IQGAP3 and PAK6 using a proximity ligation assay, 
overexpressing IQGAP3 and PAK6 labelled with a non-fluorophore tag would need to be 
employed. Indeed, co-transfecting IQGAP3-HA and myc tagged PAK6 constructs in BT-549 cells 
was deemed optimal as this would allow staining with previously optimised rabbit raised IQGAP3 
and mouse raised c-myc antibodies. The interaction of IQGAP3 and PAK1 was sought to be 
similarly tested by co-transfecting IQGAP3-HA and PAK1-myc in order to assess whether 
IQGAP3 exhibits preferential binding with either PAK1 or PAK6. BT-549 cells transfected with 
IQGAP3-HA alone but otherwise treated exactly the same as the experimental conditions acted 
as a negative control to account for non-specific PLA signal. Traditional immunofluorescent 
staining was also performed alongside the PLA in order to confirm efficient overexpression of 
transfected constructs.  
Following co-transfection of IQGAP3-HA with either PAK6-myc or PAK1-myc, BT-549 cells were 
fixed and stained for IQGAP3 (red) and c-myc (green) as well as phalloidin to visualise the actin 
cytoskeleton. This proved that cells had been successfully transfected and thus the PLA signal 






Figure 5.11 BT-549 cells co-transfected with IQGAP3-HA and PAK-myc. BT-549 cells were transfected 
with IQGAP3-HA and either PAK1-myc or PAK6-myc. Cells transfected with IQGAP3-HA alone were used 
as a control. Cells were fixed 48h post transfection and stained with anti- IQGAP3 (1:50) and anti – c-myc 
(1:100) for 2h followed by anti-mouse 488, anti-rabbit 568 and phalloidin 647 for 1h. Scale bar corresponds 






Having established that the transfected constructs had been effectively over-expressed in BT-
549 cells from the traditionally stained controls (figure 5.11), the PLA signal for each condition 
could be analysed. The PLA signal was individually quantified for each imaged cell using particle 
analysis on ImageJ while the area of each cell was also obtained. This allowed to calculate the 
PLA signal relative to the cell area in order to account for potential cell area differences across 
different conditions. The results of the PLA indicated that the mean PLA signal exhibited by 
IQGAP3:PAK6 complex was significantly higher compared to the one of IQGAP3:PAK1 as well 
as the IQGAP3-HA negative control (figure 5.12). This suggests that IQGAP3 preferentially 
associates  with PAK6 in BT-549 cells (figure 5.12). Consistent with this result, overexpressed 
PAK6-GFP pulled down endogenous IQGAP3 (figure 5.7) while technical difficulties prevented 





Figure 5.12 Proximity Ligation Assay detecting interactions of IQGAP3-HA with either PAK1-myc or 
PAK6-myc in BT-549 cells. (A): BT-549 cells were co-transfected with IQGAP3-HA and PAK1-myc or PAK6 
myc. Overexpression of IQGAP3-HA alone was included as a control. Cells were stained with IQGAP3 
(rabbit, 1:50) and c-myc (mouse 1:100) for 2 h and were subsequently subjected to the PLA assay (red) as 
well as stained with Phalloidin 488. Scale bar corresponds to 10μm (B): The quantification of the PLA signal 
and the cell area of each cell were obtained on ImageJ and results were presented as a ratio of PLA spots 
over cell area. Bars represent the mean relative particle count and error bars represent the SEM. The total 
number of cells analysed for each condition over 3 independent experiments are noted on the graph. 
Statistical analysis involved one way ANOVA followed by Tukey’s post hoc testing. Statistically significant 
comparisons are indicated on the graph, (***) = p ≤ 0.001. There was no significant difference between 






5.2.9 Functional significance of the interaction between IQGAP3 and PAK6 
Having confirmed the complex of IQGAP3 and PAK6 by both immunoprecipitation experiments 
and a proximity ligation assay in the BT-549 cells, the functional value of this relationship was 
sought to be tested in the context of cell morphology. It is already established that depletion of 
either IQGAP3 (figure 4.5) or PAK6 (personal communication) leads to an elongated morphology 
in breast cancer cells. Both IQGAP3 and PAK6 have independently been suggested to function 
upstream of Rho–ROCK influencing cell contractility and cell morphology (figures 5.1 – 5.4, 
personal communication). To further explore whether IQGAP3 and PAK6 function as a regulatory 
complex in mediating cell morphology changes, the effect of overexpressing PAK6 in IQGAP3 
depleted cells was sought to be assessed. Indeed, IQGAP3 depleted BT-549 cells seeded on 
fibronectin coated coverslips were subjected to transient overexpression of PAK6-GFP or GFP 
alone as a negative control. Cells were fixed 96h post IQGAP3 knockdown and stained with 
TRITC-Phalloidin to visualise the actin cytoskeleton. IQGAP3 depleted cells transfected with 
PAK6-GFP remained significantly more elongated than cells transfected with negative siRNA 
control. However, they were also found to be significantly rounder than IQGAP3 depleted cells 
and IQGAP3 depleted cells transfected with GFP alone (figure 5.13). Consequently, 
overexpression of PAK6-GFP and not GFP alone partially rescued the elongated phenotype 
caused by IQGAP3 depletion ultimately suggesting that IQGAP3 is important in potentiating PAK6 





Figure 5.13 Partial phenotypic rescue of IQGAP3 depletion mediated morphology by overexpression 
of PAK6. (A): BT-549 cells were subjected to IQGAP3 knockdown and subsequent overexpression of PAK6-
GFP or GFP alone. Cells were fixed 96h post siRNA transfection and stained with TRITC-Phalloidin and 
DAPI. Scale bar corresponds to 10μm. (B): Morphological analysis of imaged cells was performed on ImageJ 
and the elongation parameter was obtained. Bars represent the mean elongation values and error bars 
represent the SEM. Statistical analysis involved one way ANOVA followed by Tukey’s post hoc testing. 
Statistically significant comparisons are indicated on the graph, (***) = p ≤ 0.001. There was no significant 





This chapter identified potential mechanisms and protein interactions via which IQGAP3 might be 
influencing cell morphology. Indeed, IQGAP3 depletion significantly reduced levels of 
phosphorylated MLC in both MB-231 and BT-549 cells. LPA induced - RhoA activation in IQGAP3 
depleted cells rescued the defective morphology suggesting that IQGAP3 promotes actomyosin 
contractility. IQGAP3 was found to associate with PAK1 and PAK6 in HEK-293 cells but the 
significance of the relationship between IQGAP3 and PAK6 was further highlighted by performing 
additional immunoprecipitation experiments and the proximity ligation assay on BT-549 cells. 
IQGAP3 was also found to form a complex with Filamin-A, a known actin filament cross-linker 
previously found to associate with PAK6 and coordinate cell morphology (personal 
communication). Ultimately, by investigating the functional aspect of the relationship between 
IQGAP3 and PAK6 it was revealed that overexpression of PAK6 in IQGAP3 depleted cells 
partially rescued the elongated phenotype suggesting that Rho activity had been restored.  
A reduction in phosphorylation levels of regulatory MLC upon IQGAP3 depletion established 
IQGAP3 as a regulatory element of actomyosin contractility. It is unlikely that this is a result of 
reduced total levels of regulatory MLC as it is a very stable molecule with a longer half-life than 
the course of the experiment (Zak, 1977).  IQGAP3 has previously been reported to interact with 
essential MLC but the functional significance of this interaction is unknown (Atcheson et al., 2011). 
It can be argued that the interaction between IQGAP3 and essential MLC creates a 
conformational change that in turn promotes phosphorylation of the regulatory MLC and/or the 
association of myosin with actin filaments. The implication of IQGAP3 in actomyosin contractility 
also supports the argument that the elongated cell morphology conferred by diminished levels of 
IQGAP3 is a direct result of disrupted actomyosin contractility and loss of cell contraction. 
Interestingly, PAK1 which is a novel binding partner of IQGAP3 (figure 5.6) has been shown to 
phosphorylate myosin light chain kinase (MLCK) and thus inhibit its activity as well as reduce 
phosphorylated levels of MLC in Hela cells (Sanders et al., 1999). In contrast to this early finding, 
PAK1 depletion reduced levels of pMLC in T47D breast cancer cells (Coniglio et al., 2008). This 
chapter reported binding of IQGAP3 with PAK1 (figure 5.6) as well as attenuated myosin light 
chain activation upon IQGAP3 depletion (figure 5.1). These observations, together with the 
previously shown interaction of IQGAP3 with essential MLC (Atcheson et al., 2011), might 
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suggest that IQGAP3 could also display scaffolding activity in the regulation of PAK1 mediated 
regulatory MLC phosphorylation.  
 
The morphological rescue of IQGAP3 depleted cells mediated by treating them with LPA 
highlighted the fact that loss of IQGAP3 disrupted RhoA activity. Interestingly, it is widely accepted 
that IQGAP3 does not directly interact with RhoA (Adachi et al., 2014; Wang et al., 2007).  At the 
same time, IQGAP3 has been known to bind Rac1 and Cdc42 and act as their effector stabilising 
their activated state (Wang et al., 2007; Smith et al., 2015). Together these observations suggest 
that IQGAP3 adopts different mechanisms in mediating the effects of the small Rho GTPases.   
Interestingly, protein levels of RhoA have been found to be significantly increased in invasive 
breast cancers compared to normal tissue (del Pulgar et al., 2005). Consistent with this finding, 
RhoA depletion in MB-231 cells inhibited invasion through a 3D matrigel matrix while cells notably 
remained atop the matrix spreading elongated protrusions (Poincloux et al., 2011)  in a similar 
fashion as the IQGAP3 depleted MB-231 cells (figure 4.4). Furthermore, ROCK1 and ROCK2 
were found to be over-expressed in advanced breast tumours compared to early stage breast 
cancer (Liu et al., 2009) . Meanwhile, the use of MB-231 cells in a mouse orthotopic mouse model 
engrafted with human bone showed that pharmacological inhibition of ROCK by Y27632 reduced 
metastases to engrafted human bone and the mouse skeleton (Liu et al., 2009).  
Consistent with morphological evidence presented in this thesis, treating MB-231 cells with 50 
μΜ of Fasudil, a known ROCK inhibitor, induced cell elongation while the administration of Fasudil 
in a mouse orthotopic model injected with MB-231 decreased the number of tumour bearing mice 
(Ying et al., 2006). Overall, there is compelling evidence suggesting that IQGAP3 depletion 
phenocopies the disruption of Rho-ROCK signalling in breast cancer cells while the use of LPA 
as a means of re-establishing Rho activity confirms that IQGAP3 lies upstream of Rho influencing 
Rho activity and cell contraction in breast cancer cells.   
 
IQGAP3 was found to associate with both PAK1 and PAK6 which has never been described 
before (figure 5.5, 5.6). This chapter suggests that the IQGAP3:PAK6 association is a much more 
frequent event than the IQGAP3:PAK1 association in BT-549 cells based on the results obtained 
from the PLA (figure 5.12). At the same time, the partial morphological rescue of IQGAP3 
depleted cells by overexpressing PAK6 further highlighted the physiological significance of the 
complex as it suggests that IQGAP3 recruits PAK6 and maintains PAK6 induced RhoA activity, 
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ultimately achieving cell contraction and tail retraction. Interestingly, previous work from our lab 
focusing on the invadopodia life-cycle in melanoma cells has revealed that RhoA activity is 
specifically coordinated by PAK4 (a group II PAK like PAK6) and not PAK1 (Nicholas et al., 2016).   
Nonetheless, the PLA results did not reveal a particular cell location where the IQGAP3:PAK6 
complex might be more active as the signal was scattered throughout the cell area (figure 5.12). 
Therefore, the complex is likely influencing global cell contraction rather than tail retraction 
specifically.  
 At the same time, no morphological defect was observed in PAK1 depleted MB-231 cells 
suggesting that loss of PAK1 does not phenocopy the loss of either IQGAP3 or PAK6 (Dart et al., 
2015). Hence, the complex containing IQGAP3 and PAK1 is less likely to integrate in a common 
signalling pathway influencing cell morphology. However, It can be argued that similarly to 
IQGAP1 (Choi and Anderson, 2017) expression levels of IQGAP3 could also be dictating different 
interacting partners and integration in different signalling pathways. Based on this assumption 
and results outlined in this chapter, endogenous IQGAP3 might interact with PAK6 and promote 
cell contractility while overexpressed IQGAP3 might potentiate the interaction with PAK1 and 
become implicated in an entirely different pathway. 
This chapter also revealed the association between IQGAP3 and Filamin-A. Interestingly, Filamin-
A deficient neutrophils exhibited a tail retraction defect which was caused from the fact that 
Filamin-A regulates RhoA activity and actomyosin contractility at the neutrophil uropod (Sun et 
al., 2013). Furthermore, Filamin-A recruited FilGAP that in turn supressed Rac activity in response 
to phosphorylation by ROCK thereby contributing to the antagonistic actions of Rac and Rho and 
promoting cell polarity (Ohta et al., 2006). Filamin-A is thus implicated in the coordination of RhoA 
activity and cell morphology. Consequently, the novel relationship between IQGAP3 and Filamin-
A further supports the possibility that IQGAP3 complexes with PAK6 and Filamin-A thus 
integrating with contractility pathways previously reported in my lab (personal communication). 
Despite evidence presented here, supporting the functional significance of IQGAP3:PAK6 in 
maintaining RhoA activity, IQGAP3 could be influencing RhoA activity via different mechanisms. 
A complex of IQGAP1 and Filamin-A is reported to be recruited at integrin activation sites in the 
cell periphery during cell spreading on fibronectin. IQGAP1 then recruits and couples to RacGAP1 
which locally deactivates Rac1 thereby ensuring balanced cell protrusion and directional cell 
migration of human osteosarcoma U2OS cells (Jacquemet et al., 2013). Furthermore, integrin 
trafficking in human ovarian cancer A2780 cells migrating in 3D induced the phosphorylation of 
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RacGAP1 which is recruited by IQGAP1 at the tips of invasive protrusions termed as pseudopods. 
There, RacGAP1 locally suppressed Rac1 allowing RhoA activity to be increased and promote 
pseudopod extension and invasion ((Jacquemet et al., 2013b). Interestingly, this describes a 
migration mode where RhoA activity induced cell elongation (Jacquemet et al., 2013a). IQGAP3 
could also be implicated in deactivating Rac1 thus allowing the coordinated activation of RhoA. 
Results presented in this chapter as well as the literature highlight the fact that IQGAP1 and 
IQGAP3 share Filamin-A as a binding partner (figure 5.9), (Jacquemet et al., 2013b). It would 
thus not be surprising if IQGAP3 were able to bind RacGAP1 and elicit the deactivation of Rac1. 
However, no morphological defects were reported for IQGAP1 depleted MB-231 cells (Sakurai-
Yageta et al., 2008) which suggests that the mechanism via which IQGAP3 integrates with 
contractility pathways is not shared by IQGAP1.  
Ultimately, this chapter yielded novel IQGAP3 binding partners via which IQGAP3 might be 
influencing cell morphology.  It also presented the prospect of IQGAP3 influencing Rho activity 
despite being known to act as a scaffold for Rac1 and Cdc42 thus expanding the cellular 




5.4 Future work  
This chapter sought to expose a functional IQGAP3:PAK6:Filamin-A complex able to regulate 
actomyosin contractility. A closer examination of the cell areas where this complex becomes 
active would point to mechanisms via which this complex elicits its morphological effects. The 
association between IQGAP3 and PAK6 can be further investigated by using domain mutants of 
either proteins to provide more structural and entirely novel evidence on the interaction between 
IQGAP3 and PAKs. The elucidation of specific IQGAP3 domains in motility pathways could trigger 
the investigation of whether they have therapeutic value. Indeed, IQGAP1 domains have been 
considered as pharmacological targets with the WW domain showing particular promise when 
administered systemically in a mouse model of pancreatic cancer (Jameson et al., 2013). A similar 
approach could thus be employed for IQGAP3. Furthermore, looking into the effects of IQGAP3 
depletion in the Rho-ROCK signalling would further support the argument that IQGAP3 is able to 
influence Rho activity as this would provide concrete evidence that IQGAP3 does not only mediate 
the effects of Rac1 and Cdc42. This could be approached by measuring levels of active RhoA 
following manipulation of IQGAP3 levels either by western blotting or by FRET microscopy using 
a RhoA biosensor (Fritz et al., 2013).     
 It would also be interesting to further explore the relationship between IQGAP3 and novel binding 
partner Filamin-A by assessing whether one precedes and recruits the other similarly to the 
relationship of IQGAP1 and Filamin-A (Jacquemet et al., 2013b). The localisation of Filamin-A 
could be primarily assessed in a background of IQGAP3 depletion to check whether IQGAP3 acts 
like IQGAP1 in terms of recruiting Filamin-A at particular cellular sites (Jacquemet et al., 2013b). 
Finally, it would be interesting to see whether Filamin-A overexpression rescues the defective 









Chapter 6 : Concluding Remarks 
Triple negative breast cancer is the most lethal form of the disease due to its aggressive and 
metastatic behaviour as well as high rates of relapse (Dent et al., 2009). Additionally, TNBC 
patients cannot benefit from the targeted therapies that have significantly improved outcomes in 
ER and HER2 positive breast cancers ultimately relying on standard chemotherapy regimens 
(Reis‐Filho and Tutt, 2008). Nonetheless, TNBC comprises a wide range of tumours whose 
common characteristic remains the lack of hormone and HER2 positive amplification; hence the 
need to elucidate and therapeutically target the signalling pathways that drive the invasive 
phenotype of these tumours is highlighted (Hudis and Gianni, 2011). Indeed, genetic profiling has 
revealed specific subtypes within the triple negative spectrum based on specific expression 
patterns; basal-like tumours exhibit an upregulation of proliferation and growth factor signalling 
pathways while the mesenchymal-like type is enriched with pathways enabling cell motility such 
as the regulation of cytoskeletal dynamics by the Rho GTPases (Lehmann et al., 2011a).  
This study originated from a tissue micro-array performed at the Breast Cancer Now Unit of Guy’s 
Hospital that revealed the specific upregulation of IQGAP3 mRNA levels in triple negative tumours 
compared to other types of the disease as well as normal tissue (de Rinaldis et al., 2013). Little 
is known about IQGAP3 compared to the earlier discovered IQGAP1 and IQGAP2 (White et al., 
2009).  However, considering the scaffolding activity of IQGAP3 for the Rho GTPases Rac1 and 
Cdc42 as well as the actin cytoskeleton, this study asked the question of whether IQGAP3 could 
be contributing to the necessary cytoskeletal rearrangements that would explain the invasive 
phenotype of triple negative tumours. 
At first, suitable cell models exhibiting the motile phenotype of TNBC were sought to be 
established, paying particular attention to cell morphology and the ability of cells to migrate in 2D 
as well as make invadopodia. Presence of invadopodia was chosen as an indication of invasive 
potential as these protrusions have been heavily associated with cancer cell intravasation while 
IQGAP1 has been implicated with invadopodia mediated matrix degradation (Gligorijevic et al., 
2012; Sakurai-Yageta et al., 2008). Initially, IQGAP3 protein expression was detected across a 
panel of triple negative lines including the MCF10A cell line as a near normal representative. Even 
though mRNA levels of IQGAP3 had been measured in triple negative cell lines and tumours 
before (de Rinaldis et al., 2013), protein expression had not been previously reported. 
Interestingly, near normal MCF10A cells displayed lower IQGAP3 expression levels than most 
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triple negative cell lines whereas no triple negative line exhibited higher levels of IQGAP1 than 
the near normal representative (figures 3.2, 3.3). Additionally, the high IQGAP3 expressing MB-
231 and MB-436 (figure 3.2) cells also exhibited an elongated morphology which is associated 
with EMT and tumour progression (Kalluri and Weinberg, 2009). Nonetheless, IQGAP3 
expression did not correlate with either cell morphology, migration or invadopodia capacity across 
the cell line panel. Interestingly, based on the cell lines assessed in this study, invadopodia 
capacity did not predict invasive potential as non invadopodia making MB-436 and HCC38 have 
been shown to be invasive in other in vitro and in vivo settings (Iida et al., 2012; Thompson et al., 
1992). Systematic analysis revealed that a rounder morphology is more permissive of 
invadopodia formation in breast cancer cells (figures 3.9, 3.10) ultimately suggesting that there 
may be a cross-talk between invadopodia formation and cell morphology. 
Notably, IQGAP3 depleted MB-231 and BT-549 triple negative breast cancer cells displayed a 
very elongated phenotype along with reduced cell speed, and formation of mature focal adhesions 
and invadopodia. The mechanisms involved in conferring these features appear to be unique to 
IQGAP3 as no morphological defect was reported in IQGAP1 depleted MB-231 cells (Sakurai-
Yageta et al., 2008). Additionally, IQGAP1 depleted MB-231 cells retain their actin rich 
invadopodia structure but exhibit diminished matrix degradation (Sakurai-Yageta et al., 2008) 
whereas IQGAP3 depletion eliminates the entire invadopodia structure (figure 4.10, 4.11). 
Moreover, the loss of invadopodia capacity in the IQGAP3 depleted cells is in agreement with the 
fact that a rounded morphology was found to be more permissive of invadopodia formation. 
Unexpectedly, IQGAP3 overexpression also conferred cell elongation and loss of invadopodia 
capacity, even though the morphological defect was less pronounced than the one observed in 
IQGAP3 depleted cells (figures 4.12, 4.13, 4.15). Ultimately, this meant that depletion and 
overexpression of IQGAP3 had similar phenotypic results. This could be explained by an 
observation previously made for IQGAP1 (Choi and Anderson, 2017). IQGAP1 expression levels 
have been observed to dictate which signalling pathways IQGAP1 scaffolds; IQGAP1 acts as a 
scaffold for both the MAPK cascade and the PI3K-Akt pathway. Depletion or overexpression of 
IQGAP1 disrupted ERK activation while overexpression of IQGAP1 was only found to promote 
activation of Akt (Choi and Anderson, 2017). In a similar fashion, endogenous IQGAP3 levels 
could be supporting normal morphological integrity and invadopodia formation while any variation 
of IQGAP3 expression levels could be driving the activation of other pathways disrupting these 
normal processes. More specifically, IQGAP3 overexpression could be prolonging the activated 
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state of Rac1 and Cdc42 ultimately contributing to actin polymerisation and cell elongation via 
enhanced formation of lamellipodia (figure 6.1). 
In contrast, the time-lapse movies of IQGAP3 depleted cells indicated that cells had lost the ability 
to retract their tail and thus move forward suggesting a defect in cell contractility. Additionally, 
RhoA depleted MB-231 cells were also reported to exhibit the same elongated phenotype as well 
as reduced migration (Vega et al., 2011). In fact, RhoA depleted cells were observed to extend 
towards opposite directions ultimately not moving at all (Vega et al., 2011) which was a feature 
that was sometimes observed in IQGAP3 depleted cells too. Together these observations lead to 
the hypothesis that IQGAP3 depletion is phenocopying RhoA depletion and is thus interfering 
with cell contractility. 
To test this hypothesis, levels of phosphorylated regulatory MLC were assessed in IQGAP3 
depleted cells in order to examine whether IQGAP3 has a direct effect on cell contractility. 
Activation of regulatory MLC was found to be attenuated in IQGAP3 depleted cells which further 
supported the fact that cell contractility is disrupted upon loss of IQGAP3 (figures 5.1, 5.2). This 
is particularly interesting as the interaction between IQGAP3 and essential MLC has previously 
been reported (Atcheson et al., 2011). Ultimately, this suggests that IQGAP3 might promote 
actomyosin contractility by interacting with essential MLC thereby creating a conformational 
change that enables phosphorylation of regulatory MLC and/or the association of myosin with 
actin filaments. 
 Additionally, IQGAP3 depleted cells were also treated with LPA to re-activate RhoA. LPA 
treatment rescued the elongated phenotype and restored contractility ultimately suggesting that 
IQGAP3 can also impact RhoA activity (5.3, 5.4). It can thus be postulated that IQGAP3 can 
contribute to the regulation of cell contractility by being active both upstream and downstream of 
RhoA. The concept of IQGAP3 scaffolding different parts of the same pathway is not novel as it 
has also been previously described to scaffold for the MAPK cascade by interacting with both 
Ras (Nojima et al., 2008)   and ERK (Yang et al., 2014).  
 This finding is particularly important because IQGAP3 had so far only been reported to act as a 
scaffold for Rac1 and Cdc42 while the absence of direct interaction between IQGAP3 and Rho 
has been repeatedly shown (Adachi et al., 2014; Wang et al., 2007; White et al., 2009). This 
suggests that IQGAP3 is able to promote RhoA activity indirectly.  Meanwhile, IQGAP1 has been 
suggested to directly act as a scaffold for RhoA and p190-RhoGAP ultimately promoting 
downregulation of RhoA activity and airway smooth muscle relaxation (Bhattacharya et al., 2014). 
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At the same time, IQGAP1 has also been shown to indirectly promote RhoA activity by inhibiting 
Rac activation via RacGAP1 (Jacquemet et al., 2013a). It becomes obvious that IQGAPs can 
potentially influence Rho activity via multiple pathways. Nonetheless, the morphological defect 
resulting from disruption of contractility in IQGAP3 depleted triple negative breast cancer cells is 
likely to be driven by mechanisms unique to IQGAP3 as no morphological defect was reported in 
IQGAP1 depleted MB-231 cells (Sakurai-Yageta et al., 2008). Ultimately, it can be postulated that 
despite the high homology and similar scaffolding activity shared by IQGAPs, fine-tuned 
spatiotemporal regulation as well as the potential of multiple binding partners (Hedman et al., 
2015)  allow them to also possess unique functionality that is likely to be tissue specific.  
The disruption of actomyosin contractility in invasive breast tumours such as the ones that fall 
under the triple negative spectrum is an exciting therapeutic opportunity as expression levels of 
RhoA as well as ROCK1 and ROCK2 have been found to be higher in advanced tumours 
compared to early stage disease and normal tissue (del Pulgar et al., 2005; Liu et al., 2009). 
Additionally, the amoeboid type of migration which is characterised by increased RhoA activity 
and cell contractility, (Sahai and Marshall, 2003) is also observed at the invasive front of multiple 
tumour types including the one of the breast (Gao et al., 2017). High actomyosin contractility is 
hence likely to contribute to the aggressive behaviour of triple negative tumours. Nonetheless, 
inhibition of ROCK has yielded contradictory results as a therapeutic approach for cancer perhaps 
due to the intrinsic cell plasticity of certain cell types (Wei et al., 2015). 
 Therapeutic targeting of IQGAPs has only recently been explored and presents promise 
especially in cases where resistance has developed to other targeted therapies or where kinase 
targeting has non-specific effects (Kumar et al., 2008; Sanchez-Laorden et al., 2013). The use of 
IQGAP1 domains as potential therapeutic agents have shown promise by competing with the 
targeted pathway of interest (Jameson et al., 2013; Monteleon et al., 2015). The same concept 
could thus be applied in the case of IQGAP3 in the attempt to downregulate cell contractility in 
TNBC. In fact, IQGAP3 expression is much more tissue specific than IQGAP1 which reduces the 
chance of side effects (White et al., 2009). At the same time, similarly to IQGAP1, IQGAP3 is 
likely to have multiple binding partners (Hedman et al., 2015). This implies that IQGAP3 might be 
involved in many different signalling pathways and thus the possibility of off target effects upon 
therapeutic targeting cannot be ruled out.  
Moreover, considering the unique morphological defect observed in IQGAP3 depleted TNBC cells 
as well as the potential implication of high actomyosin contractility in the metastatic behaviour of 
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TNBC, the mechanisms via which IQGAP3 is promoting actomyosin contractility in TNBC cells 
are most likely specific to IQGAP3. This could explain why IQGAP3 mRNA levels were found to 
be upregulated in triple negative tumours compared to other types of breast cancer and normal 
tissue (de Rinaldis et al., 2013).  
In the attempt to provide a mechanism via which IQGAP3 is able to influence RhoA activity, this 
study revealed novel complexes containing IQGAP3 and PAK6 (figure 5.7) as well as IQGAP3 
and Filamin-A (figure 5.9). Filamin-A has been shown to regulate RhoA activity and tail retraction 
in neutrophils (Sun et al., 2013)  while unpublished work from my lab has previously revealed a 
role of PAK6:Filamin-A complex in influencing contractility and cell morphology. In fact, depletion 
of PAK6 also induced elongation in MB-231 cells (personal communication). It can thus be 
deduced that both IQGAP3 and PAK6 depletion mimic loss of RhoA in conferring morphological 
consequences (Vega et al., 2011). This thesis hence proposed that IQGAP3 could act as a 
scaffold for this functional complex in order to potentiate RhoA activity. In agreement with this 
argument was the fact that overexpression of PAK6-GFP in IQGAP3 depleted BT-549 cells 
partially rescued the defective elongated phenotype (figure 5.13). Contrary to what is presented 
in this thesis, it was recently suggested that PAK6 inhibits cell contraction by mediating RhoD 
induced inhibition of RhoC (Durkin et al., 2017). Even though this seems to be directly 
contradicting the work presented here, it merely adds to the complexity of the cross-talk between 
Rho GTPases and their spatiotemporal regulation mediated by GEFs and GAPs. PAK6 could in 
fact be inhibiting RhoC mediated cell contraction but promoting RhoA mediated cell contraction. 
The action of PAK6 could also be different in the context of cancer cell migration as described in 
this thesis and viral infection which is the biological process involved in Durkin et al. 
 
In conclusion, this thesis provided evidence suggesting that IQGAP3 is directly influencing 
actomyosin contractility by regulating the activation of myosin light chain. Additionally, this thesis 
proposed that IQGAP3 can be found as part of complexes with PAK6 and Filamin-A which might 
contribute to the regulation of RhoA activity and cell contractility ultimately coordinating cell 
morphology and efficient cell migration in TNBC cells. Without the scaffolding activity of IQGAP3, 
the spatial regulation, recruitment and perhaps activation of PAK6 and Filamin-A could be 
disrupted, resulting in attenuated actomyosin contractility and subsequently defective cell 




Figure 6.1 Proposed model of IQGAP3 action. (A): Upon IQGAP3 depletion, PAK6 and Filamin-A are not 
recruited to induce RhoA activity and therefore actomyosin contractility is disrupted Additionally, IQGAP3 no 
longer scaffolds essential MLC which attenuates the phosphorylation of regulatory MLC. Ultimately, cells 
become hyper-elongated while contractility and cell migration is diminished. (B): Endogenous levels of 
IQGAP3 form complexes with PAK6 and Filamin-A which are postulated to induce RhoA activity thereby 
increasing actomyosin contractility. IQGAP3 also interacts with essential MLC which is most likely supporting 
the phosphorylation of regulatory MLC and/or the association of myosin with actin filaments. As a result, 
cells are contractile, maintain morphological integrity and are capable of forward moving. (C): IQGAP3 
overexpression is likely promoting the activation of other signalling pathways. Considering that IQGAP3 is 
primarily scaffolding the activity of Rac1 and Cdc42, it is possible that overexpression of IQGAP3 is 
prolonging the activated state of these Rho GTPases. Consequently, this contributes to increased actin 
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